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ABSTRACT 
 Quorum sensing is a term that describes an environmental sensing system that 
allows bacteria to monitor their own population density. Many gram negative bacteria 
use N-acyl-homoserine lactones (AHLs) as autoinducing quorum sensing signal 
molecules. This cell-density dependent regulation of gene expression contributes 
significantly to the size and development of the biofilm. Acinetobacter spp. are now 
emerging as important nosocomoial pathogens and it has been shown that they form 
biofilms with enhanced antibiotic resistance. In this study, we sought to find out if the 
biofilm formation among clinical isolates of Acinetobacter spp. is under the control of 
autoinducing quorum sensing molecules. We have also evaluated various quorum 
quenching strategies which can be used to attenuate the pathogenicity of these 
organisms.  
 Biofilm formation among clinical isolates of Acinetobacter spp. was assessed and 
the production of signal molecules were detected with Chromobacterium violaceum 
CV026 biosensor system. Characterisation of autoinducers was carried out by thin layer 
chromatography bioassay followed by mass spectrometric analysis. An autoinducer 
synthase gene, abaΙ was identified among the isolates that produce quorum sensing 
signal molecules. The abaI gene was cloned, a mutant of abaI gene was created, and the 
biofilm forming capability of the mutant abaI gene was analysed. The quorum 
quenching property of the extracts from two soil isolates with a strong AHL-
inactivating enzyme activity and the plant extracts of Phyllanthus spp., garlic bulb and 
lemon on clinical Acinetobacter spp. isolates was elucidated.  
 Using a microtitre-plate assay it was shown that 60% of the 50 Acinetobacter spp. 
isolates significantly formed biofilms. Chromobacterium violaceum CV026 biosensor 
system detected the production of long chain AHLs among seven of these biofilm 
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forming isolates. Thin layer chromatography bioassay and mass spectrometric analysis 
revealed that five of these isolates produced N-decanoyl homoserine lactone and two 
isolates produced acyl-homoserine lactone with a chain length equal to C12. The abaΙ 
gene was identified and it was shown that there was considerable inhibition in biofilm 
formation in the abaI::Tc mutant. Further, two soil isolates of the genus Bacillus with a 
strong AHL-inactivating enzyme activity were identified and the extracts from these 
soil bacilli was used to inhibit the biofilm forming capabilities of quorum sensing signal 
molecule producing clinical isolates of Acinetobacter spp. The quorum quenching 
properties of Phyllanthus spp. extracts, garlic bulb and lemon on the clinical 
Acinetobacter spp. isolates have also been reported. 
 These data are of great significance as the signal molecules aid in biofilm 
formation which in turn confer various properties of pathogenicity to the clinical 
isolates including drug resistance. The use of quorum sensing signal blockers to 
attenuate bacterial pathogenicity is therefore highly attractive, particularly with respect 
to the emergence of multi antibiotic resistant bacteria. The results also showed that the 
extracts were capable of inhibiting the biofilm formation and also degrade the AHLs 
produced by these clinical isolates of Acinetobacter spp. Our results indicate that the 
AHLs -inactivation approach represents a promising strategy for prevention of diseases 
in which virulence is regulated by quorum sensing.  
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ABSTRAK 
―Quorum sensing‖ adalah istilah yang menggambarkan sistem ―sensing‖ 
(perangsangan) bakteria terhadap alam sekitar yang membolehkan pemantauan 
kepadatan populasinya. Kebanyakan bakteria gram negatif menggunakan ―N-acyl-
homoserine lactones (AHLs)‖ sebagai isyarat molekul untuk ―autoinducing quorum 
sensing‖.  Pengaturan ekspresi gen ini yang bergantung terhadap kepadatan sel 
menyumbang kepada saiz dan pembentukan ―biofilm‖. Acinetobacter spp. kini muncul 
sebagai  patogen nosokomial yang penting dalam pembentukan ―biofilm‖ dengan 
rintangan antibiotik. Kajian ini bertujuan untuk mengetahui sama ada pembinaan 
―biofilm‖ oleh Acinetobacter spp. pencilan klinikal adalah di bawah kawalan molekul 
―autoinducing quorum sensing‖. Pelbagai strategi ―quorum quenching‖ yang dapat 
digunakan untuk melemahkan kepatogenan organisma ini juga dinilai.  
Dalam kajian ini, pembentukan ―biofilm‖ oleh Acinetobacter spp. pencilan 
klinikal dinilai dan produksi isyarat molekul dikesan dengan menggunakan sistem 
biosensor Chromobacterium violaceum CV026. Pencirian ―autoinducers‖ dijalankan 
dengan menggunakan bioassai kromatografi lapis tipis dan ini diikuti dengan analisis 
spektrometrik jisim. Suatu gen, abaI, yang merupakan gen ―autoinducer synthase‖ telah 
dikenalpasti di dalam pencilan tersebut sebagai pembentuk isyarat molekul ―quorum 
sensing‖. Gen abaI tersebut telah diklon untuk menghasilkan gen mutan abaI dan 
kebolehan gen mutan ini untuk menghasilkan ―biofilm‖ dianalisa. Selain itu, ciri-ciri 
―quorum quenching‖ yang dimiliki oleh dua jenis ekstrak tanah dan juga ekstrak 
tumbuhan Phyllanthus spp., bawang putih dan lemon telah diuji.  
 Dengan menggunakan asai ―microtitre-plate‖, sebanyak enam puluh peratus 
daripada lima puluh pencilan Acinetobacter spp. telah menunjukkan pembentukan 
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―biofilm‖ yang signifikan. Tujuh daripada pencilan pembentuk ―biofilm‖ ini 
menunjukkan produksi rantai panjang AHL yang telah dikesan oleh sistem biosensor 
Chromobacterium violaceum CV026. Dalam analisis spektrometrik jisim dan 
kromatografi lapis tipis pula, lima daripada pencilan ini menunjukkan produksi ―N-
decanoyl homoserine lactone‖ dan dua lagi menunjukkan produksi ―acyl-homoserine 
lactone‖ dengan kepanjangan rantai bersamaan dengan C12. Gen abaI telah dikenalpasti 
dan ditunjukkan bahawa terdapat perencatan dalam pembentukan ―biofilm‖ dalam 
mutan abaI::Tc. Kajian lanjutan juga telah dapat mengenalpasti dua pencilan tanah dari 
genus Bacillus dengan aktiviti enzim pentakaktifan AHL yang kuat. Ekstrak daripada 
bacilli tanah ini telah digunakan untuk merencatkan kebolehan pembentukan ―biofilm‖ 
dalam isyarat molekul ―quorum sensing‖ Acinetobacter spp. pencilan klinikal. Selain 
itu, pencirian ―quorum quenching‖ ekstrak Phyllanthus spp., bawang putih dan lemon 
pada Acinetobacter spp. pencilan klinikal dapat dilaporkan. 
Penemuan kajian ini adalah sangat signifikan kerana isyarat molekul yang 
terlibat dalam pembentukan ―biofilm‖ dapat mencirikan kepatogenan Acinetobacter 
spp. pencilan klinikal yang salah satunya termasuk kerintangan terhadap pelbagai jenis 
ubat. Oleh yang demikian, penggunaan ―quorum sensing signal blockers‖ untuk 
melemahkan kepatogenan bakteria memainkan peranan yang amat penting terutamanya 
dengan kemunculan bakteria yang rintang terhadap pelbagai antibiotik. Selain itu, hasil 
kajian ini juga menunjukkan ekstrak-ekstrak yang diuji dapat merencatkan 
pembentukan ―biofilm‖ dan juga menurunkan penghasilan ―AHLs‖ oleh Acinetobacter 
spp pencilan klinikal. Penemuan kajian ini juga membuktikan bahawa pendekatan 
pentakaktifan AHLs merupakan strategi yang menjanjikan dalam pencegahan penyakit 
di mana ―virulence‖ (kemudaratan) dikawal oleh ―quorum sensing‖. 
ACKNOWLEDGEMENTS 
 
 
 
 
 
 ACKNOWLEDGEMENTS 
 First and foremost, I would like to thank the one above all, the omnipresent God, 
for answering my prayers and for giving me the strength to plod on despite my 
constitution wanting to give up, thank you so much Dear Lord. 
 I would like to express my sincere gratitude to my supervisor, Prof. Dr. Shamala 
Devi, Department of Medical Microbiology, University of Malaya. She provided me 
with many helpful suggestions, important advices and constant encouragement during 
the course of this work. I have been fortunate to have an advisor who gave me the 
freedom to explore on my own and at the same time the guidance to recover when my 
steps faltered. Thanks for pushing me.  
 I also wish to express my appreciation to Prof. Dr. Marzida Mansor and Prof. Dr. 
Gracie Ong from the Department of Anaesthesiology, University of Malaya, for 
showing intense academic interest in this study.  
 In my lab, I was surrounded by knowledgeable and friendly people. I would like 
to thank all my lab mates, especially, Dr. Gobianand, Dr. Ravindran Thayan, Dr. 
Ramapraba, Mrs. Rajeshwari, Ms. Thamil Vaani, Mr. Le Cheng Foh, Mr. Mohammed, 
Mr. Tan Yin Quan, Mr. Tan Wee Chee and Ms. Lee Sau Har for all their support. In 
addition to the people in my own laboratory, I was lucky enough to have fellow friends 
from my department. I would like to thank Mrs. Kumutha Malar, who had been a great 
source in discussing practical information and was happy to hear to my outrage and glee 
on everyday events, Ms. Vanitha Mariappan, for all her humour and support and Ms. 
Yalda. Very special thanks to Mrs. Sujithara Devi, Department of Anaesthesiology, for 
all her support in office work. 
 ACKNOWLEDGEMENTS 
 
viii 
 
 I also would like to thank the University of Malaya for providing the postgraduate 
research fund (PS154/2009B) and research facilities that made this study possible.  
Special thanks to University of Malaya for the Graduate Research Assistantship Scheme 
(GRAS), for providing financial support to complete my study.  Thanks to all the staffs 
and members from Department of Medical Microbiology, Faculty of Medicine, 
University of Malaya. 
 Finally, I would like to thank those closest to me, whose presence helped make 
the completion of my graduate work possible. I would like to express my appreciation 
to my parents, Mr. Anbazhagan and Mrs. Priya and to my brother Mr. Deepan. They 
had been a constant source of love, support, concern and strength throughout. My best 
friend for the past 15 years, Mrs. Shiny has to be thanked for all the hope that she had 
on me. Very special thanks to my husband Mr. Sathishkumar, for his mental support 
and help in every step of this dissertation and for the absolute confidence he had in me. 
Thanks to my little daughter Sanchaya for the unlimited happiness and pleasure. 
  
  
TABLE OF CONTENTS  
 
 
 
 
 
 
TABLE OF CONTENTS 
 
ABSTRACT .................................................................................................................... iii 
ABSTRAK ....................................................................................................................... v 
ACKNOWLEDGEMENTS .......................................................................................... vii 
TABLE OF CONTENTS ............................................................................................... ix 
LIST OF FIGURES ..................................................................................................... xiii 
LIST OF TABLES ....................................................................................................... xvi 
LIST OF SYMBOLS AND ABBREVIATIONS ..................................................... xviii 
1 Introduction ................................................................................................................ 1 
1.1 Taxonomy and epidemiology of Acinetobacter spp. ............................................... 2 
1.2 Phenotypic and genotypic characteristics of Acinetobacter spp. ............................. 8 
1.3 Emergence of nosocomial infections caused by Acinetobacter spp. ..................... 13 
1.4 Treatment of Acinetobacter spp. infections ........................................................... 16 
1.5 Resistance mechanisms in Acinetobacter spp. ...................................................... 20 
1.6 Biofilms 27 
1.6.1 Biofilm formation ................................................................................. 27 
1.6.2 Resistance to antimicrobial agents ........................................................ 28 
1.6.3 Biofilms on medical devices and its relationship with the disease ....... 29 
1.6.4 Regulation of biofilms .......................................................................... 31 
1.6.5 Biofilm formation in Acinetobacter spp. .............................................. 32 
1.7 Quorum Sensing (QS) ........................................................................................... 33 
1.7.1 Bacterial cell-cell communication......................................................... 33 
1.7.2 Types of quorum sensing signal molecules .......................................... 35 
1.7.3 Quorum sensing regulation through networking .................................. 37 
1.7.4 Bacterial AHL biosensor reporter strains .............................................. 39 
1.7.5 QS in Acinetobacter spp. ...................................................................... 43 
1.8 Quorum Quenching ............................................................................................... 45 
1.8.1 Biological screening for quorum sensing inhibitors ............................. 46 
1.8.2 Quorum sensing inhibitors .................................................................... 46 
1.9 Justification and objectives of the study ................................................................ 50 
TABLE OF CONTENTS  
 
x 
 
2 Materials & Methods ............................................................................................... 52 
2.1 Bacterial strains ..................................................................................................... 53 
2.1.1 Sample strains .................................................................................. 53 
2.1.2 Biosensor strains .............................................................................. 53 
2.1.3 Characterization of the bacterial isolates ......................................... 54 
2.2 Quantification of biofilm formation ...................................................................... 55 
2.2.1 Microtiter plate method ................................................................... 55 
2.2.2 Statistical Analysis .......................................................................... 55 
2.3 Screening for Acyl Homoserine Lactones (AHLs) ............................................... 56 
2.3.1 Chromobacterium violaceum CV026 induction assay .................... 56 
2.3.2 Chromobacterium violaceum CV026 inhibition assay .................... 56 
2.4 Quantification of AHLs ......................................................................................... 57 
2.4.1 Well-diffusion assays (Induction and Inhibition) ............................ 57 
2.4.2 Standard curve derivation ................................................................ 57 
2.4.3 Well-diffusion assay for the positive isolates .................................. 58 
2.5 Identification of AHLs ........................................................................................... 59 
2.5.1 Extraction of AHLs from the culture Supernatants ......................... 59 
2.5.2 Thin Layer Chromatography Bioassay ............................................ 59 
2.5.3 Mass Spectrometry (MS) ................................................................. 60 
2.6 Identification of the QS gene in Acinetobacter spp. and construction of its 
mutant ...................................................................................................... 63 
2.6.1 Identification of abaI gene in Acinetobacter spp. producing 
the QS signal molecules by Polymerase Chain Reaction (PCR) ..... 63 
2.6.2 Sequencing and identity of the abaI gene PCR product .................. 64 
2.6.3 Sequence analysis and Bioinformatics tools ................................... 65 
2.6.4 Cloning of the abaI gene ................................................................. 65 
2.6.5 Transformation of One Shot TOP10 E.coli competent cells ........... 68 
2.6.6 Confirmation of the clone by colony PCR ...................................... 69 
2.6.7 Confirmation of the clone by restriction digestion .......................... 70 
2.6.8 Confirmation by sequencing ............................................................ 72 
2.6.9 Construction of the mutant of abaI gene ......................................... 72 
2.6.10 Transformation of the abaI:Tc mutant plasmid ............................... 75 
2.6.11 Inactivation of the abaI gene in the chromosome of the 
Acinetobacter spp. S117 .................................................................. 75 
2.6.12 Confirmation of the exconjugant clone for the presence of 
tetracycline gene by colony PCR ..................................................... 76 
2.6.13 AHL production in wildtype and mutant abaI gene ........................ 77 
TABLE OF CONTENTS  
 
xi 
 
2.6.14 Biofilm formation in wildtype and mutant abaI gene ..................... 77 
2.7 Natural sources as potential quorum quenchers .................................................... 79 
2.7.1 AHL inactivation activity of environmental bacterial isolates ........ 79 
2.7.2 Inhibition of biofilm and inactivation of AHLs among the 
clinical Acinetobacter spp.  isolates ................................................ 82 
2.7.3 AHL inactivation activity of plant extracts ..................................... 83 
2.7.4 Inhibition of biofilm formation and inactivation of AHLs 
among the clinical Acinetobacter spp.  isolates after treatment 
with plant extracts ............................................................................ 84 
3 Results ....................................................................................................................... 86 
3.1 Bacterial strains ..................................................................................................... 87 
3.1.1 Identification using standard laboratory methods. .......................... 89 
3.2 Quantification of biofilm formation using microtiter plate method ...................... 93 
3.3 Screening for Acyl Homoserine Lactones (AHLs) ............................................... 95 
3.3.1 Chromobacterium violaceum CV026 induction assay .................... 95 
3.3.2 Chromobacterium violaceum CV026 inhibition assay .................... 97 
3.4 Quantification of the AHLs by well-diffusion assay ............................................. 99 
3.5 Identification of AHLs ......................................................................................... 104 
3.5.1 Thin Layer chromatography and Bioassay .................................... 104 
3.5.2 Mass Spectrometry (MS) ............................................................... 107 
3.6 Identification of the QS gene in Acinetobacter spp. and construction of its 
mutant .................................................................................................... 124 
3.6.1 Identification of abaI gene in Acinetobacter spp. producing 
the QS signal molecules ................................................................ 124 
3.6.2 Sequencing of the abaI gene of the test isolates ............................ 126 
3.6.3 Cloning of the abaI gene (blue-white selection) and 
construction of the mutant of abaI gene (Tetracycline mutant) .... 135 
3.6.4 Biofilm formation in wild type and mutant abaI gene .................. 140 
3.7 Natural sources as potential quorum quenchers .................................................. 142 
3.7.1 Isolation of soil Bacilli and detection of aiiA homologue gene .... 142 
3.7.2 AHL inactivation assay of the soil Bacillus spp. extracts ............. 144 
3.7.3 Inhibition of biofilm formation among the clinical 
Acinetobacter spp. isolates ............................................................ 146 
3.7.4 Use of plant extracts to inactivate AHLs among clinical  
Acinetobacter spp. isolates ............................................................ 148 
4 Discussion ................................................................................................................ 152 
4.1 Biofilm formation by Acinetobacter spp. clinical isolates .................................. 154 
TABLE OF CONTENTS  
 
xii 
 
4.2 Identification of QS signal molecules among clinical Acinetobacter spp. 
isolates ................................................................................................... 156 
4.3 Investigation of the gene involved in QS and construction of its mutant as a 
QS control strategy ................................................................................ 160 
4.4 Preliminary investigations into possible natural sources as potential quorum 
quenchers ............................................................................................... 163 
5 Conculsion ............................................................................................................... 167 
REFERENCES ............................................................................................................ 170 
APPENDIX – 1 ............................................................................................................ 203 
APPENDIX - 2 ............................................................................................................. 206 
PUBLICATIONS & PRESENTATIONS ................................................................. 219 
 
 
  LIST OF FIGURES  
 
 
 
 
 
 
LIST OF FIGURES 
Figure 1.1: Scanning electron micrograph of A. baumannii type strain ATCC 
19606. (Final magnification, 318,000). ................................................ 10 
Figure 1.2: Structures of some representative quorum sensing signalling 
molecules .............................................................................................. 34 
Figure 1.3: QS regulation through networking ........................................................ 39 
Figure 3.1: Morphology of Acinetobacter spp. ....................................................... 90 
Figure 3.2: Gram stain of Acinetobacter spp. .......................................................... 90 
Figure 3.3: Biochemical tests used for the identification of Acinetobacter spp. ..... 91 
Figure 3.4: Confirmation Acinetobacter spp. identification using API20NE. ........ 92 
Figure 3.5: Biofilm formation among the clinical isolates of Acinetobacter spp.  
in microtiter plates ................................................................................ 94 
Figure 3.6: Chromobacterium violaceum CV026 induction assay .......................... 96 
Figure 3.7: Chromobacterium violaceum CV026 inhibition assay ......................... 98 
Figure 3.8: Chromobacterium violaceum CV026 well-diffusion assay in LB 
agar. ....................................................................................................... 100 
Figure 3.9: Std. curve for Extraction Efficiency of the Standard AHLs ................. 101 
Figure 3.10: Well-diffusion assay for the tested isolates. ........................................ 102 
Figure 3.11: Thin layer chromatography bioassay. ................................................. 106 
Figure 3.12: Standard curves generated for the initial quantification experiment 
measuring all samples. .......................................................................... 109 
Figure 3.13: AHL Profiling - Summary of Calculated Potenial AHLs. .................. 112 
Figure 3.14: TIC of a mixture of standards ............................................................. 116 
Figure 3.15a: TIC trace of Sample 1 ....................................................................... 116 
Figure 3.15b: Combined overlay of TIC and Extracted compounds of sample 1 ... 116 
Figure 3.15c: Magnified view of extracted compounds in sample 1 ....................... 117 
Figure 3.15d: Overlaid spectra of all common precursor Ions common in 
sample 1 providing fragment Ions (71.1, 74.1, and 102.1): .................. 117 
Figure 3.16a: TIC trace of Sample 11 ..................................................................... 117 
Figure 3.16b: Combined overlay of TIC and extracted compounds of sample 11 .. 118 
Figure 3.16c: Magnified view of extracted compounds in sample 11 ..................... 118 
Figure 3.16d: Overlaid spectra of all common precursor Ions common in 
sample 11 providing fragment Ions (71.1, 74.1, and 102.1): ................ 118 
Figure 3.17a: TIC trace of Sample 53 ..................................................................... 119 
  LIST OF FIGURES  
 
xiv 
 
Figure 3.17b: Combined overlay of TIC and Extracted compounds of sample 
53 .......................................................................................................... 119 
Figure 3.17c: Overlaid spectra of all common precursor Ions common in 
sample 53 providing fragment Ions (71.1, 74.1, and 102.1): ................ 119 
Figure 3.18a: TIC trace of Sample 54 ..................................................................... 120 
Figure 3.18b: Combined overlay of TIC and Extracted compounds of sample 
54 .......................................................................................................... 120 
Figure3.18c: Magnified view of extracted compounds in sample 54. ..................... 120 
Figure 3.19a: TIC trace of Sample 93 ..................................................................... 121 
Figure 3.19b: Magnified view of extracted compounds in sample 93..................... 121 
Figure 3.20b: Combined overlay of TIC and Extracted compounds of sample 
102 ........................................................................................................ 122 
Figure 3.21a: TIC trace of Sample 117 ................................................................... 122 
Figure 3.21b: Combined overlay of TIC and Extracted compounds of sample 
117 ........................................................................................................ 122 
Figure 3.21c: Magnified view of extracted compounds in sample 117 ................... 123 
Figure 3.22: The electrophoretic banding patterns of the PCR products using 
the primers for the abaI gene ................................................................ 125 
Figure 3.23: Sequence analysis of abaI gene from isolate S1 ................................. 127 
Figure 3.24: Sequence analysis of abaI gene from isolate S11 ............................... 128 
Figure 3.25: Sequence analysis of abaI gene from isolate S53 ............................... 129 
Figure 3.26: Sequence analysis of abaI gene from isolate S54 ............................... 130 
Figure 3.27: Sequence analysis of abaI gene from isolate S93 ............................... 131 
Figure 3.28: Sequence analysis of abaI gene from isolate S102 ............................. 132 
Figure 3.29: Sequence analysis of abaI gene from isolate S117 ............................. 133 
Figure 3.30: NCBI Genbank submission of abaI gene (Accession number 
HQ013310) ........................................................................................... 134 
Figure 3.31: Blue-white selection of the E.coli transformants carrying the abaI 
gene ....................................................................................................... 136 
Figure 3.32: Colony PCR of E. coli transformants for confirmation of the 
presence of abaI gene ........................................................................... 137 
Figure 3.33: EcoRI fast digestion of the recombinant plasmid DNA ...................... 137 
Figure 3.34: Conjugants with abaI::Tc mutant ....................................................... 138 
Figure 3.35: Confirmation of the abaI:Tc mutant by colony PCR for tet gene ....... 139 
Figure 3.36a: Biofilm formation of the wild type abaI and abaI::Tc mutant in 
microtiter plate ...................................................................................... 141 
Figure 3.36b: Mutation complementation experiment ............................................ 141 
Figure 3.37: PCR amplication of the soil bacterial isolates for the presence of 
16S rDNA gene specific for the genus Bacillus. ................................... 143 
  LIST OF FIGURES  
 
xv 
 
Figure 3.38: PCR detection of the soil bacterial Bacillus sp. isolates (B1 and 
B2) for the presence of aiiA homologue gene (coding for AHL-
degrading enzyme). ............................................................................... 143 
Figure 3.39: Bioassay for the detection of AHL-degrading enzyme activity of 
the soil Bacillus sp. isolates B1 and B2. ............................................... 145 
Figure 3.40: Biofilm formation in Acinetobacter spp. isolates treated with the 
soil Bacilli extracts (24 hrs) .................................................................. 147 
Figure 3.41: Biofilm formation in Acinetobacter spp. isolates treated with the 
soil Bacilli extracts (48 hrs) .................................................................. 147 
Figure 3.42: Anti-QS activity using Chromobacterium violaceum CV026 
monitor system. ..................................................................................... 150 
Figure 3.43: Biofilm formation in Acinetobacter spp. isolates treated with the 
extracts from Phyllanthus species, garlic and lemon. ........................... 151 
 
  
  LIST OF TABLES  
 
 
 
 
 
LIST OF TABLES 
Table 1.1: Delineation of Acinetobacter genomic species ........................................... 4 
Table 1.2 Intrinsic Mechanisms of Antibiotic Resistance in Acinetobacter 
baumannii .................................................................................................... 22 
Table 1.3 Acquired Resistance Mechanisms to Antibiotics in Acinetobacter 
baumannii .................................................................................................... 23 
Table 2.1: Chromatographic conditions. ...................................................................... 61 
Table 2.2: DMRM List used for quantification. .......................................................... 62 
Table 2.3: Parameters for amplification of abaI gene. ................................................. 64 
Table 2.4. Bioinformatics tools, websites and their functions. .................................... 65 
Table 2.5: Components of the cloning reaction. .......................................................... 68 
Table 2.6: Reaction components used for the restriction digestion of the 
recombinant plasmid. .................................................................................. 71 
Table 2.7: NEBcutter V2.0 analysis of the abaI gene for the selection of the 
restriction enzyme for blunt end ligation. .................................................... 73 
Table 2.8: Reaction components used for the restriction digestion of the 
recombinant plasmid. .................................................................................. 74 
Table 2.9: Reaction components used for the dephosphorylation of the 
restriction digested recombinant plasmid. ................................................... 75 
Table 2.10: Reaction components used for the ligation of restriction digested 
abaI gene and tetracycline gene cassette. .................................................... 75 
Table 2.11: Parameters for amplification of tetracycline gene. ................................... 77 
Table 2.12.: Parameters for amplification of 16S rDNA gene of Bacillus spp. ........... 80 
Table 2.13.: Parameters for amplification of aiiA gene of Bacillus spp. ..................... 81 
Table 3.1: Strain number, patient number, ward, source and date of isolation of                     
50 Acinetobacter spp. isolates. .................................................................... 88 
Table 3.2: Comparison of biochemical test among family members of 
Enterobacteriaceae and Non-Enterobacteriaceae. ..................................... 92 
Table 3.3: Table showing the extraction efficiencies of the test isolates. .................... 103 
Table 3.4: Initial quantification results expressed in micromolar (µM) ...................... 110 
Table 3.5: Homology percentages of the abaI region in Acinetobacter spp. 
(S117) .......................................................................................................... 126 
Table A1.1: Selected compounds with observed mass, retention time and 
observed fragment ion in sample 1. ............................................................. 206 
Table A1.2: Full list of compounds found in Sample 1 ............................................... 206 
Table A1.3: Selected compounds with observed mass, retention time and 
observed fragment ion in sample 11. ........................................................... 208 
Table A1.4: Full list of compounds found in Sample 11 ............................................. 208 
  LIST OF TABLES  
 
xvii 
 
Table A1.5: Selected compounds with observed mass, retention time and observed 
fragment ion in sample 53. .......................................................................... 210 
Table A1.6: Fill list of compounds found in Sample 53 .............................................. 210 
Table A1.7: Selected compounds with observed mass, retention time and observed 
fragment ion in sample 54. .......................................................................... 212 
Table A1.8: Full list of compounds found in Sample 54. ............................................ 212 
Table A1.9: Selected compounds with observed mass, retention time and observed 
fragment ion in sample 93. .......................................................................... 213 
Table A1.10: Full list of extracted compounds found in Sample 93 ........................... 214 
Table A1.11: Selected compounds with observed mass, retention time and observed 
fragment ion in sample 102. ........................................................................ 215 
Table A1.12: Full list of extracted compounds found in Sample 102. ........................ 216 
Table A1.13: Selected compounds with observed mass, retention time and observed 
fragment ion in sample 117. ........................................................................ 217 
Table A1.14: Full list of extracted compounds found in Sample 117 ......................... 217 
 
 
 
 
LIST OF OF SYMBOLS AND ABBREVIATIONS 
 
 
 
 
 
 
LIST OF SYMBOLS AND ABBREVIATIONS 
µg microgram 
µl microliter 
µM micromolar 
µm micromole 
bp base pair 
g gram 
L/ min Litre per minute 
M molar 
m/ z mass- to- charge ratio 
ml milliliter 
mM milimolar 
mm millimeter 
nM nanomolar 
nm nanometer  
ºC degree Celcius 
U unit 
V volt 
v/ v volume/ voloume 
vs. versus 
ABC Acinetobacter baumannii- calcoaceticus complex 
ACN acetonitrile  
AHLs acyl homoserine lactones 
ARDRA  amplified ribosomal DNA restriction analysis 
BLAST basis local alignment search tool 
CFU colony forming units 
CIP calf intestinal phosphatase 
CviR  Chromobacterium violaceum repressor 
dATP 2‘- deoxyadenosine triphosphate 
DHL N- Decanoyl homoserine lactone 
DMRM Dynamic multiple reaction monitor 
LIST OF OF SYMBOLS AND ABBREVIATIONS 
xix 
 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleotide triphosphate 
EDTA ethylene diamine tetraacetic acid 
FA formic acid 
HHL N- Hexanoyl homoserine lactone 
HPLC High- performance liquid chromatography 
ICUs Intensive care units 
IPTG isopropyl-beta-D-thiogalactopyranoside 
LB  Luria-Bertani 
LPS lipopolysaccharide  
MS  mass spectrometry  
NA nutrient agar 
NCBI National Centre for Biotechnology Information 
OD optical density 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR  polymerase chain reaction 
Rf retention factor 
RNA ribonucleic acid 
Rpm rotation per minute 
TAE tris-acetic EDTA 
TLC thin layer chromatography 
UMMC University Malaya Medical Centre 
X-gal 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
Introduction 
1 Introduction
INTRODUCTION 
 
    
Page: 2 
 
1.1 Taxonomy and epidemiology of Acinetobacter spp. 
 Acinetobacter spp. are gram negative aerobic coccobacilli. The members placed 
under this genus have a long history of taxonomic changes. Taxonomic changes 
occurred frequently with increasing knowledge of the characteristics of the 
microorganisms and with the emergence of new genetic analysis tools. Thus, the 
taxonomic place of some species among a group was often changing and these were 
published in the subsequent editions of Bergey’s Manual of Determinative Bacteriology, 
the reference book for bacteriology.  
 A series of Gram-negative bacilli within a similar morphology exhibited divergent 
biochemical tests, conditions of growth, epidemiology, and pathogenic roles which 
varied with different potential sites in human or in different environmental sites. 
Technical uncertainties made the identification and classification of these organisms 
difficult. Thus, these Gram-negative bacteria remained unclassified for a long time. 
Some of these bacteria were designated as Bacterium anitratum (Schaub et al, 1948); 
Herellea vaginicola and Mima polymorpha (DeBord, 1939); or Achromobacter, 
Alcaligenes, Neisseria, Micrococcus calcoaceticus, Diplococcus, B5W, and Cytophaga 
(Juni, 1972). The common characteristics of these organisms were that they were all 
Gram negative and all of them were strict aerobes. With some of these organisms a 
confusing morphology in Gram stained preparations has contributed towards the 
difficulty in identifying and classifying these bacteria. They appear as coccoid or 
coccobacilli cells with a trend toward diplococcic arrangement which make them look 
like Neisseria spp. That‘s why these bacteria were designated as Micrococcus and 
Diplococcus earlier. In the same time two other species, Moraxella glucidolytica and 
Moraxella lwoffi were recognized. This was the beginning of the classification of these 
aerobic Gram-negative bacilli. The final designation Acinetobacter was proposed by 
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Brisou in 1957 and confirmed by the Subcommittee of the Taxonomy of Moraxella and 
allied bacteria. The genus Acinetobacter was definitively accepted in the Bergey’s 
Manual of Determinative Bacteriology only in June 1984.  
 The genus Acinetobacter, as currently defined, comprises gram-negative, strictly 
aerobic, nonfermenting, nonfastidious, nonmotile, catalase-positive, oxidase-negative 
bacteria with a DNA G-C content of 39% to 47%. Based on more recent taxonomic 
data, it was proposed that member of the genus Acinetobacter should be classified in the 
new family Moraxellaceae within the order Gammaproteobacteria, which includes the 
genera Moraxella, Acinetobacter, Psychrobacter, and related organisms (Rossau et al., 
1991). There was a major breakthrough in the history of the genus Acinetobacter was 
achieved in 1986 by Bouvet and Grimont, who, based on DNA-DNA hybridization 
studies, distinguished 12 DNA (hybridization) groups or genospecies. Some of these 
genospecies were given formal species names, including A. baumannii, A. 
calcoaceticus, A. haemolyticus, A. johnsonii, A. junii, and A. lwoffii (Bouvet and 
Grimont, 1986). Work done by some of the researchers (Bouvet and Jeanjean, 1989; 
Tjernberg and Ursing, 1989; Nishimura et al, 1987) resulted in the description of further 
Acinetobacter genomic species, including the named species A. radioresistens, which 
corresponds to Acinetobacter genomic species 12 described previously (Bouvet and 
Grimont, 1986). Some of the independently described (genomic) species turned out to 
be synonyms, for example, A. lwoffii and Acinetobacter genomic species 9 or 
Acinetobacter genomic species 14, described by Bouvet and Jeanjean (14BJ), and 
Acinetobacter genomic species 13, described by Tjernberg and Ursing (13TU). More 
recently, 10 additional Acinetobacter species were described, including 3 species of 
human origin, A. parvus, A. schindleri, and A. ursingii (Nemec et al., 2003; Nemec et 
al., 2001), and 7 species isolated from activated sludge, A. baylyi, A. bouvetii, A. 
grimontii, A. tjernbergiae, A. towneri, A. tandoii, and A. gerneri (Carr et al., 2003; 
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Anton et al., 2008), increasing the actual number of validly described (genomic) species 
to 31, of which 17 have been given valid species names (Table 1.1). Four of the above 
listed species, A. calcoaceticus, A. baumannii, Acinetobacter genomic species 3, and 
Acinetobacter genomic species 13TU, are very closely related and difficult to 
distinguish from each other by phenotypic properties. It has therefore been proposed to 
refer to these species as the A. calcoaceticus-A. baumannii complex (Gerner-Smidt, 
1992; Gerner-Smidt et al., 1991). However, this group of organisms comprises not only 
the three most clinically relevant species, A. baumannii, Acinetobacter genomic species 
3, and Acinetobacter genomic species 13TU, but also an environmental species, A. 
calcoaceticus, that has frequently been recovered from soil and never been implicated in 
serious clinical disease.   
 
Table 1.1: Delineation of Acinetobacter genomic species  
 
Species name Genomic species number Type strain 
A. baumannii  2 ATCC 19606 
A. baylyi   DSM 14961 
A. bouvetii   DSM 14964 
A. calcoaceticus 1 ATCC 23055 
A. gerneri   DSM 14967 
A. grimontii   DSM 14968 
A. haemolyticus  4 ATCC 17906 
A. johnsonii  7 ATCC 17909 
A. junii  5 ATCC 17908 
A. lwoffii 8/9 ACTC 15309; ATCC 9957 
A. parvus   NIPH384 
A. radioresistens 12 IAM 13186 
A. schindleri  NIPH1034 
A. tandoii   DSM 14970 
A. tjernbergiae   DSM 14971 
A. towneri   DSM 14962 
A. ursingii   NIPH137 
A. venetianus   ATCC 31012 
 3 ATCC 19004 
 6 ATCC 17979 
 10 ATCC 17924 
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11 ATCC 11171 
 13TU ATCC 17903 
 13BJ, 14TU ATCC 17905 
 14BJ CCUG 14816 
 15BJ SEIP 23.78 
 15TU M 151 
 16 ATCC 17988 
 17 SEIP Ac87.314 
 Between 1 and 3 10095 
 Close to 13TU 10090 
 
(Adapted from Anton et al., 2008) 
 
 Members of the genus Acinetobacter are considered ubiquitous organisms. This is 
true as acinetobacters can be recovered after enrichment culture from virtually all 
samples obtained from soil or surface water (Baumann, 1968a). These earlier findings 
have contributed to the common misconception that A. baumannii is also ubiquitous in 
nature (Fournier and Richet, 2006). In fact, not all species of the genus Acinetobacter 
have their natural habitat in the environment. However, a systematic study to investigate 
the natural occurrence of the various Acinetobacter species in the environment has 
never been performed. Most Acinetobacter species that have been recovered from 
human clinical specimens have at least some significance as human pathogens (Seifert 
et al., 1993; Seifert et al., 1994). Acinetobacters are part of the human skin flora. In an 
epidemiological survey performed to investigate the colonization of human skin and 
mucous membranes with Acinetobacter species, up to 43% of nonhospitalized 
individuals were found to be colonized with these organisms (Seifert et al., 1997). The 
most frequently isolated species were A. lwoffii (58%), A. johnsonii (20%), A. junii 
(10%), and Acinetobacter genomic species 3 (6%). In a similar study, a carrier rate of 
44% was found for healthy volunteers, with A. lwoffii (61%), Acinetobacter genomic 
species 15BJ (12%), A. radioresistens (8%), and Acinetobacter genomic species 3 (5%) 
being the most prevalent species (Berlau et al., 1999b). In patients hospitalized on a 
Table 1.1 Continued 
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regular ward, the carriage rate of Acinetobacter species was even higher, at 75% (Seifert 
et al., 1997). The fecal carriage of Acinetobacter was studied and found a carrier rate of 
25% among healthy individuals, with A. johnsonii and Acinetobacter genomic species 
11 predominating (Dijkshoorn et al., 2005). In contrast, A. baumannii, the most 
important nosocomial Acinetobacter species, was found only in 0.5% and 3% on human 
skin (Berlau et al., 1999b; Seifert et al., 1997) and in human feces (0.8%) (Dijkshoorn 
et al., 2005), and Acinetobacter genomic species 13TU was not found at all (Berlau et 
al., 1999b; Dijkshoorn et al., 2005; Seifert et al., 1997). More recently, the nares of 
healthy U.S. soldiers were investigated and acinetobacters were not found, but they did 
not use enrichment culture to increase the recovery rate (Griffith et al., 2006). In a 
subsequent study, Griffith et al. did not detect skin carriage of the A. calcoaceticus-A. 
baumannii complex among a representative sample of 102 U.S. Army soldiers deployed 
in Iraq, but again, they performed cultures without enrichment and with an extremely 
long transport time that may have contributed to this finding (Griffith et al., 2007). 
Notably, in tropical climates, the situation may be different. In Hong Kong, it was found 
that 53% of medical students and new nurses were colonized with acinetobacters in 
summer versus 32% in winter (Chu et al., 1999). Such a seasonal variability in skin 
colonization may contribute to the seasonal variation seen in the prevalence of A. 
baumannii in clinical samples (McDonald et al., 1999). Acinetobacter genomic species 
3 (36%), Acinetobacter genomic species 13TU (15%), Acinetobacter genomic species 
15TU (6%), and A. baumannii (4%) were the most frequently recovered species, while 
A. lwoffii, A. johnsonii, and A. junii were only rarely found. Although various 
Acinetobacter species have been isolated from animals and A. baumannii was 
occasionally found as an etiologic agent in infected animals (Francey et al., 2000; 
Vaneechoutte et al., 2000), the normal flora of animals has never been studied 
systematically for the presence of acinetobacters. A. baumannii was recovered from 
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22% of body lice sampled from homeless people (La Scola et al., 2004). The inanimate 
environment has also been studied for the presence of acinetobacters. Berlau et al. 
investigated vegetables in the United Kingdom and found that 30 of 177 vegetables 
(17%) were culture positive for Acinetobacter (Berlau et al., 1999a). Interestingly, A. 
baumannii and Acinetobacter genomic species 11 (each at 27%) were the predominant 
species, followed by A. calcoaceticus and Acinetobacter genomic species 3 (each at 
13%), while Acinetobacter genomic species 13 was found only once. In Hong Kong, 
51% of local vegetables were culture positive for Acinetobacter species, the majority of 
which were Acinetobacter genomic species 3 (75%), but one sample grew A. baumannii 
(Houang et al., 2001). They also found acinetobacters in 22 of 60 soil samples in Hong 
Kong, and the most frequent species were Acinetobacter genomic species 3 (27%) and 
A. baumannii (23%), with only one sample yielding A. calcoaceticus (Houang et al., 
2001). Some recently described Acinetobacter species are A. baylyi, A. bouvetii, A. 
grimontii, A. tjernbergiae, A. towneri, and A. tandoii. These were isolated from 
activated sludge and are environmental species and have never been found in humans 
(Carr et al., 2003). In contrast, two other recently described species, A. schindleri and A. 
ursingii, have been recovered only from human specimens, while A. parvus was found 
in humans and was also cultured from a dog (Dortet et al., 2006; Nemec et al., 2001; 
Nemec et al., 2003). In conclusion, although available data derive from only a few 
studies, some Acinetobacter species indeed seem to be distributed widely in nature. A. 
calcoaceticus is found in water and soil and on vegetables; Acinetobacter genomic 
species 3 is found in water and soil, on vegetables, and on human skin; A. johnsonii is 
found in water and soil, on human skin, and in human feces; A. lwoffii and A. 
radioresistens are found on human skin; and Acinetobacter genomic species 11 is found 
in water and soil, on vegetables, and in the human intestinal tract. The natural habitats 
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of both A. baumannii and Acinetobacter genomic species 13TU still remain to be 
defined. 
As it is a multi-drug resistant organism, infections are difficult to treat (Falagas and 
Karveli, 2007), resulting in mortalities of 23% for hospitalised patients and 43% for 
patients under intensive care
 
(Falagas et al., 2006). The Antimicrobial Availability Task 
Force of the infectious Diseases Society of America recently identified A.baumannii, 
along with Aspergillus spp., extended–spectrum β-lactamase producing 
Enterobacteriaceae, Vancomycin-resistant Enterococcus faecium, Pseudomonas 
aeruginosa and methicillin-resistant Staphylococcus aureus, as ‗particularly 
problematic pathogens‘ for which there is a desperate need for new drug development 
(Talbot, 2006). Similarly, the SENTRY Antimicrobial Surveillance Program lists 
Acinetobacter spp. as the causative agent in 2.3 to 3.0% of health care-associated 
pneumonia and as the eighth most common pathogen (4.0%) isolated from ICU patients 
worldwide (Jones, 2003). Thus, Acinetobacter spp. is emerging as an increasingly 
important multidrug resistant pathogen, spreading in hospitals, and causing severe 
adverse outcomes. Besides that, Acinetobacter spp. seems to be spreading from hospital 
to hospital, and it has caused endemic infections in various geographical areas through 
multiple hospital outbreaks. It has become a leading nosocomial pathogen in many 
hospitals as compared to other non-fermenting Gram-negative bacilli.  
1.2 Phenotypic and genotypic characteristics of Acinetobacter spp.  
 The genus Acinetobacter originally (Brisou, 1957; Brisou and Pre´vot, 1954; 
Pie´chaud et al., 1956) included a heterogeneous collection of nonmotile, gram-
negative, oxidase-positive, and oxidase-negative saprophytes that could be 
distinguished from other bacteria by their lack of pigmentation (Ingram and Shewan, 
1960). Extensive nutritional studies (Baumann et al.,1968b) showed clearly that the 
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oxidase-negative strains differed from the oxidase- positive strains, and in 1971, the 
Subcommittee on the Taxonomy of Moraxella and Allied Bacteria recommended that 
the genus Acinetobacter comprise only oxidase-negative strains (Lessel, 1971). This 
division has been supported by the use of transformation tests (Juni, 1972), which have 
now been used for over two decades as the basis for inclusion of individual isolates 
within the genus. 
 Acinetobacters are short, plump, gram-negative rods, typically 1.0 to 1.5 by 1.5 to 
2.5 mm in the logarithmic phase of growth but often becoming more coccoid in the 
stationary phase (Figure 1.1). They are often seen as pairs or clusters of cells. Variations 
in Gram staining (sometimes does not destain), variations in cell size and arrangement, 
can often be observed within a single pure culture (Baumann et al., 1968b). 
Acinetobacter spp. normally form smooth, sometimes mucoid, pale yellow to greyish-
white colonies on solid media, although some environmental strains that produce a 
diffusible brown pigment have been described (Pagel and Seyfried, 1976). The colonies 
are comparable in size to those of enterobacteria. All members of the genus are strict 
aerobes, oxidase negative, catalase positive, and nonfermentative. It is the negative 
oxidase test that serves as a rapid presumptive test to distinguish Acinetobacter spp. 
from otherwise similar nonfermentative bacteria. Most strains are unable to reduce 
nitrate to nitrite in the conventional nitrate reduction assay. Some clinical isolates, 
particularly those belonging to genomic species 4 (A. haemolyticus), may show 
hemolysis on sheep blood agar plates.  
 Most of the Acinetobacter strains can grow in a simple mineral medium 
containing a single carbon and energy source. A wide variety of organic compounds can 
be used as carbon sources, although relatively few strains can use glucose (Baumann et 
al., 1968b), but no single metabolic test enables unambiguous differentiation of this 
genus from other similar bacteria. Clinical isolates can grow at 37C, but some 
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environmental isolates prefer incubation temperatures of between 20 to 30C. However, 
only A. baumannnii are able to grow at a higher temperature of 44C which is the basis 
of differentiation between A. baumannii and A. calcoaceticus (Bouvet and Grimont, 
1987). 
Figure 1.1: Scanning electron micrograph of A. baumannii type strain ATCC 
19606. (Final magnification, 318,000). 
 
(Adapted from Bergogne and Towner, 1996). 
    A scheme of 28 phenotypic tests that claimed to discriminate between 11 of the 
initial 12 genomic species described was originally proposed (Bouvet and Grimont, 
1986). Following this, a simplified scheme of 16 tests which, except for tests for 
glucose acidification and detection of hemolysis on sheep blood agar, comprised growth 
temperature and carbon source utilization was described (Bouvet and Grimont, 1987). 
However, these tests failed to differentiate between closely related genomic species. A 
more detailed and successful phenotypic identification scheme has been described 
(Ka¨mpfer et al., 1993), but it seems that single or even a few tests cannot be used for 
unambiguous phenotypic identification of the different genomic species of 
Acinetobacter. 
 As far as commercial identification systems are concerned, the widely used API 
20NE system, based largely on carbon source assimilation tests, contained only A. 
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baumannii, A. haemolyticus, and A. lwoffii in the 1993 database release, together with A. 
junii and A. johnsonii as a combination, whereas the type species A. calcoaceticus and 
the other genomic species were not included at all. This system sometimes has problems 
with sensitivity and reproducibility (Kropec et al., 1993). Indeed, two studies comparing 
the API 20NE system with species identification by DNA-DNA hybridization have 
demonstrated a poor correlation (Horrevorts et al., 1995; Weernink et al., 1995). 
Another commercial system, Biolog, differentiates bacteria on the basis of their 
oxidation of 95 different carbon sources and this system has been shown to give 
promising results for those strains that have been previously identified by DNA-DNA 
hybridization (Bernards et al., 1995).  
 Among the few methods that have been validated for identification of 
Acinetobacter species, DNA-DNA hybridization remains the standard method (Bouvet 
and Grimont, 1986). The phenotypic identification scheme proposed in 1986 is based on 
28 phenotypic tests (Bouvet and Grimont, 1986). This identification scheme was refined 
in 1987 by the same authors and includes growth at 37°C, 41°C, and 44°C; production 
of acid from glucose; gelatine hydrolysis; and assimilation of 14 different carbon 
sources (Bouvet and Grimont, 1987). This method does not permit identification of the 
more recently described genomic species. In particular, the closely related and clinically 
most relevant species A. baumannii and Acinetobacter genomic species 13TU cannot be 
distinguished, while A. calcoaceticus and Acinetobacter genomic species 3 can only be 
separated by their growth properties at different temperatures (Gerner-Smidt et al., 
1991). Unfortunately, simple phenotypic tests that are commonly used in routine 
diagnostic laboratories for identification of other bacterial genera to the species level are 
unsuitable for unambiguous identification of even the most common Acinetobacter 
species. Both DNA-DNA hybridization and the phenotypic identification system of 
Bouvet and Grimont are laborious and far from being suitable for routine microbiology 
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laboratories. Molecular methods that have been developed and validated for 
identification of acinetobacters include amplified 16S rRNA gene restriction analysis 
(ARDRA) (Vaneechoutte et al., 1995; Dijkshoorn et al., 1998; Wong et al., 2010), 
high-resolution fingerprint analysis by amplified fragment length polymorphism 
(AFLP) (Nemec et al., 2001; Janssen & Dijkshoorn, 1996), ribotyping (Gerner-Smidt, 
1992), tRNA spacer fingerprinting (Ehrenstein et al., 1996), restriction analysis of the 
16S-23S rRNA intergenic spacer sequences (Dolzani et al., 1995), sequence analysis of 
the 16S-23S rRNA gene spacer region (Chang et al., 2005), and sequencing of the rpoB 
(RNA polymerase β-subunit) gene and its flanking spacers (La Scola et al., 2006). 
ARDRA and AFLP analysis are currently the most widely accepted and validated 
reference methods for species identification of acinetobacters. Both ribotyping and 
sequence analysis of the 16S-23S rRNA gene spacer region were found to discriminate 
between species of the A. calcoaceticus- A. baumannii complex but have not been 
applied to other Acinetobacter species. All of these methods have contributed to a better 
understanding of the epidemiology and clinical significance of Acinetobacter species 
during recent years, but they are too laborious to be applied in routine diagnostic 
microbiology, and their use for the time being is also confined mainly to reference 
laboratories. More recent developments include the identification of A. baumannii by 
detection of the blaOXA-51-like carbapenemase gene intrinsic to this species (Turton et 
al., 2006), PCR-electrospray ionization mass spectrometry (PCR–ESI-MS) (Ecker et 
al., 2006), and a simple PCR-based method (Higgins et al., 2007) that exploits 
differences in their respective gyrB genes to rapidly differentiate between A. baumannii 
and Acinetobacter genomic species 13TU. Promising results with matrix-assisted laser 
desorption ionization–time-of-flight MS have been obtained for species identification of 
552 well characterized Acinetobacter strains representing 15 different species (Seifert et 
al., 2007). Matrix-assisted laser desorption ionization–time-of-flight MS allows for 
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species identification in less than 1 hour, but it requires expensive equipment and needs 
further evaluation. Species identification with manual and semiautomated commercial 
identification systems that are currently used in diagnostic microbiology, such as the 
API 20NE, Vitek 2, Phoenix, and MicroScan WalkAway systems, remains problematic 
(Bernards et al., 1995; Bernards et al., 1996; Horrevorts et al., 1995). This can be 
explained in part by their limited database content but also because the substrates used 
for bacterial species identification have not been tailored specifically to identify 
acinetobacters. In particular, the three clinically relevant members of the A. 
calcoaceticus-A. baumannii complex cannot be separated by currently available 
commercial identification systems. A. baumannii, Acinetobacter genomic species 3, and 
Acinetobacter genomic species 13TU share important clinical and epidemiological 
characteristics (Dijkshoorn et al., 1993; Lim et al., 2007; Seifert and Gerner-Smidt. 
1995). From a clinical and infection control point of view, it is necessary to distinguish 
between the A. baumannii group and acinetobacters outside the A. baumannii group 
since the latter organisms rarely have infection control implications. In addition, these 
organisms are usually susceptible to a range of antimicrobials, and infections caused by 
these organisms are most often benign. In research it is necessary that proper methods 
for species identification of acinetobacters, including those within the A. baumannii 
group, are mandatory to increase our knowledge of the epidemiology, pathogenicity, 
and clinical impact of the various species of this genus.  
1.3 Emergence of nosocomial infections caused by Acinetobacter spp.  
 The majority of A. baumannii isolates are from the respiratory tracts of 
hospitalized patients. In many circumstances, it is very difficult to distinguish upper 
airway colonization from true pneumonia. There is no doubt, however, that true 
ventilator-associated pneumonia (VAP) due to A. baumannii is reported. In large 
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surveillance studies from the United States, between 5 and 10% of cases of ICU-
acquired pneumonia were due to A. baumannii (Gaynes and Edwards, 2005). Patients 
with A. baumannii infections have had prolonged ICU stays (Garnacho et al., 2005). 
Community-acquired pneumonia due to A. baumannii has been described for tropical 
regions of Australia and Asia (Anstey et al., 2002; Anstey etal., 1992; Bick and Semel, 
1993; Gottlieb and Barnes, 1989;  Leung et al., 2006). The disease most typically 
occurs during the rainy season among people with a history of alcohol abuse and may 
sometimes require admission to an ICU (Anstey et al., 2002). It is characterized by a 
fulminant clinical course, secondary bloodstream infection, and mortality rate of 40 to 
60% (Leung et al., 2006). The source of infection may be throat carriage, which occurs 
in up to 10% of community residents with excessive alcohol consumption (Anstey et 
al., 2002).  
 A. baumannii was the 10th most common etiologic agent of bloodstream infection 
in a large study in the United States (1995–2002). They were responsible for 1.3% of all 
monomicrobial nosocomial bloodstream infections (Wisplinghoff et al., 2004). A. 
baumannii was a more common cause of ICU-acquired bloodstream infection than of 
non-ICU-ward infection. Crude mortality overall from A. baumannii bloodstream 
infection was 34.0% to 43.4% in the ICU and 16.3% outside the ICU. A. baumannii 
bloodstream infection had the third highest crude mortality rate in the ICU, exceeded 
only by P. aeruginosa and Candida sp. infections. A. baumannii infections were the 
latest of all bloodstream infections to occur during hospitalization (Wisplinghoff et al., 
2004). It is notable that 102 patients had bloodstream infections at sites treating U.S. 
military members injured in Iraq or Afghanistan from 1 January 2002 and 31 August 
2004 (CDC, 2004). The sites of origin of these infections were not described in this 
report.  
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 A. baumannii may occasionally cause skin/soft tissue infections outside of the 
military population. The organism caused 2.1% of ICU-acquired skin/soft tissue 
infections in one assessment (Gaynes and Edwards, 2005). It is a well-known pathogen 
in burn units and may be difficult to eradicate from such patients (Trottier et al., 2007). 
However, its contribution to poor outcome in burn patients is debated (Albrecht et al., 
2006, Wisplinghoff et al., 1999). A. baumannii is commonly isolated from wounds of 
combat casualties from Iraq or Afghanistan (Johnson et al., 2007; Murray et al., 2006; 
Petersen et al., 2007; Scott et al., 2007; Whitman, 2007; Yun et al., 2006). It was the 
most commonly isolated organism (32.5% of cases) in one assessment of combat 
victims with open tibial fractures (Johnson et al., 2007).  
 A. baumannii is an occasional cause of UTI, being responsible for just 1.6% of 
ICU-acquired UTIs in one study (Gaynes and Edwards, 2005). Typically, the organism 
is associated with catheter associated infection or colonization. It is not usual for this 
organism to cause uncomplicated UTI in healthy outpatients. 
 Nosocomial, postneurosurgical A. baumannii meningitis is an increasingly 
important entity. The microbial epidemiology of nosocomial meningitis is evolving to 
include more gram negative pathogens (Briggs et al., 2004; Durand et al., 1993; 
Palabiyikoglu et al., 2006; Siegman et al., 1993) and thus multidrug-resistant A. 
baumannii is included among the pathogens implicated (Metan et al., 2007; Nguyen et 
al., 1994; Nunez et al., 1998; O‘Neill et al., 2006). Typical patients have undergone 
neurosurgery and have an external ventricular drain (Metan et al., 2007). Mortality may 
be as high as 70%. There is a report of neurosurgically related nosocomial 
Acinetobacter baumannii meningitis (Krol et al., 2009). 
 A small number of case reports of Acinetobacter endocarditis exist (Menon et al., 
2006; Olut and Erkek, 2005; Rizos et al., 2007; Starakis et al., 2006; Valero et al., 
1999). Most of the cases have involved prosthetic valves. Acinetobacter spp. may cause 
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endophthalmitis or keratitis, sometimes related to contact lens use or following eye 
surgery (Corrigan et al., 2001; Kau et al., 2002; Levy et al., 2005; Lindbohm et al., 
2005). A single case report exists of a Shiga toxin-producing A. haemolyticus strain, 
which was associated with bloody diarrhea in a 3-month-old infant (Grotiuz et al., 
2006).  
1.4 Treatment of Acinetobacter spp. infections 
 There are many reports that have documented the high rates of antibiotic 
resistance in Acinetobacter spp. (Bergogne-Be´re´zin and Joly-Guillou, 1985; Buisson 
et al., 1990; French et al., 1980; Joly-Guillou et al., 1992; Larson, 1984; Belkum, 1993; 
Bou et al., 2000; Quale et al., 2003; Wong et al., 2010; Wong et al., 2009; Neonakis et 
al., 2011).  
 The emergence of frequent multiple antibiotic resistance exhibited by nosocomial 
Acinetobacter spp. and the resulting therapeutic problems involved in treating patients 
with nosocomial infections in ICUs is of particular concern. Thus far, carbapenems have 
been thought of as the agents of choice for serious A. baumannii infections. However, 
although these drugs are still active against the vast majority of A. baumannii strains 
worldwide, the clinical utility of this class of antimicrobial is increasingly being 
jeopardized by the emergence of both enzymatic and membrane-based mechanisms of 
resistance (Bou et al., 2000; Quale et al., 2003).  Sulbactam is one of three 
commercially available β-lactamase inhibitors. Unlike clavulanic acid and tazobactam, it 
has clinically relevant intrinsic antimicrobial activity against certain organisms, 
specifically Acinetobacter (Brauers et al., 2005; Corbella et al., 1998; Higgins et al., 
2004; Levin et al., 2002; Levin et al., 2003; Obana et al., 1990; Rodriguez et al., 2001) 
and Bacteroides spp. (Williams, 1997) which is mediated by its binding to penicillin-
binding protein 2 (Noguchi and Gill, 1988). Sulbactam is commercially available in a 
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combined formulation with either ampicillin or cefoperazone and also as a single agent 
in France, Germany, and Spain (Brauers et al., 2005; Levin, 2002). Studies assessing 
the activity of sulbactam alone compared to its combination with a β-lactam clearly 
demonstrate the intrinsic activity of the agent rather than its ability to inhibit β-
lactamase (Brauers et al., 2005; Corbella et al., 1998; Higgins et al., 2004).  Efficacy of 
sulbactam to that of imipenem has also been shown for treatment of A. baumannii 
bloodstream infection (Choi et al., 2006; Cisneros et al., 1996; Jellison et al., 2001), 
with one study demonstrating a reduction in pharmaceutical costs (Jellison et al., 2001). 
In a further study, treatment of highly drug-resistant A. baumannii bacteremia 
(susceptible only to sulbactam and polymyxin E) with ampicillin- sulbactam was 
comparable to treatment of more susceptible strains with other therapies, including 
imipenem, aminoglycosides, and quinolones (Smolyakov et al., 2003; Betrosian and 
Douzinas, 2009). These data indicate that when A. baumannii is susceptible to 
sulbactam, this antimicrobial is efficient. There are in vitro studies which have shown 
enhanced activity when sulbactam is combined with cefepime (Sader and Jones, 2005; 
Tong et al., 2006), imipenem (Choi et al., 2004; Song et al., 2007), meropenem (Kiffer 
et al., 2005; Ko et al., 2004), amikacin (Savov et al., 2002), rifampin (Appleman et al., 
2000), and ticarcillin-clavulanate (Joly-Guillou et al., 1995).  
 The emergence of A. baumannii strains resistant to all routinely tested 
antimicrobials has led to the necessary revival of the polypeptide antibiotics known as 
the polymyxins (colistin or polymyxin E and polymyxin B). These positively charged 
antimicrobial peptides were discovered in 1947, originating from Bacillus polymyxa. 
They target the anionic LPS molecules in the outer cell membranes of gram-negative 
bacteria, leading to interactions between the inner and outer cell membranes, with 
associated lipid exchange, membrane disturbance, osmotic instability, and eventual cell 
death (Clausell et al., 2007; Falagas and Kasiakou, 2005). There are two commercially 
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available forms of colistin, namely, colistin sulfate for oral and topical use, and CMS, 
also known as sodium colistin methanesulfonate or colistin sulfomethate sodium, for 
parenteral use (Li et al., 2006a). Both forms are available for nebulization. Our 
understanding of the critical pharmacological parameters that govern dosing for 
maximal efficacy and minimal toxicity is poor. As a consequence, confusion exists 
among clinicians and in the literature regarding formulations, nomenclature, and dosing 
(Falagas and Kasiakou, 2006; Li et al., 2006a; Li et al., 2006b). In vitro, colistin 
demonstrates concentration-dependent bactericidal activity against A. baumannii strains 
with various susceptibility profiles, as determined by time-kill analyses (Montero et al., 
2002; Owen et al., 2007; Rodriguez et al., 2004). Colistin in combination with a 
carbapenem and/or rifampin appears most promising (Giamarellos et al., 2001; Hogg et 
al., 1998; Manikal et al., 2000; Montero et al., 2004; Pantopoulou et al., 2007; Song et 
al., 2007; Tascini et al., 1998; Timurkaynak et al., 2006; Yoon et al., 2004). 
Understandably, in the presence of significant carbapenemase activity, as opposed to 
membrane-based changes (porins and efflux pumps) that are likely disrupted by the 
polymyxins, synergy with carbapenems may be lost (Wareham and Bean, 2006). 
 A concerning void of new therapeutic options exists for A. baumannii infections. 
Of the recently licensed antimicrobials, tigecycline, a 9-t-butylglycylamido 
semisynthetic derivative of minocycline, has provided some hope, but clinical data are 
still limited. As with other tetracycline derivatives, tigecycline inhibits the 30S 
ribosomal subunit (Fluit et al., 2005; Petersen et al., 1999). Thus far, the in vitro activity 
of tigecycline against A. baumannii has been assessed largely by MIC testing. More 
recently, combination therapy with tigecycline has been studied using time-kill and 
Etest synergy methodology (Sands et al., 2007; Scheetz et al., 2007). When it was 
tested against a noncarbapenem- susceptible A. baumannii strain, tigecycline alone 
allowed maximal killing at concentrations near the MIC, which was 1 g/ml, with no 
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benefit of using higher concentrations (Scheetz et al., 2007). There are reports for 
effective control of A. baumannii outbreak (Jamal et al., 2009). However, the 
pharmacokinetic considerations exist for the tigecycline treatment (Cunha, 2009). 
Recently fosfomycin for the treatment of infections caused by multidrug-resistant non-
fermenting Gram-negative bacilli has been reported (Falagas et al., 2009). 
 The use of combination therapy to treat multidrug- or pandrug- resistant gram-
negative organisms has become an area of great interest (Rahal, 2006). This strategy 
aims to create an active combination out of two agents to which the organism tests 
nonsusceptible in the laboratory. Apart from trying to improve efficacy, combination 
therapy may also help to prevent the emergence of resistance when at least one agent is 
active in vitro (Chait et al., 2007; Pachon et al., 2006). The studies involving 
combination therapy with either sulbactam or the polymyxins are the most promising 
group. Other combinations have also been studied using in vitro techniques and animal 
models, including various combinations of quinolones, β-lactams, and/or amikacin 
(Bonapace et al., 2000; Chang et al., 1995; Drago et al., 2004; Jung et al., 2004; 
Roussel et al., 1996). The results for quinolone combination therapy are varied, with 
reduced efficacy being described when ciprofloxacin was used for ciprofloxacin-
resistant A. baumannii (Ermertcan et al., 2001), as well as a lack of enhanced activity 
with levofloxacin combined with imipenem or amikacin in a mouse pneumonia model 
(Joly et al., 2000). Interestingly, enhanced activity was seen when aztreonam was tested 
in combination with other β-lactams against a select group of MBL-producing A. 
baumannii strains (Sader et al., 2005).  
 The increasing incidence of multidrug-resistant A. baumannii in addition to a lack 
of new antimicrobial agents has reawakened interest in the utilization of colistin due to 
its good activity against this organism (Katragkou and Roilides, 2005). It has been 
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recently shown that intrathecal colistin is a safe and curative treatment drug for 
multidrug-resistant Acinetobacter spp meningitis (Sahin et al., 2008). Optimal therapy 
for the multi-drug resistant Acinetobacter baumannii has been suggested (Cunha, 2010; 
Fishbain et al., 2010; Garnacho and Amaya, 2010). Also the length of the course of 
treatment has to be minimized for prevention of the development of drug resistance 
(Giamarellou, 2010).  
 In general, the recommended drugs in most recent studies have been extended-
spectrum penicillins, broad-spectrum cephalosporins, or imipenem, combined with an 
aminoglycoside. 
1.5 Resistance mechanisms in Acinetobacter spp. 
 Most Acinetobacter spp. research to date has focused on cataloguing and 
understanding the variety of antimicrobial resistance genes and mechanisms found 
within the species. Since it is largely a nosocomial pathogen, Acinetobacter spp. is 
bombarded by the selective pressure of a broad variety of antibiotics. An overview of 
the intrinsic and acquired mechanisms of antibiotic resistance reported for this organism 
is provided in Table 1.2 and Table 1.3, respectively. In addition, A. baumannii has a 
number of intrinsic mechanisms, including ß-lactamases and efflux pumps, which 
contribute to resistance. 
 Clinical isolates of A. baumannii encodes an array of ß-lactamases. Some of the 
genes encoding these are intrinsic to essentially all isolates of this species and are 
encoded on the chromosome, while the majority of the genes are acquired from other 
species or other Acinetobacter isolates, with the determinants encoded on mobile 
genetic elements. As illustrated in Table 1.2, all isolates of A. baumanii have a 
chromosomally encoded ampC cephalosporinase gene analogous to the species-specific 
ampC gene found in Escherichia coli. Consensus reached from many studies indicates 
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that this ampC gene is not inducible with ß-lactams and is normally expressed at low 
levels (Poirel et al., 2006; Lopez et al., 2001; Perilli et al., 1996).  
 More recent DNA sequence analysis and enzymatic characterization of ampC 
cephalosporinases from various Acinetobacter isolates have led to a more uniform 
designation of these enzymes, defining variants including ADC (for Acinetobacter-
derived cephalosporinases)-1 to -7 (Hujer et al., 2006). Another variant, recently 
characterized from A. baylyi, ADC-8, shares less than 50% amino acid identity with the 
other ADC variants, yet it appears to confer a similar cephalosporin resistance 
phenotype in this species (Beceiro et al., 2007).  
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Table 1.2 Intrinsic Mechanisms of Antibiotic Resistance in Acinetobacter baumannii 
Antibiotic class Resistance gene(s) Antibiotics affected Reference 
ß-lactams  
Penicillins Chromosomally encoded AmpC (basal) Penicillin and ampicillin 
Poirel & Nordmann, 2006; Joly et al., 1988; 
Lopez et al., 2001; Blechschmidt et al., 1992; 
Perilli et al., 1996; Beceiro et al., 2004 
Cephalosporins 
ampC overexpression via insertion 
sequence promoters 
Cephaloridine, cefotaxime and 
ceftazidime 
Beceiro et al., 2007; Segal et al., 2004; Heritier et 
al., 2006 
Chromosomally-encoded bla OXA-51 
Low carbapenemase activity 
Low-level cephalosporin resistance Poirel and Nordmann, 2006 
Changes in penicillin-binding proteins Penicillins and cephalosporins Fernandez et al., 2003 
Loss of porins (e.g., CarO) 
Cephalosporin resistance, particularly 
with overexpression of ampC  
Vila et al., 2007; Siroy et al., 2005; Mussi et al., 
2005 
Overexpression of efflux pump AdeABC High-level cephalosporin resistance Marchand et al., 2004; Ruzin et al., 2007 
Fluoroquinolones 
Point mutations in gyrA alone or combined 
with mutations in parC  
Sequential, multiple mutations elevate 
MICs to all available fluoroquinolones 
Bonomo & Szabo, 2006; Wisplinghoff et al., 2003 
Porin loss and efflux AdeABC 
overexpression with gyrA and parC 
mutations 
High-level resistance to all available 
agents 
Van et al., 2004 
Tigecycline Overexpression of AdeABC efflux pump 
MICs to tigecycline elevated to 4-32 
µg/ml 
Peleg et al., 2007; Navon et al., 2007 
Polymyxin B 
Mutation in genes leading to membrane 
alterations  
Van et al., 2004; Hawley et al., 2007 
Colistin 
Mutations in genes leading to membrane 
changes  
Van et al., 2004; Antoniadou et al., 2007; Hawley 
et al., 2007 
(Adapted from Thomas et al., 2008) 
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Table 1.3 Acquired Resistance Mechanisms to Antibiotics in Acinetobacter baumannii 
Antibiotic class Resistance gene(s) Antibiotics affected Reference 
ß-lactams 
Class A, extended-spectrum ß-lactamase 
genes; TEM-92, VEBv1 and PER  
Penicillins and cephalosporins 
Bonomo & Szabo, 2006; Endimiani et 
al., 2007; Naas et al., 2006; Arduino 
et al., 2002  
Class D, OXA carbapenemases bla 
OXA-23, -24, -25, -26, -27, -40 and -58  
Penicillins, cephalosporins and 
carbapenems  
Poirel and Nordmann, 2006; Brown 
and Amyes, 2006; Brown and Amyes, 
2005; Heritier et al., 2005 
Class B metallo-ß-lactamases 
VIM, IMP and SIM variants 
Primarily carbapenems and some 
cephalosporins  
Poirel and Nordmann, 2006; Lee et 
al., 2005; Ellington et al., 2007; Yong 
et al., 2006 
Tetracyclines Tet(A) efflux pump Resistance to tetracycline 
Van et al., 2004; Vila et al., 2007; 
Ribera et al., 2003 
Tet(B) efflux pump Resistance to tetracycline and minocycline 
 
Van et al., 2004; Vila et al., 2007; 
Ribera et al., 2003 
Aminoglycosides AbeM efflux pump 
Fluoroquinolones and 
aminoglycosides 
Vila et al., 2007 
Acquired genes encoding 
acetyltranserases, 
phosphotransferases and 
nucleotidyltransferases 16S rRNA 
methylation 
All available aminoglycosides depending 
on the modifying enzyme and its level of 
expression 
 
Bonomo & Szabo, 2006; Noppe et al., 
1999; Huys et al., 2005 
Chloramphenicol 
Acquisition of gene encoding 
chlorapmphenicol acetyl transferase 
Chloramphenicol Van et al., 2004 
(Adapted from Thomas et al., 2008)
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 In one study, 42 A. baumannii strains, including strains susceptible (MIC ≤ 8 
µg/ml), intermediate (MIC 32 µg/ml) or highly resistant (MIC ≥ 256 µg/ml) to 
ceftazidime, were examined at the ampC-gene sequence, including regions adjacent to 
its 5'-end. An 1180-bp IS was detected in all the non-susceptible isolates (Corvec et al., 
2003). Since the initial studies describing the acquisition of this IS element fused to the 
ADC gene, additional observations have demonstrated that this arrangement leads to the 
overproduction of cephalosporinase. Cloning and sequencing of this region from the A. 
baumannii strain, RAN, identified several putative promoters in the IS that could 
increase ampC expression (Segal et al., 2004). The IS, now identified as 'IS Aba1-like' 
once inserted ahead of the structural gene, resulted in a single nucleotide change in the 
ribosome binding site (TGAG to GGAG) in the bla AMPC gene (Heritier et al., 2006).  
Apparently, A. baumannii applies this elegant mechanism of ISAba1 for upregulating 
other resistance genes, such as the bla OXA-23 and bla OXA-27 carbapenemases and the 
sulII gene (Segal et al., 2005).
 
 In addition to the presence of the ADC and OXA-51 intrinsic ß-lactamases, 
similar to other Gram-negatives, A. baumannii has a number of acquired bla genes, 
including several Ambler class A serine ß-lactamases (Table 1.3). Many variants of the 
TEM, SHV, VEB, PER and CTX-M enzymes are found occasionally in this organism, 
including many that are extended-spectrum ß-lactamases (ESBLs) with potent activity 
against third-generation cephalosporins (Bonomo and Szabo, 2006; Endimiani et al., 
2007; Sechi et al., 2004; Naas et al., 2006; Walther and Hoiby, 2004; Naas et al., 2007; 
Carbonne et al., 2005; Paterson and Bonomo, 2005). The Ambler class D oxacillinases 
appear to be more widely distributed in clinical strains of A. baumannii (Poirel and 
Nordmann, 2006). A study showed that, of the 39 carbapenem resistant isolates of 
Acinetobacter spp., only 2 harbored a blaIMP-4   carbapenemase and the remaining 37 
isolates were positive for blaOXA (Wong et al., 2010). The OXA carbapenemases found 
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in Acinetobacter have been organized into either three or four subgroups (OXA-23-like, 
OXA-24-like, OXA-51-like and OXA-58) based on their sequence divergence (Brown 
and Amyes, 2005). Outbreaks of MDR acinetobacters where these bla and oxa genes 
are implicated have occurred (Hujer et al., 2006; Bogaerts et al., 2006; Pournaras et al., 
2006; Bertini et al., 2007; Giordano et al., 2007; Navia et al., 2002; Brown et al., 2005; 
Valenzuela et al., 2007; Koh et al., 2007; Zhou et al., 2007; Depardieu et al., 2007).  
 In addition to the Ambler class D carbapenemases, clear evidence exists that the 
Ambler class B metallo-ß-lactamases VIM, IMP and SIM are present in acinetobacters 
(Lee et al., 2005). ß-lactamases have spread widely in populations of A. baumanii, 
including those that can encode carbapenem resistance, leaving few choices for 
effective therapy. The available evidence strongly suggests that additional mechanisms 
of resistance can be found in the same MDR strain, such as overexpressed efflux and 
outer membrane alterations that can augment the level of resistance to important 
antimicrobials.  
 Aminoglycoside resistance is common in clinical isolates of acinetobacters. As 
with other Gram-negative bacilli, the major mechanism of resistance to these agents is 
due to the dissemination of genes encoding aminoglycoside-modifying enzymes 
(Bonomo and Szabo, 2006).  
 Porins are outer membrane proteins that form water-filled pores, allowing the 
access of nutrients and antibiotics into the cell. Acinetobacters can easily downregulate 
porin expression in the presence of antibiotic selective pressure without acquiring new 
genetic material. As discussed in a recent review (Vila et al., 2007), the relatively low 
permeability of Acinetobacter to antibiotics may be due to either a reduced number of 
porins in the outer membrane or their poor diffusion characteristics for small molecules. 
There have been at least five putative porins detected in acinetobacters. The best 
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characterized is the 35,636-Da heat-modifiable protein (HMP-AB). The second most 
characterized putative porin in acinetobacters is the 29-kDa CarO protein (Vila et al., 
2007). Loss of other putative porins of A. baumannii have been implicated in resistance 
to carbapenems, either alone or in combination with efflux systems or carbapenemase 
genes, such as bla OXA (Bou et al., 2000; Limansky et al., 2002; Clark, 1996). A 29-kDa 
OMP has been identified to be the major outer membrane protein in A. baumannii / 
calcoaceticus and loss of this porin and overexpression of IROMPs have been shown to 
contribute to carbapenem resistance (Wong et al., 2010).  
 Efflux of structurally unrelated classes of antibiotics from MDR, Gram-negative 
bacilli is now established as an important mechanism of resistance. The most 
extensively studied efflux system is the AdeABC efflux operon that is under regulation 
by a two-component signal transduction system (Vila et al., 2007; Magnet et al., 2001; 
Marchand et al., 2004; Piddock, 2006). Disruption of the ade gene resulted in lower 
MIC values than the parent strains for ceftazidime, cefotaxime, gentamicin, amikacin, 
ciprofloxacin, amoxicillin and meropenem. Knocking the gene out showed that the 
decrease in the MICs was greater in the mutants lacking adeB gene, adeR gene and adeS 
gene, while all the mutants showed no differences in the MIC values for imipenem as 
compared to the wild-type strains. This shows that the efflux pump has an effect on the 
resistance to meropenem compared to imipenem, and the resistance may be due to 
meropenem upregulating the efflux pump (Wong et al., 2009). The AdeABC efflux 
pump has been implicated in the enhanced resistance to aminoglycosides, ß-lactams, 
chloramphenicol, tetracyclines and fluoroquinolones (Vila et al., 2007). Recent studies 
indicate that the AdeABC efflux pump is implicated in decreased susceptibility to the 
new antimicrobial, tigecycline.  
 The Tet(A), Tet(B) and AbeM efflux pumps (Table 1.2) have also been detected 
in A. baumannii (Vila et al., 2007).  The Tet(A) pump confers resistance to tetracycline, 
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while Tet(B) confers resistance to tetracycline and minocycline, the AbeM pump 
belongs to the MATE family of transporters and its presence has been implicated in 
raising MICs to norfloxacin, ofloxacin, ciprofloxacin and gentamicin. Resistance to 
fluoroquinolones in acinetobacters most commonly results from sequencial 
accumulation of point mutations in the topoisomerase gyrA and parC genes (Bonomo 
and Szabo et al., 2006).  
 Apart from being highly resistant to antibiotics, the members of the Acinetobacter 
spp. are highly resistant to desiccation. These organisms can persist for a long time in 
inanimate surfaces. A. baumannii is one of the most common causes of device-related 
nosocomial infections, possibly because it is able to resist physical and chemical 
disinfection. Biofilm formation is a possible explanation for the resistance to 
desiccation and disinfection. Further, it could also be responsible for an important 
number of the device-related nosocomial infections (Donlan, 2002; Tomaras et al., 
2003). 
1.6  Biofilms   
1.6.1 Biofilm formation  
 
 Biofilms are microbially derived sessile communities characterized by cells that 
are irreversibly attached to a substratum or interface or to each other, are embedded in a 
matrix of extracellular polymeric substances that they have produced, and exhibit an 
altered phenotype with respect to growth rate and gene transcription. A biofilm is 
composed of a congregation of bacterial cells to a solid surface and enclosed within a 
polysaccharide matrix. The basic building block of the biofilm is the microcolony, and 
an elucidation of basic biofilm processes, such as quorum sensing, antimicrobial 
resistance, and detachment and may hinge on an understanding of the physiological 
interactions of microcolonies within a developed biofilm. Confocal laser scanning 
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microscopy (CLSM) observations of living biofilms have shown that this basic 
community structure is universal.  
1.6.2 Resistance to antimicrobial agents 
 The nature of biofilm structure and the physiological attributes of biofilm 
organisms confer an inherent resistance to antimicrobial agents, whether these 
antimicrobial agents are antibiotics, disinfectants, or germicides. Mechanisms 
responsible for resistance may be one or more of the following: (i) delayed penetration 
of the antimicrobial agent through the biofilm matrix, (ii) altered growth rate of biofilm 
organisms, and (iii) other physiological changes due to the biofilm mode of growth. 
 The encased cells in the biofilm matrix can be inactivated by the use of 
antimicrobial molecules only if the antimicrobials diffuse through the matrix. The 
extracellular polymeric substances constituting this matrix present a diffusional barrier 
for these molecules by influencing either the rate of transport of the molecule to the 
biofilm interior or the reaction of the antimicrobial material with the matrix material. 
Suci et al., (1994) demonstrated a delayed penetration of ciprofloxacin into 
Pseudomonas aeruginosa biofilms; what normally required 40 s for a sterile surface 
required 21 min for a biofilm-containing surface. Hoyle et al., (1992) found that 
dispersed bacterial cells were 15 times more susceptible to tobramycin than were cells 
in intact biofilms. DuGuid et al., (1992) examined Staphylococcus epidermidis 
susceptibility to tobramycin and concluded that the organization of cells within biofilms 
could in part explain the resistance of this organism to this antimicrobial agent.
 Another proposed mechanism for biofilm resistance to antimicrobial agents is that 
biofilm-associated cells grow significantly more slowly than planktonic cells and, as a 
result, take up antimicrobial agents more slowly. Using a method of cell culture 
designed to determine the effect of growth rate apart from other biofilm processes, 
Evans et al., (1990) found that the slowest growing Escherichia coli cells in biofilms 
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were the most resistant to cetrimide. At growth rates higher than 0.3 per h, biofilm and 
planktonic cells were equally susceptible. 
 Nutrient limitation and increases in toxic metabolite concentrations might be 
particularly acute within the depths of established biofilms. Tresse et al., (1995) found 
that agar-entrapped E. coli cells were more resistant to an aminoglycoside as oxygen 
tensions were decreased. They suggested that the persitence was due to lowered uptake 
of the antibiotic by the oxygen-starved cells. Dagostino et al. (1991) proposed that 
initial bacterial association with a surface may result in the repression or induction of 
genes, which in turn results in a number of physiological responses. 
 
1.6.3 Biofilms on medical devices and its relationship with the disease  
 There are varied environments that are suitable for microorganisms to colonize 
and establish biofilms. Costerton et al., (1999) provided a partial listing of medical 
devices that have been shown to become colonized by biofilms. Biofilms of various 
medical devices have been studied extensively over the last 20 years, through 
techniques such as viable culture techniques and scanning electron microscopy, to 
characterize the microbial diversity and visualize the biofilms.  
 Prosthetic valve endocarditis following the valve replacement is due to the 
infection caused by organisms such as streptococci, enterococci, S. aureus, gram-
negative coccobacilli, or fungi which form biofilm on the valve (Karchmer and 
Gibbons, 1994). Central venous catheters pose a greater risk of device-related infection 
than does any other indwelling medical device, with infection rates of 3 to 5%. 
Catheters may be inserted for administration of fluids, blood products, medications, 
nutritional solutions, and hemodynamic monitoring (Flowers et al., 1989). Biofilms 
have been shown by scanning electron microscopy and transmission electron 
microscopy to be universally present on central venous catheters and may be associated 
with either the outside of the catheter or the inner lumen (Raad et al., 1993). Organisms 
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like S. aureus and S. epidermidis that colonize originate either from the skin insertion 
site, migrating along the external surface of the device, or from the hub, due to 
manipulation by health care workers, migrating along the inner lumen (Elliott et al., 
1997; Raad, 1998). Urinary catheters are tubular, latex, or silicone devices that are 
inserted through the urethra into the bladder to measure urine output, collect urine 
during surgery, prevent urinary retention, or control urinary incontinence (Kaye and 
Hessen, 1994). Stickler (1996) noted one study that measured P. aeruginosa cells at 
catheter surface. Catheters are colonized by single species, such as S. epidermidis, 
Enterococcus faecalis, E. coli, or Proteus mirabilis. As the catheter remains in place, 
the number and diversity of organisms increase. Mixed communities develop, 
containing such organisms as Providencia stuartii, P. aeruginosa, Proteus mirabilis, 
and Klebsiella pneumoniae (Stickler, 1996). Other organisms isolated from urinary 
catheter biofilms include M. morganii, Acinetobacter calcoaceticus (Stickler et al., 
1993a), and Enterobacter aerogenes (Stickler et al., 1993b). Hard contact lenses are 
constructed of polymethylmethacrylate and move with each blink, allowing oxygen-
containing tears to flow underneath the lens (Dart, 1996). Bacteria adhere readily to 
both types of lenses (Dart, 1996; Miller and Ahearn, 1987; Stapleton and Dart, 1995; 
Stapleton et al., 1993). Organisms that have been shown to adhere to contact lenses 
include P. aeruginosa, S. aureus, S. epidermidis, Serratia spp., E. coli, Proteus spp., 
and Candida spp. (Dart, 1996). Intrauterine devices use has been shown to result in 
pelvic inflammatory disease (Chesney, 1994; Lewis, 1998; Wolf and Kreiger, 1986). 
Dental units are equipped with small-bore flexible plastic tubing that supplies water to 
different hand pieces, such as the air-water syringe, the ultrasonic scaler, and the high-
speed hand piece. Organisms generally isolated from these units include Pseudomonas 
spp., Flavobacterium spp., Acinetobacter spp., Moraxella spp., Achromobacter spp. 
(Tall et al., 1995), Methylobacterium spp. (Whitehouse, 1991), Rhodotorula spp., 
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hyphomycetes (Cladosporium spp., Aspergillus spp., and Penicillium spp.), Bacillus 
spp., Streptococcus spp., CoNS, Micrococcus spp., and Corynebacterium spp. (Mills et 
al., 1986). Legionella pneumophila has also been isolated from these systems (Atlas et 
al., 1995; Callacombe and Fernandes, 1995; Pankhurst et al., 1990). 
 It is clear from epidemiologic evidence that biofilms have a role in infectious 
diseases, both for specific conditions such as cystic fibrosis and periodontitis and in 
bloodstream and urinary tract infections as a result of indwelling medical devices. The 
process may be particularly relevant for immunocompromised patients, who lack the 
ability to combat invading organisms.   
1.6.4 Regulation of biofilms 
 Antibiotic susceptibility of planktonic bacteria and resistance of corresponding 
biofilm cells is a well-established phenomenon (Tenke et al., 2006). In most cases, 
treatment with antibiotics slows down biofilm progression by eliminating planktonic 
cells and interfering with biofilm metabolism (Tenke et al., 2006). However, neither the 
biofilm nor the infection are eliminated effectively, and there is growing concern across 
all industry sectors that deal with biofilms in relation to cross-resistance exhibited by 
antibiotic- resistant strains to other antimicrobial agents, such as disinfectants (Langsrud 
et al., 2003; Lunde´n et al., 2003). 
 One of the biofilm control strategy is to prevent initial attachment of the biofilm. 
Some examples include materials coated with silver ions or within which silver ions are 
incorporated, materials containing antibiotics which are released slowly, materials in 
which intrinsic properties like surface hydrophobicity have been altered, and the use of 
anti-adhesive surfaces such as heparin coatings (Donlan and Costerton, 2002; Tenke et 
al., 2006; Morris and Stickler, 1998; Chilukuri and Shah, 2005). 
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  The other strategy to intervene biofilm is to minimize biofilm formation. Cell 
attachment to surfaces has been shown to occur within a few minutes to hours, making 
frequent cleaning unfeasible as a means to prevent cell attachment (Meyer, 2003).  
 More recent novel approaches include disruption of quorum-signalling molecules, 
which may, in turn, disrupt the biofilm structure allowing for better inactivation and 
removal (Donlan and Costerton, 2002). Davies et al., (1998) showed that Quorum 
Sensing (QS) signaling molecules, acylhomoserine lactones (AHLs) were involved in 
biofilm architecture and detachment, and it has been suggested that novel treatments 
might be based on disruption of these quorum-sensing systems (Davies et al., 1998; 
Hartman and Wise, 1998; Stickler et al., 1998). A number of laboratories are currently 
attempting to elucidate the genes that are activated or repressed during initial biofilm 
formation. In the future, treatments that inhibit the transcription of these genes might be 
able to completely inhibit biofilms. 
1.6.5 Biofilm formation in Acinetobacter spp. 
 As well as being highly resistant to the antibiotics, the members of the 
Acinetobacter spp., especially A. baumannii, are highly resistant to desiccation. These 
organisms can persist for long periods of time on inanimate surfaces. In addition A. 
baumannii is one of the most common causes of device-related nosocomial infection 
because it is able to resist chemical and physical disinfectants. Biofilm formation is one 
of the possible explanations for the resistance to desiccation and disinfection. It could 
also be responsible for a number of device-related nosocomial infections (Donlan, 2002; 
Tomaras et al., 2003). 
 In A. baumannii ATCC 19606, in vitro biofilm formation occurs mainly at the 
liquid-air interface and produces a biofilm-ring structure just above the surface of the 
medium. This structure grows further upwards from the liquid-air interface onto the 
walls of the tube. Within this biofilm, bacterial cells are attached to each other by pili-
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like structures and there are channels to provide nutrients to the individual bacteria and 
remove the waste products. A polycistronic operon involved in pili assembly (csu 
genes) has been described in this strain as a requirement for pili formation and therefore 
initial bacterial attachment to the surface (Tomaras et al., 2003 ).  
 In addition, a biofilm-associated protein (Bap) has been described in A. baumannii 
which may have a function in supporting the development of the mature biofilm 
structure. This protein is a surface-expressed protein that is structurally similar to 
bacterial adhesions and its disruption produces a reduction in the volume and thickness 
of this biofilm (Loehfelm et al., 2008).  The expression of an operon, pgaABCD, 
encoding a poly N-acetyl glucosamine (PGA) extracellular matrix has been shown to 
have a role in biofilm formation (Amini et al., 2009; Bosse et al., 2010). 
1.7 Quorum Sensing (QS) 
1.7.1 Bacterial cell-cell communication 
 Bacteria display complex social behaviors and form communities of cells 
coordinating their activities through chemical communication. Because such 
cooperative behaviour is often dependent on cell population density, it is usually 
referred to as ‗‗quorum sensing‘‘ (QS). QS involves the activation of a receptor by a 
diffusible signal molecule. The concentration of QS signal reflects the number of 
bacterial cells and the sensing of a threshold level of signal indicates that there is 
required population of bacteria (Fuqua and Greenberg, 2002; Lazdunski et al., 2004; 
Williams et al.,  2007).  
 Although QS was originally used to describe N-acylhomoserine lactone (AHL)-
dependent cell-to-cell communication in Gram-negative bacteria, QS signal molecules 
exhibit significant chemical diversity. Structures of some of the representative QS 
molecules are given in figure 1.2.  These molecules are autoinducers and bacteria may 
employ more than one QS signal molecule from the same or a different chemical class 
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and their activities may be coordinated by interacting QS systems, each of which 
incorporates a signal molecule synthase and a sensor/receptor (Fuqua and Greenberg, 
2002; Lazdunski et al., 2004; Williams et al., 2007).  
 Because bacteria co-exist in ecosystems with many other organisms, it is perhaps 
not surprising to discover that QS signals can modulate the behaviour of both bacteria 
other than the QS signal producer itself and of higher organisms, in ways advantageous 
for bacterial survival (Williams et al., 2007). Higher organisms can sometime 
manipulate QS by producing signal mimics or by modulating QS pathways through the 
action of cytokines or by blocking QS through the deployment of inhibitors or through 
the enzymatic inactivation of QS signals.  
Figure 1.2: Structures of some representative quorum sensing signalling molecules 
 
(Adapted from Williams et al., 2007) 
3-oxo-AHL, N-(3-oxoacyl) homoserine lactone; 3-hydroxy-AHL, N-(3-hydoxyacyl) 
homoserine lactone and AHL, N-acylhomoserine lactone where R ranges from C1 to 
C15. The acyl side chains may also contain one or more double bonds: A-factor, 2-
isocapryloyl-3-hydroxymethyl-g-butyrolactone; AI-2, autoinducer-2, furanosyl borate 
ester form; PQS, Pseudomonas quinolone signal, 2-heptyl-3-hydroxy-4(1H)-quinolone; 
DSF, ‗diffusible factor‘, methyl dodecenoic acid; PAME, hydroxyl-palmitic acid methyl 
ester. 
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1.7.2 Types of quorum sensing signal molecules 
 The term ‗quorum sensing‘ was coined to describe AHL mediated signalling 
(Dunny and Winans, 1999). AHL-mediated QS was found initially in few marine 
vibrios, but now it has been demonstrated in diverse Gram-negative genera including 
Agrobacterium, Aeromonas, Burkholderia, Chromobacterium, Citrobacter, 
Enterobacter, Erwinia, Hafnia, Nitrosomonas, Obesumbacterium, Pantoea, 
Pseudomonas, Rahnella, Ralstonia, Rhodobacter, Rhizobium, Acinetobacter, Serratia 
and Yersinia. The key protein components are the LuxI family of AHL synthases and 
the LuxR family of transcriptional activators. The LuxI proteins catalyse the formation 
of AHL signal molecules, and in vitro and in vivo studies have revealed that the 
homoserine lactone moeity is derived from S-adenosyl methionine (Moré et al., 1996; 
Jiang et al., 1998). The N-acyl chains, which range in length from 4–14 carbons that 
may be saturated or unsaturated and may or may not contain a C3 hydroxy or oxo 
group, are provided through the appropriately charged acyl–acyl carrier protein or acyl–
coenzyme A (Moré et al., 1996; Jiang et al., 1998). Although fatty acids and 
polyketides with an odd number of acyl chain carbons have been described, AHLs with 
odd-numbered N-linked acyl chains have been identified only recently.  
 A second family of AHL synthases, LuxM, has been identified in Vibrio spp. 
(Bassler et al., 1993; Hanzelka et al., 1999) and these direct the synthesis of N-(3-
hydroxybutanoyl)-homoserine lactone (3-hydroxy-C4-HSL and N-octanoyl-homoserine 
lactone (C8-HSL). Despite the lack of homology with the LuxI family, they appear to 
catalyse AHL formation from the same substrates as the LuxI proteins (Hanzelka et al., 
1999).  
 Most recently, evidence for a third AHL synthase, HdtS, has been obtained from 
studies of Pseudomonas fluorescens F113 (Laue et al., 2000). When expressed in 
Escherichia coli, hdtS directs the production of three AHLs, namely N-(3-hydroxy-7-
cis-tetradecenoyl) homoserine lactone, N-decanoyl-homoserine lactone (C10-HSL) and 
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N-hexanoyl-homoserine lactone (C6-HSL) (Laue et al., 2000). The HdtS protein 
sequence bears no homology to either the LuxI or LuxM families. Database searches 
reveal that HdtS is most closely related to the lysophosphatidic acid (LPA) acyl 
transferase family, which includes the PlsC protein of E. coli, responsible for the 
transfer of an acyl chain from either acyl–ACP or acyl–CoA to LPA to produce 
phosphatidic acid. It is therefore possible that HdtS transfers acyl chains from acyl–
ACP or acyl–CoA to a substrate such as S-adenosyl methionine to generate AHLs. New 
research shows that bacteria have elaborate chemical signaling systems that enable them 
to communicate within and between species. One signal called AI-2 is universal and 
facilitates interspecies communication. Many processes, including virulence factor 
production, biofilm formation, and motility, are controlled by AI-2 (Federle and 
Bassler, 2003). Strategies that interfere with communication in bacteria are being 
explored in the biotechnology industry with the aim of developing novel antimicrobials. 
 Gram-negative bacteria also utilise QS signal molecules unrelated to the AHLs. 
The study of AHL-signalling in Pseudomonas aeruginosa identified two LuxRI QS 
systems—LasRI/N-(3-oxododecanoyl)homoserine lactone (3-oxo-C12-HSL) and 
RhlRI/N-butanoyl homoserine lactone (C4-HSL) — that form a hierarchical cascade for 
the regulation of multiple structural and regulatory genes (Latifi et al., 1996). Recently, 
a new QS molecule, termed the Pseudomonas quinolone signal (PQS), whose chemical 
structure is 2-heptyl-3-hydroxy-4-quinolone, was identified as a further component of 
QS hierarchy (Pesci et al., 1999). As well as AHLs and PQS, P. aeruginosa has recently 
been shown to produce another family of putative QS signal molecules (Holden et al., 
1999). These are the cyclic dipeptides, which are capable of activating or antagonising 
LuxR-mediated QS systems possibly by competing for the AHL binding site on LuxR-
type proteins.  
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 While Gram-negative bacteria employ hydrophobic low molecular weight signal 
molecules, posttranslationally modified peptides are engaged by Gram-positive bacteria 
as quorum sensing signal molecules.  
1.7.3 Quorum sensing regulation through networking 
 The information about the cell population density provided by QS forms a part of 
network of sensory input reflecting the physical and chemical status of the prevailing 
environment. The outline of this network is shown in figure 1.3. Perhaps the simplest 
case is the integration of different AHL signals.  
 In V. harveyi, two distinct QS signals are integrated in concert with cell density to 
control bioluminescence, colony morphology and siderophore production (Freeman and 
Bassler, 1999; Lilley and Bassler, 2000). V. harveyi appears capable of making 
decisions on the basis of multiple sensory inputs and, given the two distinct QS systems, 
can use the LuxS derived signal to determine not only its own population density, but 
also its numerical strength within a mixed bacterial community. The mass action of a 
high density population of V. harveyi cells may therefore be required to induce a 
significant bioluminescent signal. The presence of other bacteria, may be a key factor in 
verifying the location of the V. harveyi population before committing it to such an 
energy-expensive phenotype.  
 QS input is also integrated with information regarding aspects of the bacterial 
environment other than cell density. In many plant-associated pseudomonads, a two-
component signal transduction system termed GacA/GacS for global antibiotic and 
cyanide control respectively, regulates the expression of many different phenotypes. In 
P. aeruginosa (Reimmann, 1997) and Pseudomonas aureofaciens, the GacA/GacS 
system also modulates quorum sensing by influencing C4-HSL production in the 
former, and regulating expression of the luxI homologue phzI in the latter (Chancey  et 
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al., 1999). In P. aeruginosa, cyanide production is produced maximally at low oxygen 
tension and high cell densities.  
 Another particularly important factor for a pathogen is the presence of the host. In 
Agrobacterium tumefaciens, plants opine hormones control the QS-dependent conjugal 
transfer of Ti plasmids (Oger et al., 1998). In E. carotovora, QS is necessary to activate 
both a battery of plant cell wall degrading exoenzymes and, in some strains, a 
carbapenem antibiotic (Jones et al., 1993). In Yersinia and Salmonella, SlyA 
homologues, which are responsible for the activation of genes required for virulence 
(Revell and Miller, 2000), are induced upon interaction with host eukaryotic cells.  
 The QS systems thus constitute mechanisms by which bacterial cells act in 
concert for the wellbeing of the population as a whole. A second, interrelated QS 
regulation involves phenotypic changes that increase the ability of the individual cell to 
survive. Examples include regulation of catabolism of specific amino acids during entry 
into stationary phase (Baca-Lancey et al., 1999), cell division (Garcia-Lara et al., 1996) 
and DNA replication (Withers and Nordström, 1998) in E. coli, and the transcriptional 
regulation of rpoS in P. aeruginosa (Latifi et al., 1996). All these processes are 
important for cell survival under conditions such as nutrient limitation and stress, most 
of which occur at high cell density and upon entry into stationary phase. It is also likely 
that these are the conditions most bacterial cells encounter outside the laboratory, and 
therefore the co-ordination of these processes would seem desirable.  
 A single bacterial cell contains a diverse array of signalling modules that may act 
in parallel or may be organised into a hierarchical cascade to give rise to the concept of 
‗neural‘ regulatory networks in bacteria. QS, as the determinant of cell population 
density, is therefore just one parameter amongst many that the cell must integrate in 
order to determine subsequent behaviour. QS signal molecules, in common with other 
environmental signals, may be internalised or detected at the cell envelope such that 
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signal transduction leads to self modulation or population modification (Withers et al., 
2001).  
Figure 1.3: QS regulation through networking 
 
(Adapted from Withers et al., 2001) 
 
 
1.7.4 Bacterial AHL biosensor reporter strains 
 
 The very large number of AHL QS systems identified has been possible mainly 
by the use of bacterial biosensors that are able to detect the presence of AHLs. These 
biosensors do not produce AHLs and contain a functional LuxR-family protein cloned 
together with a cognate target promoter, which positively regulates the transcription of a 
reporter gene (Figure. 1.4).  
 AHLs can also be extracted from spent supernatants of late exponential phase 
cultures (Shaw et al., 1997; Schaefer et al., 2000), and partial characterization can be 
carried out by Thin Layer Chromatography (TLC) on C18 reversed phase plates. This 
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organic extraction increases many fold the sensitivity of biosensors. The TLC plates are 
loaded with the sample extracts and with different standards and, after chromatography, 
overlaid with a soft-agar suspension of the AHL biosensor strain (McClean et al., 1997; 
Shaw et al., 1997; Schaefer et al., 2000). Each AHL migrates with a characteristic 
mobility and results in a spot shape depending on the reporter of the biosensor strain. 
The 3-oxo-AHLs produce tear-shaped spots, whereas alkanoyl- AHLs and 3-OH-AHLs 
migrate and form well-defined circles. It is sometimes advantageous that before TLC, 
the sample extracts are further purified by C18-reverse phase HPLC and the resulting 
fractions tested for activity against AHL-biosensors either directly or via TLC (Schaefer 
et al., 2000). Separation by TLC coupled with detection by AHL biosensors gives a 
rapid and direct visual index of the AHL(s) produced by the tester bacteria. AHLs 
cannot be unambiguously identified using TLC. However, their chromatographic 
properties can be used to assign tentative structures, as retention factors (Rfs) calculated 
for the samples can be compared with Rfs of AHL standards. AHL structures are 
unequivocally determined on the basis of spectroscopic properties (Schaefer et al., 
2000) including Mass Spectrometry (MS) and nuclear magnetic resonance spectroscopy 
(NMR). Several of the AHL biosensors can also be used for quantifying AHLs by 
measuring the activity of the reporter system present in the biosensor bacterial strain. 
This is useful for studying regulation of AHL synthesis and for identifying strain-level 
differences in AHL production. In order to quantify accurately one must determine, 
using the synthetic AHL, the minimal amount of AHL required for a response as well as 
the amount necessary for a saturated response in order to plot the linear dose response. 
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Figure 1.4:  Construction and use of a bacterial AHL biosensor  
 
 
(Adapted from Steindler and Venturi, 2007) 
 ‗R‘ refers to the moiety at position C3, which can be either unmodified or carries an oxo- 
or hydroxyl group.  
 
‗n‘ refers to the length of the acyl chain, which is most commonly from 4 to 12 and in 
some cases bacteria can produce AHLs having chains of 14 to 18 carbons.  
 
 
 Some AHL biosensors have been constructed based on several LuxR-family 
proteins that are able to detect AHLs having acyl chains of C4 to C8 in length. A 
commonly used biosensor is based on Chromobacterium violaceum, a Gram negative 
water and soil bacterium that produces the antibacterial purple pigment violacein. 
Chromobacterium violaceum regulates violacein production via the CviI/R AHL QS 
system, which produces and responds to C6-AHL (McClean et al., 1997). McClean et 
al. (1997) constructed C. violaceum CV026, a violacein and AHL-negative double 
miniTn5 mutant. One transposon is inserted into the cviI AHL synthase gene, and the 
other is inserted into a putative violacein repressor locus. Exposure of strain CV026 to 
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exogenous AHLs, which are able to interact with CviR, results in rapid production of a 
visually clear purple pigmentation. Unsurprisingly, the most active agonist AHL for 
CV026 is C6-AHL, the natural C. violaceum AHL. Other AHLs that induce reasonably 
well include C6-3-oxo-AHL and C8-AHL, C8-3- oxo-AHL and C4-AHL. AHLs with 
acyl chains of C10 and longer chain lengths, with or without oxygen at the third 
position, could be detected by inhibition of HHL mediated activation of violacein 
production. This strain is well suited for detection on solid media via a ‗T‘ streak 
analysis as well as the TLC soft-agar overlay technique.  
 Several other biosensors rely on a plasmid construct harboring the luxCDABE 
operon of Photorhabdus luminescens resulting in bioluminescence as a reporter system 
(Winson et al., 1998b). These plasmids are usually harboured in Escherichia coli, which 
do not produce AHLs. Plasmid pSB401 (Winson et al., 1998a) and pHV200I (Pearson 
et al., 1994) are both based on LuxR of V. fischeri and cognate luxI promoter 
controlling luxCDABE expression. They are most sensitive to cognate C6-3-oxo-AHL 
and display good sensitivity towards C6-AHL, C8-3-oxo-AHL and C8-AHL. Little 
agonist activity was observed by C4- AHLs, C10- and longer acyl chain AHLs. The 
presence of AHLs therefore induces bioluminescence, which, in a TLC analysis, can be 
conveniently detected by exposing the TLC overlaid with the biosensor to 
autoradiographic paper. These biosensors can also be used for ‗T‘ streak analysis. They 
are not used as frequently as CV026 as they require a photon camera.  
 AHL biosensors for specific detection of C10-AHL, C12- AHL and their 3-oxo 
derivatives are based on the LasI/R system of P. aeruginosa, which produces and 
responds to C12-3-oxo-AHL. Plasmid sensor pSB1075 contains the lasR gene and 
cognate lasI gene promoter controlling luxCDABE expression (Winson et al., 1998a). 
This plasmid can only be harbored in E. coli and can be conveniently used in TLC 
analysis responding well to C12-3-oxo-AHL, C10-3-oxo- AHL and C12-AHL.   
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 The Chromobacterium violaceum CV026 biosensor can detect the presence of 
long acyl-chains by the inhibition of AHL-induced violacein synthesis (McClean et al., 
1997). Thus CV026 can detect the presence of a broad range of AHLs. Quorum sensing 
in A. tumefaciens is involved in the regulation of conjugal transfer of many plasmids 
(Farrand et al., 2002; Von Bodman et al., 2003). AHL biosensor A. tumefaciens NT1 
(pZLR4) consists of strain NT1 cured of the Ti plasmid and thus unable to produce 
AHLs, and plasmid pZLR4. The plasmid contains the traR gene and one of the tra 
operons, responsible for Ti plasmid conjugal transfer, containing a traG::lacZ reporter 
fusion, the transcription of which is known to be regulated by the TraI/R AHL QS 
system (Cha et al., 1998; Farrand et al., 2002). A. tumefaciens displays the broadest 
sensitivity to AHLs at the lowest concentrations. This β-galactosidase-based biosensor 
is particularly well suited for TLC analysis. It is so sensitive to many AHLs that it 
requires only small volumes of AHL extracts from spent supernatants (Farrand et al., 
2002). This sensor can also be used by spotting colonies, culture supernatants or sample 
extracts onto an overlay of the sensor grown in a suitable medium containing X-Gal. 
After overnight incubation, the presence of AHLs will result in a blue zone around the 
site of application (Farrand et al., 2002). It is also particularly suited to the study of 
AHL production profiles of a large number of bacterial strains. This biosensor detects 3-
oxo-substituted AHL-derivatives with acyl chain lengths from 4 to 12 carbons and also 
3-unsubstituted AHLs, with the exception of C4-AHL.  
1.7.5 QS in Acinetobacter spp. 
 
 There are reports suggesting that quorum sensing signal molecules play an 
important role in biofilm formation (Camilli and Bassler, 2006; Domka et al., 2007). 
Studies on two fundamental bacterial small-molecule signaling pathways: extracellular 
quorum-sensing signaling and intracellular cyclic dinucleotide signalling suggested how 
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these two pathways may converge to control complex processes including 
multicellularity, biofilm formation, and virulence (Camilli and Bassler, 2006).  
 Previous studies showed AHL production by Acinetobacter spp. In A. 
calcoaceticus BD413 supernatants four compounds were detected in a time-dependent 
manner, and maximal activity was reached at stationary phase (Gonzalez et al., 2001). 
In a variety of gram-negative bacteria, it has also been demonstrated that biofilm 
development can be dependent on AHL signaling (Davies et al., 1998; Huber et al., 
2001; Lynch et al.,2002). In A. baumannii, very little is known regarding factors 
required for biofilm formation (Loehfelm et al., 2008; Tomaras et al., 2003; Vidal et al., 
1996). A putative chaperone that is required for this process has been identified 
(Tomaras et al., 2003). In addition, a homolog of a staphylococcal biofilm-associated 
protein (Bap) has been characterized in A. baumannii, where it appears to act as an 
extracellular adhesin (Loehfelm et al., 2008).There is also a report on the identification 
and characterization of an autoinducer synthase from A. baumannii that was designated 
AbaI. Mass spectrometry was used to identify AHL signals that were directed by AbaI. 
The abaI gene was activated in a positive-feedback loop by an AbaI-dependent AHL 
signal(s). An abaI mutant was impaired in the later stages of biofilm development, and 
this phenotype was rescued by ethyl acetate extracts of cell supernatants from a wild-
type strain, thus proving the QS molecules aid biofilm formation in Acinetobacter 
baumannii (Niu et al., 2008) 
 The identification of abaI gene and the corresponding AHL signals will now 
allow the identification of signal antagonists that inhibit biofilm development. These 
antagonists may also reduce the ability of A. baumannii to survive on environmental 
surfaces for extended periods, a key component of its ability to persist in intensive care 
wards. 
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1.8 Quorum Quenching 
 From the discovery of QS systems and their role in pathogenesis, elucidation of 
methods to interfere with QS, quorum quenching, as an effective infection control 
strategy has been developed. Numerous studies have established the presence of a 
globally controlled QS regulon in P. aeruginosa, of which roughly one third of the 
genes encode virulence factors. These are mainly secreted components including 
elastase, alkaline protease, rhamnolipids, phenazines, cyanide, lectins, chitinases and 
numerous proteins with unknown functions (Hentzer et al., 2003; Rasmussen et al., 
2005b; Schuster et al., 2003; Vasil, 2003; Wagner et al., 2003). Several animal infection 
models highlight the involvement of these QS-regulated virulence factors in 
pathogenicity of P. aeruginosa. The simplest infection model has been established in 
the nematode Caenorhabditis elegans. This small worm can feed on bacteria but in the 
case of an opportunistic pathogen such as P. aeruginosa, the worm is often killed within 
a short period of time after ingesting the bacteria. When feeding on P. aeruginosa, the 
worms are killed by cyanide and phenazines secreted by the bacteria. On the contrary, 
with mutations in QS regulatory systems killing is abolished and they can be maintained 
on bacteria (Darby et al., 1999; Mahajan–Miklos et al., 1999; Rasmussen et al., 2005a). 
The RhlR based QS system has been found to be important for virulence of P. 
aeruginosa towards the amoeba Dictyostelium discoideum (Cosson et al., 2002). 
Functional QS systems have been found to be important for establishment and reduced 
clearance of P. aeruginosa. If the animals are infected with QS mutants, the immune 
response is faster, the polymorphonuclear leucocytes respond by development of 
stronger oxidative bursts and antibodies accumulate faster in the infected lung 
(Bjarnsholt et al., 2005; Smith et al., 2002; Wu et al., 2001). From the above studies it 
is clear that QS is indeed involved in virulence and pathogenesis of P. aeruginosa. A 
similar relationship is found in many other predominantly opportunistic pathogens 
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including Serratia liquefaciens and Chromobacterium violaceum both of which are 
human pathogens, and Agrobacterium tumefaciens and Erwinia carotovora both of 
which are plant pathogens (Brito et al., 2004; Grimont and Grimont, 1978; Sheng and 
Citovsky, 1996; Whitehead et al., 2002). 
1.8.1 Biological screening for quorum sensing inhibitors 
 The discovery of quorum sensing inhibitor (QSI) compounds requires live 
screening systems which can identify the presence of QSI activities of pure as well as 
mixtures of compounds like plant, fungal, algal or microbial extracts. Such systems 
used for screening the QSI compound, make use of a QS-controlled promoter fused to a 
reporter gene/operon such as the violacin operon from C. violaceum, the lux gene 
cluster from V. fischeri, lacZ from Escherichia coli or gfp from Aequorea victoria. In 
presence of exogenously added AHL signal molecules, these reporters are activated to 
express their corresponding reporters. In the presence of exogenous QSI activity 
expression of the reporters is reduced or abolished and a positive result of the screen is 
manifested by a reduced signal. Several genetically modified bacteria, termed QSI 
selectors (QSIS), based on both the lux and the rhl/ las systems have been developed. 
These bacteria are killed in the presence of AHL signal molecules but rescued in the 
presence of both AHL and a QSI candidate (Rasmussen et al., 2005a). 
1.8.2 Quorum sensing inhibitors 
 In A. tumefaciens, the activity of the quorum-sensing regulator protein TraR is 
antagonized by many quorum-sensing antiactivator proteins. TraM is one among these 
proteins which is encoded by the Ti plasmid in A. tumefaciens and also found in other 
members of the family Rhizobiaceae (Luo et al., 2000; Swiderska et al., 2001). 
Therefore, the main role of TraM is to regulate the activity of the AHL-TraR complex 
such that it functions effectively only when a particular quorum is reached (Hwang et 
al., 1999, Piper and Farrand, 2000).  
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 TrlR (TraR-like regulator) is another protein which is responsible for antagonizing 
the activity of TraR in A. tumefaciens. TrlR binds to one molecule of AHL per 
monomer and thus it can potentially titrate out the amount of AHL available to activate 
TraR, especially at low population densities when AHL production is at basal levels 
(Chai et al., 2001).  
 The QscR (quorum-sensing control repressor) protein is a homolog of LasR and 
RhlR, which are the transcriptional regulators of Pseudomonas aeruginosa quorum-
sensing systems (Chugani et al., 2001; Ledgham et al., 2003). 
 The AHL that is made by the Tra quorum sensing system of A. tumefaciens is 
hydrolysed by the AHL-degrading enzyme coded by attM  gene (Zhang et al., 2002). It 
was recently shown by Zhang et al., (2004) that this degradation system is highly 
regulated by the stress alarmone signal (Zhang et al., 2004). A second enzyme, AiiB, 
which is homologous to AttM, was identified in A. tumefaciens and this was shown to 
degrade AHLs (Carlier et al., 2003). 
 Recently, AHL acylase and lactonase enzyme activities were identified in soil 
pseudomonads and P. aeruginosa PAO1 strains (Huang et al., 2003). The AHL-
degrading activity was specific towards the long-chain AHLs.  
 Recent work on the regulation of the quorum sensing systems in V. harveyi and 
Vibrio cholerae shows that small, regulatory RNAs (sRNAs) are involved in 
specifically repressing quorum sensing (Lenz et al., 2004; Cui et al., 1995).  
 A. tumefaciens causes crown gall disease in a variety of plants, causing large 
tumors in the crown of the plant. The tumor-inducing Ti plasmid of A. tumefaciens 
contains genes responsible for virulence and harbors the ability to transfer a fragment of 
its DNA (T-DNA) into the nuclear genome of the host plant. This bacterial DNA then 
directs the plant cells to synthesize specific carbohydrates called opines which are 
readily metabolized by Agrobacterium around the crown gall tumors (Zhu et al., 2000). 
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TraR is expressed only in the presence of plant-produced opines and so conjugal 
transfer of the Ti plasmid occurs only in the vicinity of host tumors (Oger and Farrand, 
2001, 2002; Piper et al., 1999). 
 Halogenated furanones are naturally produced by the Australian red alga Delisea 
pulchra and these are known to have strong inhibitory activity against fouling organisms 
and herbivores. Interestingly, the furanones have structural similarity to AHLs. Previous 
research has shown that furanones are capable of interfering with the quorum-sensing 
behavior of several bacterial strains. The Swr quorum-sensing system of S. liquefaciens 
comprises the response regulator SwrR and the synthase SwrI, which are responsible for 
the production of C4-HSL and C6-HSL (Daniels et al., 2004; Lindum et al., 1998). 
Binding of furanone to LuxR results in the rapid disruption of the quorum-sensing-
mediated gene regulation (Manefield et al., 1999; Manefield et al., 2002).  
 L-Canavanine is an arginine analog found exclusively in the seeds of legumes. It 
has been reported to be as abundant as up to 5% (dry weight) of some leguminous seeds 
(Weaks, 1977). L-canavanine has been identified as a QSI compound and showed that 
the QSI activity is independent of its effect on bacterial growth (Keshavan et al., 2005).  
 A recent study on enterohemorrhagic Escherichia coli (EHEC) showed that 
human hormones cross communicated with the bacterial quorum-sensing system 
(Sperandio et al., 2003). The LuxS dependent quorum-sensing system in EHEC controls 
several phenotypes, including pathogenicity and type III secretion, which eventually 
results in virulence on HeLa epithelial cells (Sircili et al., 2004).  
 Several AHL-degrading enzymes identified in various bacteria have the potential 
to be used as quorum quenchers. Dong et al., (2000) initially identified AiiA from 
Bacillus species and showed that this enzyme inactivates the AHL signal and attenuates 
virulence when expressed in Erwinia carotovora. This enzyme is an AHL lactonase, 
known to act by hydrolyzing the lactone bond in the AHL (Dong et al., 2001). Another 
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study showed that a soil isolate of Variovorax paradoxus not only breaks down AHLs 
but is capable of utilizing them as the sole source of carbon and nitrogen (Leadbetter 
and Greenberg, 2000). Other bacteria producing the AHL degrading enzymes belonged 
to the genera Pseudomonas, Comamonas, Variovorax, and Rhodococcus.  
 A second class of quorum-quenching enzymes was identified in Ralstonia strain 
XJ12B. The acylase AiiD isolated from this strain is a 794-amino-acid polypeptide that 
is capable of hydrolyzing the AHL amide (Huang et al., 2003).  
 Quorum sensing appears to be crucial for plant-bacterial interactions such as 
pathogenesis or symbiosis (Gonza´lez and Marketon, 2003; Loh et al., 2002; 
Wisniewski-Dye and Downie. 2002; Ma¨e et al., 2001; Zhang, 2003). This idea has 
been exploited to create transgenic plants encoding bacterial AHL synthases, such that 
the plants are now capable of producing AHL signal molecules. Fray et al., (1999) 
cloned the yenI AHL synthase from Yersinia enterocolitica and targeted it to the 
chloroplasts of tobacco plants to create transgenics that produced 3-oxo-C6-HSL and 
C6-HSL. The AHLs produced by the transgenic tobacco plants activated quorum-
sensing-related phenotypes in AHL synthase mutants of Pseudomonas aureofaciens and 
E. carotovora strains (Fray et al., 1999).  
 Many of the structural analogs for different AHL molecules have been studied for 
their effects on the quorum-sensing system of the related bacterial strain. A study on the 
analogs of the 3-oxo-C8-HSL revealed that the nature of the antagonistic activity 
strongly depends on the expression of the TraR protein (Zhu et al., 1998; Reverchon et 
al., 2002). Several furanone-based structural analogs have also been synthesized and 
analyzed for their QSI activity. A study reported the isolation of two natural products 
from a marine sponge and a Pseudomonas sp. that were structurally similar to 
furanones. These compounds, isocladospolide and acaterin, were used as templates for 
further modifications, and the resulting compounds were tested against LuxR-based E. 
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coli biosensor strains. The 5H-furan-2-ones substituted with short alkyl chains were in 
general more antagonistic than the longeralkyl- chain counterparts (Hjelmgaard et al., 
2003). Another interesting study using synthetic furanones tested on mouse lungs 
infected with different bacterial strains indicated that the QSI effect of furanones was 
functional in vivo and helped to enhance clearance of P. aeruginosa from infected lungs 
(Wu et al., 2004).   
1.9 Justification and objectives of the study 
 Acinetobacter spp. are reported to be persistent in the hospital environment 
causing a variety of opportunistic nosocomial infections. Acinetobacter spp. have been 
isolated from various types of opportunistic infections, including septicemia, 
pneumonia, endocarditis, meningitis, skin and wound infection, and urinary tract 
infection. They have now emerged as important pathogens in the ICU setting, and this is 
probably due to the increasingly invasive diagnostic and therapeutic procedures used in 
hospital ICUs. The development of multidrug resistance in this organism in recent times 
had made the treatment of the infections difficult. Thus, Acinetobacter spp. is emerging 
as an increasingly important multidrug resistant pathogen, spreading in hospitals, and 
causing severe adverse outcomes. Besides that, Acinetobacter spp. seems to be 
spreading from hospital to hospital, and it has caused endemic infections in various 
geographical areas through multiple hospital outbreaks. It has become a leading 
nosocomial pathogen in many hospitals as compared to other non-fermenting Gram-
negative bacilli. Therefore, a new strategy in the successful treatment of Acinetobacter 
infections is an absolute necessity.   
 Research findings have shown that A.baumannii forms biofilm with enhanced 
antibiotic resistance. The current view of biofilm infections leads to the realization that 
their effective control will require a concerted effort to develop therapeutic agents that 
target the biofilm phenotype and community signaling–based agents that prevent the 
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formation, or promote the detachment, of biofilms. Although such a model fits the 
concept of density-driven cell–cell communication and appears to describe biofilm 
development in several bacterial species and conditions, biofilm formation is 
multifactorial and complex. These include QS signal molecules, oligopeptides, amino 
acids such as glutamate and aspartate, and fatty methyl esters. Genetic analysis of 
biofilm formation has led to the proposal that extracellular signals and quorum sensing 
regulatory systems are essential for differentiated biofilms. 
 Disruption of the quorum sensing signals would therefore attenuate the 
pathogenicity of the organism by inhibiting the biofilm formation. There are a variety of 
quorum quenchers available which can effectively disrupt quorum sensing. 
 We through this study, proposed to elucidate the quorum sensing properties of 
clinical isolates of Acinetobacter spp. and interrupt these QS molecules by some of the 
quorum quenching strategies. Thus, the study was designed with the following 
objectives: 
1. To determine the QS properties of the Acinetobacter spp. isolates. 
2. To perform various assays to identify, quantify and characterise the QS 
molecules (N-acyl homoserine lactones
 
(AHL) in gram negative organisms).  
3. To investigate the gene involved in quorum sensing and creating mutant in the 
later stages of biofilm development which can be used for quorum quenching.  
4. To record the effects of natural sources as potential quorum quenchers. 
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2.1 Bacterial strains 
2.1.1 Sample strains 
          Fifty strains that were identified as Acinetobacter spp. were obtained from the 
Diagnostic Bacteriology Laboratory, University Malaya Medical Centre (UMMC) 
between August 2003 to March 2004. The strains were obtained from invasive and non-
invasive sites which include blood, tracheal secretion, sputum, throat swab, peritoneal 
fluid, wound, bronchial lavage, and urine. The identity of the isolates was confirmed 
using standard laboratory methods which include Gram-stain, colony morphology, 
lactose fermention, and the oxidase test. The isolates were further confirmed to belong 
to the Acinetobacter baumannii/calcoaceticus complex using API20NE kit 
(bioMerieux, France).  
          Further species level identification was done using the molecular method of 
ARDRA (Amplified ribosomal DNA restriction analysis) (Koeleman et al., 1998). All 
the strains were shown to belong to the Acinetobacter baumannii- calcoaceticus 
complex (ABC). This has been reported in our previous study with the same isolates 
(Wong et al., 2010). The test isolates were grown at 37ºC on Luria Bertani broth (LB, 
Difco) (1% peptone, 0.5% yeast extract, 0.5% NaCl; PH 7.00) (Bertani, 1951). 
2.1.2 Biosensor strains 
         The biosensor strains detect AHL signals by the activation of a reporter gene such 
as lacZ or lux or by the production of or inhibition of a purple pigment in 
Chromobacterium violaceum. Chromobacterium violaceum strain CV026 was the 
monitor strain used to screen for AHL-producing Acinetobacter strains. The CviR 
(Chromobacterium violaceum Repressor) of Chromobacterium violaceum strain CV026 
(Throup et al., 1995) regulates the production of a purple pigment when induced by 
AHL. Certain long-chained AHLs reversibly inhibit the induced CviR resulting in a lack 
of pigment when compared to a control. The CV026 strain was routinely grown in a 
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shaker incubator in LB solidified with 1.25% agar when required and supplemented 
with 20 g/l of kanamycin. For screening AHLs, TY medium containing (per liter) 8 g 
of Bacto Tryptone (Difco Laboratories), 5 g of yeast extract, and 5 g of NaCl (pH 7) 
was used. 
2.1.3 Characterization of the bacterial isolates 
 Pure cultures of the isolates were obtained and all the standard routine methods of 
identification and characterization were carried out. These include Gram staining 
reaction, motility test, and biochemical tests including Methyl Red-Voges- proskauer 
(MR-VP) test, Triple sugar iron agar test, Simmon‘s citrate, Oxidase test. All these tests 
were performed using the standard protocols available. 
 For further characterization, API20NE was used. This is a standardized system for 
the identification of non-fastidious, non-enteric Gram-negative rods, combining 8 
conventional tests which include potassium nitrate (NO3), L-tryptophane (TRP), D-
glucose (GLU), L-arginine (ADH), urea (URE), esculin ferric citrate (ESC), gelatin 
(GEL), and 4-nitrophenyl--D-galactopyranoside (PNPG), and also the 12 assimilation 
tests which include D-glucose (GLU), L-arabinose (ARA), D-mannose (MNE), D-
mannitol (MAN), N-acetyl-glucosamine (NAG), D-maltose (MAL), potassium 
gluconate (GNT), capric acid (CAP), adipic acid (ADI), malic acid (MLT), trisodium 
citrate (CIT), and phenylacetic acid (PAC). Following the tests, results were analyzed 
using the database incorporated in the APILAB software (bioMerieux, France). These 
tests were performed according to the manufacturer‘s instructions. 
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2.2 Quantification of biofilm formation  
2.2.1 Microtiter plate method 
 Biofilm formation was determined by the ability of cells to produce extracellular 
polymeric substances and adhere to the base of 96-well polystyrene plate using the 
method of Boddey et al. (2006) with modification. Briefly, 100 l of LB broth was 
added into each well of sterile 96-well polystyrene plate followed by the addition of 1 l 
of bacterial culture that was grown at 37C overnight with shaking at 150 rpm. The 
plate was incubated without shaking at 37C for 18 hours. Thereafter, 1 l from each 
well was transferred into triplicate wells of a fresh 96-well plate containing 100 l of 
fresh LB and the plates were incubated without shaking for 24 hours at 37C. Following 
incubation the supernatant was discarded carefully and the wells were stained with 150 
l of 1% crystal violet at room temperature for 30 minutes. The stain was then removed 
and the wells were washed twice with 175 l sterile deionized water, before the addition 
of 175 l of dimethyl sulfoxide (DMSO) to solubilize the crystal violet. The plate was 
then read spectrophotometrically at an absorbance wavelength of 570 nm. For each 
strain the assay was run in triplicate wells and in three independent experiments. Wells 
containing only the medium was used as control. The same protocol was followed to 
quantify the biofilm after prolonged incubation at 37C for 48 hours and then they were 
compared to the biofilms formed after incubation for 24 hours. 
2.2.2 Statistical Analysis 
 The significance of the biofilms formed by the 50 isolates were statistically 
analysed by using the independent sample two-tailed t test. All the t tests were 
performed by SPSS software.  
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2.3 Screening for Acyl Homoserine Lactones (AHLs) 
2.3.1 Chromobacterium violaceum CV026 induction assay 
 Screening for AHL production among the 50 isolates was done as follows: A 
fresh plate of C.violaceum CV026 was prepared on LB agar plates containing 20 g/ml 
kanamycin. This plate was incubated overnight at 37C. A loopful of cells was taken 
and resuspended in 10 l of sterile water and adjusted to an OD 600 nm of approximately 
0.1. Then 5 ml of this culture was added to 200 ml of cooled TY agar and poured as a 
thin plate. The test strains were grown separately in 5 ml of TY broth for 24 hours and 
then diluted to an OD 600 nm of 1.0. About 5 l drops of the test strains were then added 
to the previously prepared chromoplate and allowed to dry. The tests are done in 
duplicate and incubated for 2-3 days at 28C. This test can detect the presence of short 
chain AHL producing test strains. Monitor strains themselves served as negative control 
and monitor strains in plate containing 75nM HHL served as positive control. The basic 
concept of this method was adopted from McClean et al. (1997). This method was 
previously not used for directly screening AHL producing bacteria. 
2.3.2 Chromobacterium violaceum CV026 inhibition assay 
 For detecting the long chain AHLs producing test strains a variant of 
Chromobacterium violaceum CV026 induction assay was carried out in which the 
chromoplate was prepared along with 75 nM concentration of N-Hexanoyl Homoserine 
lactone (HHL) incorporated in the medium. The inhibition of the induced violacein 
production reveals a positive result. 
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2.4 Quantification of AHLs 
2.4.1 Well-diffusion assays (Induction and Inhibition) 
 Quantifications of the AHLs produced by the test strains can be done semi-
quantitatively by well-diffusion assays. This was done as described by Ravn et al. 
(2001)
 
with some modifications. The agar plates were prepared as follows: a preculture 
of Chromobacterium violaceum CV026 was grown in LB for 24 hours at 25C with 
aeration and 2 ml of the preculture was used to inoculate 100 l of LB broth. The 
culture was grown for 24 hours at 25C with aeration and was poured into 200 ml of LB 
agar (1.2 % agar) containing 20 g/l kanamycin maintained at 46C. The agar culture 
solution was immediately poured as 20 ml portions in petri dishes. Fifty l volumes of 
AHL containing solutions (different concentrations of the standards) were pipetted into 
wells (6mm) punched in the solidified agar. The plates were incubated at 25C for 48 
hours before the diameter of the AHL induced purple pigmented zones surrounding the 
wells were measured. For the inhibition of the induced CV026, the LB-agar was 
supplemented with 75 nM N-hexanoyl L-homoserine lactone (HHL, Sigma- Aldrich). 
Here the inhibited colourless zones were measured. 
2.4.2 Standard curve derivation  
 Standard curve showing the relationship between concentration of acylated 
homoserine lactone (N-hexanoyl homoserine lactone (HHL) & N-Decanoyl homoserine 
lactone (DHL)) and resulting diameters of induced / inhibited zones in 
Chromobacterium violaceum CV026 monitor  system was derived. This curve was used 
to test the extraction efficiencies of the isolates that tested positive for the production of 
the AHL signal molecules.  
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2.4.3 Well-diffusion assay for the positive isolates 
 For detecting the quantity of AHLs present in each of the test isolates which tested 
positive for the presence of AHL in the preliminary screening tests, their zones of 
induction or inhibition were compared with that of the standards. This was done as 
described by Ravn et al. (2001)
 
with some modifications. The agar plates were prepared 
as follows: a preculture of Chromobacterium violaceum CV026 was grown in LB for 24 
hours at 25C with aeration and 2 ml of the preculture was used to inoculate 100 l of 
LB broth. The culture was grown for 24 hours at 25C with aeration and was poured 
into 200 ml of LB agar (1.2 % agar) containing 20 g/l kanamycin maintained at 
46C. The agar culture solution was immediately poured as 20 ml portions in petri 
dishes. Fifty l volumes of AHL containing solutions (the extraction from culture 
supernatants)) were pipetted into wells (6 mm) punched in the solidified agar. The 
plates were incubated at 25C for 48 hours before the diameter of the AHL induced 
zones surrounding the wells was measured. For the inhibition of the induced CV026 
(detection of long chain AHL molecules), the LB-agar was supplemented with 75 nM 
N-hexanoyl L-homoserine lactone (HHL, Sigma- Aldrich). Quantifications were done 
based on the comparison of the induction and inhibition zone diameters of the test 
isolates with the standard curves derived.  
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2.5 Identification of AHLs  
2.5.1 Extraction of AHLs from the culture Supernatants 
 Extractions for Thin Layer Chromatography (TLC) were prepared as described by 
Shaw et al. (1997)
 
with minor modifications. Ten-milliliter volumes of the bacterial 
cultures were centrifuged and the supernatants were extracted with an equivalent 
volume of ethyl acetate acidified by supplementing with 0.5% formic acid. The mixture 
was shaken vigorously for 30 seconds and the two phases were allowed to separate. The 
shaking was repeated three times before the ethyl acetate containing fraction was 
removed and another 10 ml fraction was added. The whole extraction process was 
repeated three times. The combined extracts were dried filtered and evaporated to 
dryness. Residues were dissolved in 50-100 l of HPLC–grade ethyl acetate. 
Comparisons were made of extraction efficiencies using both acidified and non-
acidified ethyl acetate exracts.  
2.5.2 Thin Layer Chromatography Bioassay 
 This assay is used for semi-qualitatively identifying the AHLs produced by the 
isolates. Synthetic AHLs or test sample extracts dissolved in ethyl acetate in volumes of 
10-20 l were spotted onto C18 reversed phase TLC plates (aluminum sheets 20x20 cm; 
RP – 18 F254S, 1.05559, Merck 64271, Darmstadt, Germany) and the chromatogram was 
developed using a solvent system of Methanol/water (60:40v/v) as described by Shaw et 
al, (1997). After development, the solvent was evaporated and the dried plates were 
overlaid with a culture of the CV026 monitor strain (induction or inhibition). A 30 ml 
overnight culture of CV026 was used to inoculate 150 ml of LB medium, and the 
culture was spread over the surface of the developed plates. After the agar had 
solidified, the plates were incubated overnight at 30C in a sterilized closed plastic 
container. For CV026 inhibition assay the medium was incorporated with 75nM N-
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hexanoyl L-homoserine lactone obtained commercially. Synthetic Decanoyl 
Homoserine Lactone (DHL) and Dodecanoyl Homoserine Lactone (dDHL) were used 
as standards in this assay.  
2.5.3 Mass Spectrometry (MS) 
2.5.3.1 Preparation of extracts for MS 
 Extracts used for TLC were also subjected to Mass Spectrometric analysis. 
Sample pellets were re-suspended in a mixture of 50% acetonitrile:distilled water  0.1% 
formic acid (200 µl) initially using a pipette, then sonicated for several minutes. The 
samples were centrifuged for 5 minutes at maximum rpm and then the supernatant was 
carefully removed and transferred to a new vial. 10 µl of each sample was transferred to 
a sample vial with insert and diluted 1 in 5 by addition of 50% acetonitrile, 0.1 % 
formic acid (40 µl). 
2.5.3.2 Preparation of Standards 
 The standards of beta-ketocaproyl, hexanoyl, heptanoyl, octanoyl and decanoyl 
were diluted using 100% acetonitrile. The diluted standards were mixed to provide a 
stock solution containing all standards with the following concentrations: 0.1, 0.5, 1, 5, 
10, 50, 100, 500, 1000, 5000 and 10,000 micromolar (µM). Standard curves were 
generated for the initial quantification experiment using all the above mentioned 
standards. The AHLs present in the isolates culture extracts were quantified by using 
these standard curves. 
2.5.3.3 Instrumentation 
 An Agilent 6420 LC-ESI-QQQ using a dynamic multiple reaction monitor 
(DMRM) was used for quantification. Instrument conditions were: Gas Temperature: 
300°C, Gas Flow: 10.5 L/min, Nebulizer: 45 psi, Capillary (positive): 4000V. Samples 
were injected (2µl) and separated by reverse-phase chromatography on an Agilent 
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Poroshell 120 EC-C18 (2.1 x 100 mm, 2.7 µm, 600 Bar) column, using the following 
buffers (100% water/0.1% FA) and (100% ACN/0.1% FA), with temperature 
maintained at 35°C. 
The samples were analysed using an Agilent 6520 LC-ESI-QTOF in full scanning 
positive ion mode or auto-MS/MS mode in a range of 50-1600 m/z was. Instrument 
conditions were: Gas Temperature: 300°C, Gas Flow: 10.5 L/min, Nebulizer: 45 psi, 
Capillary (positive): 4000V, Fragmentor: 150V, Skimmer 65V. Samples were injected 
in 1 µl volumes and separated by reverse-phase chromatography on an Agilent 
Poroshell 120 EC-C18 (2.1 x 100 mm, 2.7 µm, 600 Bar) column, using the following 
buffers (100% water/0.1% FA) and (100% ACN/0.1% FA), with temperature 
maintained at 35°C. 
2.5.3.4 MS-MS 
 MS/MS Spectra were collected using the following parameters: MS (Full scan) 
range: 100-1600 m/z collected at a rate of 1 spectra/s. Auto MS/MS range: 50-1600 m/z 
collected at rate of 3 spectra/s with a maximum of 5 precursors selected and fragmented 
using collision energy of 25V. Precursors were excluded after 1 spectra for a period of 
30 seconds. 
Table 2.1: Chromatographic conditions. 
 
Time (minutes) % Solvent B Flow Rate (µl.min
-1
) 
0.00 15 400 
1.00 15 400 
6.00 100 400 
7.00 100 400 
7.10 15 400 
10.00 15 400 
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Table 2.2: DMRM List used for quantification. 
Compound 
Name 
Pre-
cursor 
Ion 
MS1 
Res 
Product 
Ion 
MS2 
Res 
Frag- 
mentor 
Collision 
Energy 
Ret 
Time 
(min) 
Delta 
Ret 
Time 
β-Ketocaproyl 214.1 Unit 113 Unit 75 9 1.8 1 
β-Ketocaproyl 214.1 Unit 102.1 Unit 75 9 1.8 1 
β-Ketocaproyl 214.1 Unit 74.1 Unit 75 21 1.8 1 
Hexanoyl 200.1 Unit 102 Unit 75 5 3.6 0.75 
Hexanoyl 200.1 Unit 74.1 Unit 75 13 3.6 0.75 
Hexanoyl 200.1 Unit 71.1 Unit 75 9 3.6 0.75 
Heptanoyl 214.1 Unit 113.1 Unit 80 5 4.3 0.75 
Heptanoyl 214.1 Unit 102 Unit 80 9 4.3 0.75 
Heptanoyl 214.1 Unit 85.1 Unit 80 9 4.3 0.75 
Octanoyl 228.2 Unit 102 Unit 80 9 4.8 0.75 
Octanoyl 228.2 Unit 74.1 Unit 80 13 4.8 0.75 
Octanoyl 228.2 Unit 57.1 Unit 80 17 4.8 0.75 
Decanoyl 256.2 Unit 102.1 Unit 70 9 5.75 0.75 
Decanoyl 256.2 Unit 71.1 Unit 70 13 5.75 0.75 
Decanoyl 256.2 Unit 57.1 Unit 70 17 5.75 0.75 
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2.6 Identification of the QS gene in Acinetobacter spp. and construction of its 
mutant 
 The autoinducer synthase coding gene abaI was identified among the clinical 
isolates and the PCR purified product of this gene was cloned and transformed into 
competent cells. The recombinant plasmid carrying the abaI gene was further isolated 
and a mutant of this gene was created by insertional inactivation of the coding region of 
the gene. The biofilm forming capabilities of the wild-type and the mutant genes were 
evaluated. 
2.6.1 Identification of abaI gene in Acinetobacter spp. producing the QS signal 
molecules by Polymerase Chain Reaction (PCR) 
 The presence of abaI gene encoding an autoinducer synthase was identified by 
polymerase chain reaction (PCR) using the primers published by Niu et al, (2008). The 
primers that were specific to the abaI gene, F-5‘-
GTACAGTCGACGTATTTGTTGAATATTTGGG-3‘ and R-5‘-
CGTACGTCTAGAGTAATGAGTTGTTTTGCGCC-3‘ were used. The template DNA 
for PCR was prepared using the epicentre masterpure DNA isolation kit following the 
manufacturer‘s instructions. The final PCR amplification reaction mixture contained 5.0 
mM PCR buffer,  8.3 mM MgCl2, 200 nM dNTP (MBI,  Fermentas, Vilnius, Lithuania), 
0.3 µM of each primer pair, 2 units of Taq DNA polymerase (MBI, Fermentas) and 3 µl 
of DNA template in a final volume of 25 µl. The PCR amplification was performed 
with mycyler thermocycler (BioRad laboratories, Hercules, CA). The parameters for 
amplification of abaI gene are shown in Table 2.3.  
 The PCR products were then electrophoresed on a 2% agarose gel (Pronadisa, 
Hispanlab, Spain) with ethidium bromide (0.5 µg/ml) incorporated into the gel, at 70 to 
90 V for one and half hours. A 100 bp DNA ladder (Promega, Wisconsin, USA) was 
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used to estimate the size of the PCR products. The gel was then documented using the 
gel documentation system. The resulting amplicons of all the isolates that were positive 
for the AHL production were subjected to sequence analysis. 
Table 2.3: Parameters for amplification of abaI gene.   
Step and Temperature Time 
Initial denaturation, 94C 10 minutes 
Denaturation, 94C 30 seconds 
Annealing, 66.5C 30 seconds 
DNA extension, 72C 60 seconds 
Final extension, 72C 5 minutes 
Cycles 30 
 
2.6.2 Sequencing and identity of the abaI gene PCR product 
 PCR fragments from the representative isolates for the abaI gene were sequenced 
to confirm the identity of the genes. Template DNA to be sequenced had to be sufficient 
in quantity and free of proteins, RNA, genomic DNA, EDTA and other salts to ensure 
good results. The quality and quantity of the purified DNA were measured by scanning 
the samples in a nanospectrophotometer. This was used to determine the ratio of 
A260/A280 and the concentration of the DNA sample. An optimum ratio (A260/A280) 
of > 1.8 and a concentration of between five to 20 ng/µl for a nucleotide length of 200 
to 1,000 bp were deemed to be suitable for sequencing. 
 The purified DNA samples were sequenced at the First-Base Laboratory 
(Malaysia) using the Applied Biosystems 3730 DNA Analyser (Life Technologies, 
USA). The sequences were then downloaded and analysed using the BLAST tool 
available at the GenBank (http://www.ncbi.nlm.nih.gov), which compared the sequence 
with the published sequences in the GenBank by giving the percentage of homology. 
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2.6.3 Sequence analysis and Bioinformatics tools 
 All sequencing outputs for the respective genes (forward and reverse compliment 
sequences) were aligned and combined to produce a single targeted nucleotide length 
using ClustalW program (Table 2.4). The finalized longer partial sequence of the 
respective genes were analysed for their identity, amino acid sequence homology and 
protein structure using the bioinformatics tools available online at their respective 
websites. Table 2.4 lists all the tools with their respective functions. 
Table 2.4. Bioinformatics tools, websites and their functions. 
Tools 
a
 Website addresses and functions 
BioEdit http://www.mbio.ncsu.edu/bioedit/bioedit.html 
( To do simple sequence and alignment editing and manipulations) 
Sequencher http://www.genecodes.com/ 
( To perform DNA sequence assembly and analysis ) 
Reverse Compliment http://www.bioinformatics.org/sms/rev_comp.html 
(To return the reverse compliment of the antisense DNA strand) 
ClustalW http://www. Ebi.ac.uk/Tools/clustalW/index.html 
(To align and compare multiple sequences) 
DNA-Protein http://www.expasy.org/tools/ 
(To translate nucleotide sequences to amino acid sequences) 
BLAST http://www.ncbi.nlm.nlh.gov 
(To search for homologous nucleotide or amino acid sequences in the 
GenBank and predict the sequence identity) 
 
a
Detailed instructions for using the tools are available at the respective websites. 
 
2.6.4 Cloning of the abaI gene 
2.6.4.1 Purification of the abaI PCR product 
 The PCR product to be cloned was purified using the Expin PCR purification kit 
(GeneAll Biotechnology, Korea) following the manufacturer‘s instructions. Briefly, 
about 5 volumes of buffer PB was added to 1 volume of the PCR product to be purified 
and mixed thoroughly and then the mixture was transferred to a SV column. This was 
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then centrifuged at 13,000 rpm for 30 seconds. The pass-through was discarded and the 
column was inserted back into the same tube. About 700 µl of buffer NW was added 
and centrifuged at 13,000 rpm for 30 seconds. The pass-through was again discarded 
and the column was inserted back into the collection tube. An additional centrifugation 
for 1 minute was done to remove any residual wash buffer and the SV column was 
transferred to a new 1.5 ml eppendorf tube. About 50 µl of buffer EB was then added to 
the centre of the membrane in the SV column and this was allowed to stand for 60 
seconds and then centrifuged at 13,000 rpm for 60 seconds. The purified PCR DNA was 
thus obtained. This purified DNA was further used in the cloning experiment.   
2.6.4.2 Cloning of the abaI gene  
 Cloning of the abaI gene was done using the TOPO TA cloning kit (Invitrogen 
Corporation, California) following the manufacturer‘s instructions. The purified PCR 
product was first treated with Taq polymerase buffer with dATP and 0.5 U Taq 
polymerase. This mixture was then incubated for 10-15 minutes at 72ºC and used 
immediately in the cloning reaction. The purified PCR product was cloned using the 
vector pCR 2.1-TOPO (Figure 2.1). Table 2.5 describes how the cloning reaction was 
set up. The total volume of the cloning reaction was 6 µl. This was eventually used to 
transform chemically competent E.coli. All the components were added in the same 
order as in table 2.5, mixed gently and incubated for 5 minutes at room temperature. 
This reaction mix was then placed on ice and was be stored at -20ºC overnight before 
being transformed into competent E.coli. 
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Figure 2.1: Map of pCR TOPO 2.1 
 
 
 
pCR 2.1-TOPO (3931 nucleotides): 
 
LacZa fragment: bases 1-547 
M13 reverse priming site: bases 205-221 
Multiple cloning site: bases 234-357 
T7 promoter/priming site: bases 364-383 
M13 Forward (-20) priming site: bases 391-406 
f1 origin: bases 548-985 
Kanamycin resistance ORF: bases 1319-2113 
Ampicillin resistance ORF: bases 2131-2991 
pUC origin: bases 3136-3809 
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Table 2.5: Components of the cloning reaction. 
Reagent Volume of the component reagents 
Fresh purified PCR product 2 µl 
Salt solution 1 µl 
Water 2 µl 
TOPO Vector 1 µl 
Final Volume 6 µl 
 
2.6.5 Transformation of One Shot TOP10 E.coli competent cells 
 The transformation was done following the instructions of the manufacturer. 
Before starting the transformation reaction selective LB plates containing 50 µg/ml 
ampicillin was prepared. For each transformation reaction one vial of competent cells 
was used. A water bath was set at 42ºC and S.O.C. medium was warmed to room 
temperature. The selective plates were also warmed at 37ºC for 30 minutes. 40 µl each 
of 40 mg/ml X-gal and 100 mM IPTG were spread plated on the LB selective plates and 
incubated at 37ºC until it was used. The vial containing the competent cells was thawed 
on ice. 
 The chemically competent cells of E.coli were treated with 2 µl of cloning 
reaction mixture from the previous experiment and were mixed gently. The mixture was 
incubated on ice for 30 minutes. The cells are now heat-shocked at 42ºC for 30 seconds 
without shaking and the tubes were immediately transferred to ice. Then to this tube 250 
µl of S.O.C. medium was added and capped. The tube was incubated at 37ºC for one 
hour with shaking at 200 rpm. About 20 µl of the transformation mixture was mixed 
with equal volume of S.O.C. medium and spread plated onto prewarmed selective LB 
plate and incubated at 37ºC overnight. Approximately 10 white or light blue colonies 
were picked as positive transformants for further analysis. The dark blue colonies were 
negative for transformation and so they were not carried forward for further analysis. 
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2.6.5.1 Scale-up of the Competent E.coli cells 
 The competent cells provided were grown and scaled-up for further 
transformation experiments. A loopful of the competent bacteria provided was 
inoculated into 5 ml of LB broth containing 50 mg/ml ampicillin and incubated at 37ºC 
overnight at 150 rpm. About 0.5 ml of the overnight culture was pipette into 50 ml of 
fresh LB broth and allowed to grow until it reaches an OD of 0.5 at A600nm. Then the 
culture was incubated on ice for one to two hours. The culture was then centrifuged at 
5000 rpm at 4ºC for 10 minutes. The supernatant was discarded. The pellet was 
resuspended in 1.7 ml of 0.1 M CaCl2 and 0.3 ml of 50-80% glycerol and incubated for 
one hour. About 100 µl of this mixture was aliquotted into separate 1.5 ml eppendorf 
tubes. The tubes were snap freezed in liquid nitrogen and then was stored at -80ºC until 
used for transformation experiment. 
2.6.6 Confirmation of the clone by colony PCR 
 The positive transformants were analysed directly by using PCR. The primers 
specific for the abaI gene F-5‘-GTACAGTCGACGTATTTGTTGAATATTTGGG-3‘ 
and R-5‘-CGTACGTCTAGAGTAATGAGTTGTTTTGCGCC-3‘ were used (Niu et al, 
2008). For PCR reaction the Taq Mastermix (Geneall Biotechnology, Korea) and 20 
µM each of the forward and the reverse primers were used. About 48 µl of the 
mastermix was added into the microcentrifuge tube and 1 µl each of the forward and 
reverse primers were added to the mastermix. Around 10 colonies from the suspected 
positive transformants were picked and individually resuspended into the 50 µl of PCR 
cocktail from the above step. The colonies were preserved for further analysis. The 
reaction was incubated for 10 minutes at 94ºC to lyse cells and inactivate nucleases. The 
PCR amplification was performed with mycyler thermocycler (BioRad laboratories, 
Hercules, CA) for around 30 cycles. The parameters for amplification are shown in 
Table 2.3.  
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 The PCR products were then electrophoresed on a 2% agarose gel (Pronadisa, 
Hispanlab, Spain) with ethidium bromide (0.5 µg/ml) incorporated into the gel, at 70 to 
90 Vfor one and half hours. A 100 bp DNA ladder (Promega, Wisconsin, USA) was 
used to estimate the size of the PCR products. The gel was then documented using the 
gel documentation system. The resulting amplicons of all the isolates that were positive 
for the presence of the abaI gene were subjected to further analysis. 
2.6.7 Confirmation of the clone by restriction digestion 
 The transformants were also analysed for the presence of the abaI gene by 
restriction analysis. About 2-6 white or light blue colonies from the selective plate were 
cultured overnight in LB medium containing 50 µg/ml ampicillin. The plasmid DNA 
from this culture was isolated using the Exprep Plasmid isolation kit (GeneAll 
Biotechnology, Korea), following the manufacturer‘s instructions. Briefly, a single 
colony of the recombinant E.coli carrying the plasmid with abaI gene was inoculated 
into LB broth containing ampicillin and incubated at 37ºC for 24 hrs. About 1.5 ml of 
the overnight culture was aliquoted into 1.5 ml eppendorf tube and centrifuged at 
13,000 rpm at room temperature for one minute. The supernatant was discarded and the 
pellet was stored at -20 C until use. The pellet was then resuspended thoroughly in 170 
µl of buffer S1 and 170 µl of buffer S2. The tubes were then mixed by inverting three to 
four times. This mixture is incubated for less than 5 minutes until the cell suspension 
becomes clear. Then the lysate is treated with 250 µl of buffer G3 and immediately 
mixed by inverting the tube 3 to 4 times. The lysate was then transferred carefully to the 
EzClear column stack by decanting or pipetting. The column was then centrifuged for 
30-60 seconds, the upper filter column unit discarded and the SV column was removed. 
The pass-through was discarded and the SV column was re-inserted into the collection 
tube. After this 500 µl of buffer AW was added and centrifuged for 30 seconds. The SV 
column was then removed and the pass-through was discarded and the column re-
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inserted into the collection tube. Then 700 µl of buffer PW was added and centrifuged 
for 30 seconds, SV column removed and the pass-through discarded and the column re-
inserted into the collection tube. Then an additional step of centrifugation for 1 minute 
was done to remove any residual wash buffer. The SV column was transferred to a new 
1.5 ml eppendorf tube. About 50 µl of buffer EB was added and centrifuged for 1 
minute. The tube contains the purified plasmid DNA.  
 The plasmid DNA isolated was then subjected to restriction digestion using the 
EcoRI (FastDigest EcoRI, Fermentas, Lithuania) following the manufacturer‘s 
instruction. Briefly, the reaction components listed in table 2.6 were mixed at room 
temperature in the same order as in the table. The mixture was then gently mixed and 
spinned down. The mixture was then incubated at 37ºC in a heat block for 5 minutes 
and the enzyme was inactivated by heating for 5 minutes at 80ºC.  
 The digested plasmids along with the uncut plasmid DNA was then 
electrophoresed on a 0.7% agarose gel (Pronadisa, Hispanlab, Spain) with ethidium 
bromide (0.5 µg/ml) incorporated into the gel, at 70 to 90 V for one and half hours. A 
1000 bp DNA ladder (Promega, Wisconsin, USA) was used to estimate the size of the 
plasmid DNA. The gel was then documented using the gel documentation system. The 
resulting cut fragments of the digested plasmid DNA was analysed for the presence of 
the abaI gene. 
Table 2.6: Reaction components used for the restriction digestion of the 
recombinant plasmid. 
Components Volume of the components 
Water (nuclease-free) 15 µl 
10X Fast Digest buffer 2 µl 
Pasmid DNA 2 µl 
FastDigest enzyme 1 µl 
Total volume 20 µl 
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2.6.8 Confirmation by sequencing 
 The positive clones were further confirmed for the presence and also for proper 
orientation of the cloned gene abaI by sequencing. The M13 forward and M13 reverse 
primers were used for the sequencing purpose as the cloned gene is flanked by these 
primer sequences. The map of the pCR 2.1-TOPO is given in Figure 2.1.  
 The purified PCR DNA products were sequenced at the First-Base Laboratory 
(Malaysia) using the Applied Biosystems 3730 DNA Analyser (Life Technologies, 
USA). The sequences were then downloaded and analysed using the BLAST tool 
available at the GenBank (http://www.ncbi.nlm.nih.gov), which compared the sequence 
with the published sequences in the GenBank by giving the percentage of homology and 
the presence of abaI gene.  
2.6.9 Construction of the mutant of abaI gene 
 
 The recombinant plasmid containing the abaI gene from the previous experiment 
was isolated using Exprep Plasmid isolation kit (GeneAll Biotechnology, Korea), 
following the manufacturer‘s instructions as described in section 2.7.7. The plasmid 
DNA was then checked for purity and quantified using the nanospectrophotometer and 
was run on 0.8% agarose gel prepared in TAE buffer with ethidium bromide 
incorporated within the gel in order to view the plasmids. A 1 kb DNA ladder 
(Promega, Wisconsin, USA) was run along as a marker. This plasmid was digested in 
the middle of the coding region of the abaI gene and an insertion was done to inactivate 
the abaI gene. 
2.6.9.1 Selection of the restriction enzyme for the blunt end digestion 
 The coding region of the abaI gene within the plasmid was cut by a blunt-end 
cutter SspI. This restriction enzyme was selected from the list generated by using the 
software NEBcutter V2.0. The data generated is shown in the table 2.7.    
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Table 2.7: NEBcutter V2.0 analysis of the abaI gene for the selection of the 
restriction enzyme for blunt end ligation. 
 
 
2.6.9.2 Restriction digestion of the recombinant plasmid with abaI gene 
 The recombinant plasmid DNA with abaI gene was isolated and then subjected to 
restriction digestion using the SspI (FastDigest SspI, Fermentas, Lithuania) following 
the manufacturer‘s instruction. Briefly, the reaction components listed in table 2.8 were 
mixed at room temperature in the same order as in the table. The mixture was then 
MATERIALS & METHODS 
 
   Page: 74 
  
gently mixed and spinned down and incubated at 37ºC in a heat block for 5 minutes and 
the enzyme was inactivated by heating for 5 minutes at 80ºC. The resulting cut 
fragments of the digested plasmid DNA was used for ligation reaction with the 
tetracycline gene cassette. 
Table 2.8: Reaction components used for the restriction digestion of the 
recombinant plasmid. 
Components Volume of the components 
Water (nuclease-free) 15 µl 
10X Fast Digest buffer 2 µl 
Pasmid DNA 2 µl 
FastDigest enzyme 1 µl 
Total volume 20 µl 
 
 
2.6.9.3 Blunt end ligation of the tetracycline gene and the recombinant plasmid 
 The linearized vector from section 2.6.9.1 was dephosphorylated with calf 
intestinal phosphatase (CIP) purchased from New England Biolabs following the 
manufacturer‘s instructions.  Briefly, the reaction components listed in table 2.9 were 
mixed in the same order as in the table. The mixture was then gently mixed and 
incubated at 37ºC in a heat block for 60 minutes. The resulting dephosphorylated 
fragment was treated with 20 µl of 200mM ethylene diamine tetraacetic acid (EDTA) 
and incubated at 65ºC for 10 minutes.  The digested plasmid DNA was then used for 
ligation reaction with the tetracycline gene cassette. For ligation reaction Fast DNA 
ligation kit (Fermentas, Lithuania ) was used following the manufacturer‘s instructions. 
Briefly, the reaction components listed in table 2.10 were mixed at room temperature in 
the same order as in the table. The mixture was then gently vortexed and spinned down 
and incubated at 22ºC for 5 minutes. About 2 μl of the ligation mixture was used for 
transformation. 
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Table 2.9: Reaction components used for the dephosphorylation of the restriction 
digested recombinant plasmid. 
Components Volume of the components 
10X CIP buffer 20 µl 
CIP (1unit/ml) 10 µl 
Vector DNA 20 µl 
Water (nuclease-free) 150 µl 
Total volume 200 µl 
 
Table 2.10: Reaction components used for the ligation of restriction digested abaI 
gene and tetracycline gene cassette. 
Components Volume of the components 
Water (nuclease-free)  1 µl 
5X Ligation buffer  4 µl 
Linearized vector DNA 12 µl 
Insert (Tetracycline gene cassette) 2 µl 
T4 DNA ligase (5units/ml) 1 µl 
Total volume 20 µl 
 
2.6.10 Transformation of the abaI:Tc mutant plasmid  
 
 The transformation was done as described in section 2.6.5. After the completion 
of transformation the positive transformants containing the abaI::Tetracycline 
(abaI::Tc) mutant plasmid were screened by plating on the selective plate containing 50 
μg/ml ampicillin and 20 μg/ml tetracycline. Approximately 10 colonies were picked as 
positive transformants for further analysis.  
2.6.11 Inactivation of the abaI gene in the chromosome of the Acinetobacter spp. 
S117 
 
 To inactivate the abaI gene in the chromosome of the Acinetobacter spp. S117, 
the insertion that disrupted the abaI gene in the middle along with the flanking 
chromosomal DNA was cloned into pUC18- based suicide delivery vector. This 
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plasmid pUC18.abaI::Tc was introduced into Acinetobacter spp. S117 by conjugation. 
E.coli K12 carrying the pUC18.abaI::Tc plasmid was the donor. Matings were 
performed on filter membrane. Following conjugation, the suicide vector 
pUC18.abaI::Tc would be integrated at the wildtype abaI gene, that results in the 
wildtype copy of the abaI gene and second copy with the abaI::Tc disruption. These 
exconjugants with both the wildtype and the mutant copy of the abaI gene (single 
crossover event) were selected based on their tetracycline and ampicillin resistance 
(tetracycline marker was present on the disrupted abaI gene and ampicillin marker was 
on the pUC18 vector). Following this, the exconjugants were grown without the 
antibiotic pressure. This removes the pressure to maintain the plasmid integration. Then 
the exconjugants that carry only the mutant abaI gene (double crossover event) were 
selected by eliminating any bacteria that have maintained the plasmid integration and 
selecting the bacteria that does not grow in the presence of the vector marker 
(ampicillin). 
2.6.12 Confirmation of the exconjugant clone for the presence of tetracycline gene 
by colony PCR 
 The positive transformants were analysed directly by using PCR. The primers 
specific for the tetracycline gene F-5‘-CGGCTTAGATCTAGGTCGAGGTGGCC-3‘ 
and R-5‘-TCCAACAGATCTATTTGCCGACTACCTTGGTG-3‘ were used. The PCR 
amplification reaction mixture consisted of 10X ipfu buffer, 5 % DMSO, 200 nM dNTP 
(MBI Fermentas, Vilnius, Lithuania), 0.3µM of each primer pair, 2 units of ipfu DNA 
polymerase (MBI Fermentas) to a final volume of 25 µl. The PCR amplification was 
performed with Mycycler Thermocycler (BioRad Laboratories, Hercules, California). 
Around 10 colonies from the suspected positive transformants were picked and 
individually resuspended into the 25 µl of PCR cocktail from the above step. The 
colonies were preserved for further analysis. The reaction was incubated for 10 minutes 
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at 95ºC to lyse cells and inactivate nucleases. The PCR amplification was performed 
with mycyler thermocycler (BioRad laboratories, Hercules, CA) for around 35 cycles. 
The parameters for amplification are shown in Table 2.11.  
 The PCR products were then electrophoresed on a 2% agarose gel (Pronadisa, 
Hispanlab, Spain) with ethidium bromide (0.5 µg/ml) incorporated into the gel, at 70 to 
90 Vfor one and half hours. A 1 Kp DNA ladder (Promega, Wisconsin, USA) was used 
to estimate the size of the PCR products. The gel was then documented using the gel 
documentation system. The resulting amplicons of all the isolates that were positive for 
the presence of the tetracycline gene were considered to be the abaI::Tc mutants. 
Table 2.11: Parameters for amplification of tetracycline gene.   
Step and Temperature Time 
Initial denaturation, 95C 5 minutes 
Denaturation, 95C 30 seconds 
Annealing, 60C 60 seconds 
DNA extension, 72C 90 seconds 
Final extension, 72C 10 minutes 
Cycles 35 
 
2.6.13 AHL production in wildtype and mutant abaI gene 
 The production of AHLs in Acinetobacter spp. S117 with the wildtype and mutant 
abaI gene was carried out as described in section 2.3. Both CV026 induction and 
inhibition assays were carried out and the results were recorded.  
2.6.14 Biofilm formation in wildtype and mutant abaI gene 
 Biofilm formation was determined by the ability of the cells to produce 
extracellular polymeric substances and adhere to the base of 96-well polystyrene plate 
using the method of Boddey et al. (2006) with modification as previously described in 
section 2.2. Both the wild type and mutant abaI were studied for their ability to form 
biofilm after 24 and 48 hours of incubation. The experiment was run in triplicate wells 
and in three independent experiments. Wells containing only the medium was used as 
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control. The difference in biofilm formation in Acinetobacter spp. S117 with the 
wildtype and mutant abaI genes were compared.  
To demonstrate that the biofilm inhibition in the mutant was due to the loss of the AHL 
signal, mutation complementation experiment with the exogenously added AHLs as the 
ethyl-acetate extracts of the culture supernatants from the wildtype and the mutants was 
performed. Only ethyl-acetate was added in the negative control samples.  
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2.7 Natural sources as potential quorum quenchers 
2.7.1 AHL inactivation activity of environmental bacterial isolates 
2.7.1.1 Isolation of soil Bacilli 
 Soil samples were collected and sampling was done at the surface and subsurface 
using a clean spatula. The soil samples were stored in a clean and sterile container. The 
sample was processed by removing all large particles and plant materials such as leaves. 
Each of the soil samples were suspended in sterile distilled water. The soil samples were 
vortexed and the soil bacilli were isolated by plating a serially diluted soil suspension 
(10 g/10 ml of sterile distilled water), which was previously heat treated at 100ºC for 10 
minutes to kill any vegetative forms of bacteria in the soil. The plates were incubated at 
28ºC overnight. Pure colonies were picked for further analysis.  
2.7.1.2 DNA extractions & PCR amplifications of 16S rDNA gene 
 The DNA from pure cultures of the bacterial soil isolates was extracted using the 
Masterpure complete DNA purification kit (Epicenter, USA) following the 
manufacturer‘s instructions except that the cells were initially treated with 200 µM of 
lysozyme since they are suspected to be gram positive bacteria. 
 Soil bacteria were first subjected to PCR amplification to detect the 16S rDNA 
gene sequence specific for Bacillus spp. The PCR amplification reaction mixture 
consisted of 5.0 mM PCR buffer, 8.3 mM MgCl2, 200 nM dNTP (MBI Fermentas, 
Vilnius, Lithuania), 0.3 µM of each primer pair, 2 units of TaqDNA polymerase (MBI 
Fermentas) and 3 µl of template DNA in a final volume of 25 µl. The PCR 
amplification was performed with Mycycler Thermocycler (BioRad Laboratories, 
Hercules, California). The parameters for amplification of 16S rDNA gene are shown in 
Table 2.12. The forward and reverse primers F-5‘-AGAGTTTGATCCTGGCTCAG-
3‘& R-5‘-AAGGAGGTGATCCAGCC-3‘ published by Dong et al., (2002) were used 
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to detect the presence of 16S rDNA gene of the Bacillus spp. The expected amplicon 
size was approximately equal to 1500 bp. 
 The PCR products were then electrophoresed on a 0.7% agarose gel (Pronadisa, 
Hispanlab, Spain) with ethidium bromide (0.5 µg/ml) incorporated into the gel, at 70 to 
90 V for one and half hours. A 1000 bp DNA ladder (Promega, Wisconsin, USA) was 
used to estimate the size of the PCR products. The gel was then documented using the 
gel documentation system.  
Table 2.12.: Parameters for amplification of 16S rDNA gene of Bacillus spp.   
Step and Temperature Time 
Initial denaturation, 94C 5 minutes 
Denaturation, 94C 30 seconds 
Annealing, 50.75C 30 seconds 
DNA extension, 72C 60 seconds 
Final extension, 72C 5 minutes 
Cycles 30 
 
2.7.1.3 16S rDNA gene sequence analysis 
 The sequences of the 16S rDNA products were determined using the Applied 
Biosystems 3730 DNA Analyser (Life Technologies, USA). All sequencing outputs for 
the respective genes (forward and reverse compliment sequences) were aligned and 
combined to produce a single targeted nucleotide length (http://www.genecodes.com/, 
http://www.mbio.ncsu.edu/bioedit/bioedit.html,). The finalized longer partial sequences 
of the 16S rDNA genes were analysed for their identity, amino acid sequence homology 
and protein structure with the sequences already available in the GenBank 
(www.ncbi.nlm.nih.gov) databases using the standard nucleotide–nucleotide BLAST 
program (www.ncbi.nlm.nih.gov). This would reveal the closest relatives to the 
determined sequences. 
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2.7.1.4 Detection of aiiA homologue gene 
 Bacteria which were positive for the Bacillus spp. identification were screened for 
the presence of aiiA homologue gene sequence using PCR. The presence of aiiA gene 
among the Bacillus sp. was detected by running a PCR for this gene using the forward 
primer of F-5‘-ATG GGA TCC ATG ACA GTA AAG AAG CTT TAT-3‘  & a reverse 
primer of R-5‘-GTC GAA TTC CTC AAC AAG ATA CTC CTA ATG-3‘ as reported 
by Dong et al., (2002). The expected amplicon size was approximately equal to 800 bp. 
The parameters for amplification of aiiA gene are shown in Table 2.13 
 The PCR products were then electrophoresed on a 0.7% agarose gel (Pronadisa, 
Hispanlab, Spain) with ethidium bromide (0.5 µg/ml) incorporated into the gel, at 70 to 
90 V for one and half hours. A 1000 bp DNA ladder (Promega, Wisconsin, USA) was 
used to estimate the size of the PCR products. The gel was then documented using the 
gel documentation system.  
 The protocol used was an initial denaturation at 94°C for 10 minutes followed by 
35 cycles of denaturation at 94°C for 30 seconds; primer annealing at 58.35°C for 30 
seconds, primer extension at 72°C for 1 minute and the final extension at 72°C for 5 
minutes.  
Table 2.13.: Parameters for amplification of aiiA gene of Bacillus spp.   
Step and Temperature Time 
Initial denaturation, 94C 10 minutes 
Denaturation, 94C 30 seconds 
Annealing, 58.35C 30 seconds 
DNA extension, 72C 60 seconds 
Final extension, 72C 5 minutes 
Cycles 35 
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2.7.1.5 AHL inactivation assay for the soil isolate extracts 
 To determine AHL-inactivating activity, method described by Dong et al., (2002) 
was followed with slight modification. Briefly, N-hexanoyl homoserine lactone (HHL) 
was added at a final concentration af 20 µM to an overnight soil bacterial culture which 
was diluted to an optical density of 1.1 at 600 nm. The reaction mixture was incubated 
at 28°C. At 0, 3, 6, 9, 12 hours after incubation, cultures were withdrawn and the 
supernatant was UV irradiated. Then amount of HHL remaining in the supernatant was 
determined. The heat inactivated suspension (10 µl) was inoculated onto the LB agar 
seeded with the bioreporter Chromobacterium violaceum strain CV026 and incubated at 
28 ºC. Escherichia coli DH5α strains served as negative controls. Degradation of HHL 
was visualized as loss of purple pigmentation shown by CV026 and the results were 
recorded. 
2.7.2 Inhibition of biofilm and inactivation of AHLs among the clinical 
Acinetobacter spp.  isolates 
 Acinetobacter spp. isolates were cultured in 1.5-ml eppendorf tubes. After 
incubation for 16 h, the bacterial culture was reinoculated into 1.5 ml of fresh medium 
and mixed with an equal volume of culture supernatant from the O/N culture of the soil 
Bacillus sp. which was previously uv-irradiated for 60 min. The mixtures were 
incubated at 28°C for 9 hours for soil isolate B1 and 3 hours for isolate B2, followed by 
the assays to detect the inactivation of AHL and inhibition of biofilm formation.  
 Screening for AHLs among the 7 clinical isolates was done as follows: A fresh 
plate of C.violaceum CV026 was prepared an LB agar plates containing 20 g/ml 
kanamycin. This plate was incubated overnight at 37C. A loopful of cells was taken 
and resuspended in 10 l of sterile water and adjusted to an OD 600 nm of approximately 
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0.4. Then 5 ml of this culture was added to 200 ml of cooled LB agar and poured as a 
thin plate along with 75 nM concentration of N-Hexanoyl Homoserine lactone (HHL) 
incorporated in the medium.  About 5 l drops of the test strains (Acinetobacter spp. 
isolates treated with the soil extracts) were then added to the previously prepared 
chromoplate and allowed to dry. The tests are done in replicate and incubated for 2-3 
days at 28C. Monitor strains themselves served as negative control and monitor strains 
in plate containing 75nM HHL served as positive control. The basic concept of this 
method was adopted from McClean et al, (1997).  
 The extracts from Acinetobacter spp. treated with the soil bacilli were also 
subjected to thin layer chromatography (TLC) bioassay by the method described by 
Shaw et al. (1997) to detect the presence of any AHLs. 
 About 1l of the treated sample was further analysed for biofilm formation. 
Biofilm formation was determined by the ability of cells to produce extracellular 
polymeric substances and adhere to the base of 96-well polystyrene plate using the 
method of Boddey et al. (2006) with modification. The biofilm forming capabilities of 
both the soil extract treated and untreated clinical isolates were analysed in this study. 
2.7.3 AHL inactivation activity of plant extracts 
2.7.3.1 Preparation of the plant extracts 
             Methanolic extracts of four Phyllanthus species (P.amarus, P.niruri, P.urinaria, 
and P.watsonii), garlic bulb and lemon were analysed for their quorum sensing 
inhibition properties. Freshly harvested plant samples were washed, dried in room 
temperature and then freeze dried. For preparing the methanol extract, dried plant 
sample were soaked with absolute methanol. The samples were then homogenized with 
extraction buffer and the supernatant collected after three rounds of extraction.  
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           For garlic and lemon, they were cut into small pieces and dried for 24 hours. 
Dried materials were then ground and 95% ethanol (100 g/1 litre) was added and 
allowed to stand for 24 hours. This was then filtered through whatman no.1 filter paper 
and the filtrate evaporated to dryness under vacuum using a rotary evaporator. The 
resultant residues were stored at -20 ºC until used. Before being used for AHL 
inactivation assay it was reconstituted in 95% ethanol. 
2.7.3.2 AHL inactivation assay for the plant extracts  
 The Chromobacterium violaceum quorum sensing system was used for this assay. 
Cultures of Chromobacterium violaceum CV026 were prepared by growing bacteria in 
Luria Bertani broth (Merck, Germany) and incubated for 16-18 h in an orbital incubator 
running at 30 °C and 150 rpm. Cultures were then adjusted to 0.5 McFarland standard 
(Ca. 108 CFU/mL). CV026 was spread plated on chromoplate containing 75 nM 
concentration of N-Hexanoyl Homoserine lactone (HHL) incorporated in the medium. 
Wells (6 mm diameter) were bored on the chromoplate and ethanol extracts of plants 
dissolved in sterile DMSO were dispensed into the wells. Luria Bertani plates were then 
incubated at 30 °C for 24 h after which results were recorded. To ensure the sterility of 
the sample and to minimize any introduction of exogenous anti QS compounds, extracts 
were membrane (0.2 μm) sterilized and were tested for microbial contamination before 
the anti QS assay by streaking onto Luria Bertani agar (LB) plates and incubation at 37 
°C for overnight. Control plate with DMSO that was used to dissolve the extracts was 
also included to exclude the potential effect of DMSO on the quorum quenching.  
2.7.4 Inhibition of biofilm formation and inactivation of AHLs among the clinical 
Acinetobacter spp.  isolates after treatment with plant extracts 
 Acinetobacter spp. isolates were cultured in 1.5-ml Eppendorf tubes. After 
incubation for 16 h, the bacterial culture was reinoculated into 1.5 ml of fresh medium 
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and mixed with an equal volume of extracts from all the four Phyllanthus species, garlic 
and lemon as used for the above mentioned AHL inactivation assay. The treated clinical 
isolate mixtures were incubated at 28°C for 12 hours after the addition of the extracts, 
followed by the assays to detect the inactivation of AHL and inhibition of biofilm 
formation.  
 Screening for AHLs among the 7 clinical isolates was done as follows: A fresh 
plate of C.violaceum CV026 was prepared on LB agar plates containing 20 g/ml 
kanamycin. This plate was incubated overnight at 37C. A loopful of cells was taken 
and resuspended in 10 l of sterile water and adjusted to an OD 600 nm of approximately 
0.4. Then 5 ml of this culture was added to 200 ml of cooled LB agar and poured as a 
thin plate along with 75 nM concentration of N-Hexanoyl Homoserine lactone (HHL) 
incorporated in the medium.  About 5 l drops of the test strains (Acinetobacter spp. 
isolates treated with the soil extracts) were then added to the previously prepared 
chromoplate and allowed to dry. The tests are done in replicate and incubated for 2-3 
days at 28C. Monitor strains themselves served as negative control and monitor strains 
in plate containing 75 nM HHL served as positive control. The basic concept of this 
method was adopted from McClean et al, (1997). This method was previously not used 
for directly screening AHL producing bacteria. 
 The extracts from Acinetobacter spp. treated with the plant extracts, garlic and 
lemon were also subjected to thin layer chromatography (TLC) bioassay by the method 
described by Shaw et al., (1997) to detect the presence of any AHLs. About 1l of the 
treated sample from the above experiment was further analysed for biofilm formation. 
Biofilm formation was determined by the ability of cells to produce extracellular 
polymeric substances and adhere to the base of 96-well polystyrene plate using the 
method of Boddey et al. (2006) with modification. The biofilm forming capabilities of 
both the treated and untreated clinical isolates were analysed in this study.  
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3.1 Bacterial strains 
 A total of 50 strains were obtained from the Diagnostic Bacteriology Laboratory, 
University Malaya Medical Centre (UMMC) between August 2003 and March 2004. 
The strains were isolated from various body sites of infections from patients who were 
hospitalized mainly in the intensive care unit (ICU), surgical and general wards as listed 
in Table 3.1. All the Acinetobacter spp. isolates were sporadic cases of bacterial 
infections and could have been community-acquired. Majority of the isolates were from 
tracheal secretion (45%), wound swab (12%), bronchoalveolar lavage (11%), sputum 
(8%), blood (6%), peritoneal fluid (4%), followed by urine (2%), and other body sites 
such as epidermal catheter, abrasion over back, suture line swab, foot pressure sore 
swab, pus swab, and double lumen tips (12%). 89.8% of the strains were from non-
invasive sites while 10.2% were from invasive sites. However, for simplicity of 
analysis, the sites of isolation were re-assigned as upper respiratory tract (tracheal 
secretion, nasopharyngeal secretion) (46%), lower respiratory tract (sputum, 
bronchoalveolar lavage) (18%), peritoneal fluid (4%), blood (6%), wound (12%), urine 
(2%), and others (12%). 
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Table 3.1: Strain number, patient number, ward, source and date of isolation of                     
50 Acinetobacter spp. isolates. 
Strain No. Patient No. Date Collected Ward Source 
11 1147833 03/12/2003 8U Tracheal secretion  
124 1184548 25/02/2004 13U Tracheal aspiration 
1 1106728 29/08/2003 ICU Tracheal aspiration 
62 1161661 04/01/2004 13U Tracheal secretion 
80 1171825 27/01/2004 13U Tracheal secretion 
9 11464697 01/12/2003 6TE Tracheal secretion 
6 1147974 04/12/2003 6U Tracheal secretion 
35 1157917 26/12/2003 6U Tracheal secretion 
57 1164572 09/01/2004 6U Tracheal secretion 
48 1163171 07/01/2004 7U Tracheal secretion 
69 1167282 15/01/2004 7U Tracheal secretion 
12 1149607 08/12/2003 CICU Tracheal secretion 
21 1152147 12/12/2003 ICU Tracheal secretion 
93 1170717 25/01/2004 ICU Tracheal secretion 
14 1149626 08/12/2003 ICU Tracheal secretion 
15 1150413 09/12/2003 ICU Tracheal secretion 
30 1156504 22/12/2003 ICU Tracheal Secretion 
46 1160751 01/01/2004 ICU Tracheal secretion 
61 1162426 06/01/2004 ICU Tracheal secretion 
90 1171487 26/01/2004 ICU Tracheal secretion 
125 1185678 26/02/2004 ICU Tracheal secretion 
113 1186526 01/03/2004 8D Throat swab 
70 1166501 14/01/2004 P5 Throat swab 
114 1186122 28/02/2004 12U Sputum 
49 1163189 07/01/2004 13U Sputum 
99 1176996 09/02/2004 13U Sputum 
52 1162203 05/01/2004 7U Sputum 
33 1157503 24/12/2003 7U BAL 
117 1188198 04/03/2004 ICU BAL 
59 1165166 11/01/2004 7U Bronchial lavage 
63 1162120 05/01/2004 P1 Bronchial lavage 
73 1168513 18/01/2004 7U Bronchial 3 plugged & mucous 
77 1167614 15/01/2004 ICU Peritoneal fluid  
26 1155939 21/12/2003 P1 Peritoneal fluid 
8 1146957 02/12/2003 P2 Blood 
4 1137968 07/11/2003 6TD Blood C+S 
3 1133309 28/10/2003 6TD Blood-PICC 
107 1180637 16/02/2004 12U Wound swab 
55 1161540 03/01/2004 6U Wound swab 
96 1176799 09/02/2004 7D Wound Swab 
102 1179797 14/02/2004 7U Wound swab 
13 1149580 08/12/2003 8D Wound swab 
22 1151037 10/12/2003 CICU Wound swab 
54 1164238 09/01/2004 P5 Urine 
45 1159599 30/12/2003 6U Abrasion over back 
104 1177833 10/02/2004 ICU Double lumen tips 
94 1176566 08/02/2004 6U Pus swab 
53 1161971 05/01/2004 8U Suture line swab 
81 1171359 26/01/2004 13U Swab & foot pressure sore 
29 1157633 24/12/2003 ICU Tip for epidermal catheter 
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3.1.1 Identification using standard laboratory methods. 
The identification of the organisms was performed using standard laboratory 
methods which include Gram staining and other routine sugar fermentation tests. The 
members of the genus Acinetobacters are Gram-negative coccobacilli that are strictly 
aerobic, non-fermentative, oxidase-negative, catalase-positive, and non-motile bacteria. 
They appear as white mucoid colonies on Mueller Hinton (MH) agar as shown in Figure 
3.1. The Gram stained slide of Acinetobacter spp. under light microscope with 100X 
magnification showed that they appear as pink, plump and short rods as shown in Figure 
3.2. They utilize carbon and ammonium as its only source of energy and the results of 
the sugar tests carried out to confirm this are shown in Figure 3.3. The results of 
standard identification tests of Acinetobacter spp. in comparison to other family 
members of Enterobacteriaceae and Non-Enterobacteriaceae are shown in Table 3.2. 
In addition, API20NE test was carried out as confirmatory test for the 
identification of this organism. This test is also to differentiate between Acinetobacter 
spp. with other Non-Enterobacteriaceae. The API20NE test showed that all the 50 
strains were identified as Acinetobacter baumannii/calcoaceticus complex as shown in 
Figure 3.4.  
Further species level identification was done using molecular method ARDRA 
(Amplified ribosomal DNA restriction analysis). All the strains were shown to belong to 
the Acinetobacter baumannii- calcoaceticus complex. This has been reported in our 
previous study with the same isolates (Wong et al., 2010).  
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Figure 3.1: Morphology of Acinetobacter spp. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Acinetobacter spp. isolates appear as white mucoid colonies. 
 
Figure 3.2: Gram stain of Acinetobacter spp. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gram stain shows that they are Gram-negative coccobacilli or rod shaped. 
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Figure 3.3: Biochemical tests used for the identification of Acinetobacter spp. 
Indole production test of 
Acinetobacter spp. 
MR test of Acinetobacter 
spp. 
VP test of Acinetobacter 
spp. 
Citrate utilization test of 
Acinetobacter spp. 
TSI test of Acinetobacter 
spp. 
     
Negative test: 
The organism does not 
produce tryptophanase, an 
enzyme that cleaves 
tryptophan producing indole 
and other products. 
Negative test: 
The organism does not 
ferment glucose and so no 
acid end products. 
 
Negative test: 
No Fermentation of glucose. 
Positive test: 
The organism produces 
Citrate permease and Citrate 
is utilized as its only source 
of carbon; and ammonium as 
its only source of nitrogen. 
Negative test: 
No Fermentation of glucose, 
lactose or sucrose; peptone 
utilized. 
E. coli A. spp E. coli A. spp E. coli A. spp 
E. coli A. spp 
E. coli A. spp E. coli A. spp 
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Table 3.2: Comparison of biochemical test among family members of Enterobacteriaceae and Non-Enterobacteriaceae. 
                Abbreviation: 
  A Motility test          
  B Indole production 
  C Methyl Red           
  D Voges-Proskauer 
  E Citrate utilization 
  F Triple Sugar Iron Agar test 
  G Oxidase test 
  H Catalase test 
  I Lactose  fermentation 
Figure 3.4: Confirmation Acinetobacter spp. identification using API20NE.
  
 
Species 
A B C D E F 
Slant                Butt              H2S 
G H I 
 Acinetobacter spp. - - - - + Alkaline         Alkaline           - - + - 
P. aeruginosa + - - - + Alkaline         Alkaline            - + + - 
E. coli + + + - - Acid               Acid                 - - - + 
K. pneumoniae - - - + + Acid               Acid                 - - - + 
C. freundii + - + - + -                     -                      + - - + 
Enterobacter spp. + - - + + Acid               Acid                 - - - + 
M. morganii + + + - - Acid              Alkaline             - - - - 
E. coli 
A. spp 
All 50 Acinetobacter spp. 
isolates were identified as A. 
baumannnii/calcoaceticus 
complex. 
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3.2 Quantification of biofilm formation using microtiter plate method 
 Quantification of biofilm produced by the 50 clinical isolates of Acinetobacter 
spp. was carried out using the microtiter plate method. The isolates which were capable 
of producing exopolysaccharide and bind to the surface of the polyvinyl plates were the 
ones that form efficient biofilms. The biofilms were stained with crystal violet and the 
stain was further extracted over by dimethyl sulfoxide and read spectrophotometrically 
at an absorbance wavelength of 570 nm. All the isolates were in the same logarithmic 
phase at the initial inoculation and the quantification of the biofilm was based on the 
biofilm absorbance at a wavelength of 570 nm. 
 The significance of the biolfilms formed by the 50 isolates were statistically 
analysed by using the independent sample two-tailed t test. All the t tests were 
performed by SPSS software. The analysis revealed that 30(60%) isolates significantly 
formed biofilms under 48 hrs of incubation (p value <0.05). Figure 3.5 shows the 
graphical representation of the biofilm formation among all the 50 isolates. 
Quantification of biofilm formation after prolonged incubation periods showed that in 
all the 50 isolates 48 hrs incubation showed higher biofilm formation compared to 24 
hrs of incubation. The microtitre plate assay was done in triplicates and the data were 
pooled from these experiments.  
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Figure 3.5: Biofilm formation among the clinical isolates of Acinetobacter spp.  in 
microtiter plates 
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3.3 Screening for Acyl Homoserine Lactones (AHLs) 
3.3.1 Chromobacterium violaceum CV026 induction assay 
 The preliminary screening for the production of AHLs by all the 50 clinical 
isolates of Acinetobacter spp. was done using the biosensor reporter strain 
Chromobacterium violaceum CV026. Chromobacterium violaceum produces the 
characteristic purple pigment violacein. Previously, a violacein-negative, mini-Tn5 
mutant of C. violaceum (CV026) was described in which pigment production can be 
restored by incubation with supernatants from the wild-type strain. This mutant was 
developed to be used as a general biosensor for AHLs (Throup et al., 1995).  In CV026, 
violacein is inducible by all the AHL compounds evaluated with N-acyl side chains 
from C4 to C8 in length, with varying degrees of sensitivity. Although AHL compounds 
with N-acyl side chains from C10 to C14 are unable to induce violacein production, if an 
activating AHL is incorporated into the agar, these long-chain AHLs can be detected by 
their ability to inhibit violacein production.  
 When CV026 induction test was carried out for the detection of short chain AHLs, 
all the 50 isolates produced colourless colonies. This showed that none of these 
Acinetobacter spp. clinical isolates produced short chain AHL molecules (Figure 3.6). 
The CV026 induction test was done on the chromoplate and the positive colonies 
producing the AHLs are expected to produce purple colonies. The isolates which are 
negative for the production of the AHL molecules produced colourless colonies. None 
of the tested isolates were positive for the induction test.  
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Figure 3.6: Chromobacterium violaceum CV026 induction assay 
Controls CV026 Induction Assay  
(for the detection of short chain AHLs) 
  
Positive Representative Negative Results 
 
 
Negative Representative Negative Results 
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3.3.2 Chromobacterium violaceum CV026 inhibition assay 
 In CV026 inhibition test, 7 of the isolates marked as S1, S11, S53, S54, S93, 
S102, S117 tested positive for long- chain AHL production. They produced colourless 
colonies in the induced chromoplate, while the negative isolates produced purple 
colonies (Figure 3.7). CV026 inhibition test was carried in a chromoplate to which the 
synthetic AHL was previously added. Here long-chain AHLs are expected to inhibit the 
induced CV026 and thus produce colourless colonies in the purple background. Seven 
of the Acinetobacter spp. clinical isolates tested positive for long-chain AHLs. These 
positive isolates producing AHLs were further quantified and characterized (Section 
3.4).  
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Figure 3.7: Chromobacterium violaceum CV026 inhibition assay 
 
Arrows show isolates positive for AHL production 
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3.4 Quantification of the AHLs by well-diffusion assay 
 AHLs were extracted and quantified by the well diffusion assay. Increasing 
amounts of AHL added to the wells in the well-diffusion assay caused increase in the 
size of induced and inhibited zones surrounding the wells in Chromobacterium 
violaceum CV026 (Figure 3.8). Standard curves were created by comparing log (amount 
of AHL) to surface area of the zones (Figure 3.9). Based on the standard curves, 
extraction efficiencies were calculated for DHL (Decanyl Homoserine Lactone) and 
HHL (3-N-Hexanoyl homoserine lactone) using both acidified and non-acidified ethyl 
acetate. Approximately twice as much AHL was extracted when using acidified ethyl 
acetate as compared to non-acidified. Extraction efficiencies were tested on 
supernatants from Acinetobacter strains and it was observed that acidified extractions 
gave better yields as compared to the non-acidified extractions. Yields obtained were in 
the range of 1 x 10
-9 
moles to 6 x 10
-9 
moles of AHLs (Figure 3.10). The extraction 
efficiencies of the seven isolates that tested positive for the AHLs production are shown 
in the table 3.3. 
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Figure 3.8: Chromobacterium violaceum CV026 well-diffusion assay in LB agar. 
 
 
 
 
 
 
 
N-hexanoyl homoserine lactone (HHL) was added to wells in agar containing 
Chromobacterium violaceum CV026. Zones of HHL-induced violacin production is 
seen surrounding the wells. Increasing concentration of AHL shows the increase in zone 
diameters.  
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Figure 3.9: Std. curve for Extraction Efficiency of the Standard AHLs  
 
 
Standard curve showing the relationship between concentration of acylated homoserine 
lactone (N-hexanoyl homoserine lactone (HHL) & N-Decanoyl homoserine lactone 
(DHL)) and resulting diameters of induced / inhibited zones in Chromobacterium 
violaceum CV026 monitor  system. 
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Figure 3.10: Well-diffusion assay for the tested isolates. 
 
 
Extraction efficiencies were tested on supernatants from Acinetobacter strains. Yields 
obtained were in the range of 1 x 10
-9 
moles to 6 x 10
-9 
moles of AHLs. 
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Table 3.3: Table showing the extraction efficiencies of the test isolates. 
 
Sample No Extraction Efficiencies (p mol/50 μl) 
1 ≈  4000 
11 ≈  4000 
53 > 2000 
54 > 4000 
93 = 2000 
102 < 2000 
117 6000 
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3.5 Identification of AHLs 
3.5.1 Thin Layer chromatography and Bioassay 
 As the screening for AHLs showed that none of the clinical isolates of 
Acinetobacter spp. produced short-chain AHL molecules, TLC induction bioassay was 
carried out to confirm this. However, the TLC inhibition bioassay carried out for the 7 
isolates which tested positive for long-chain AHL molecules showed varying inhibition 
zones (Figure 3.11). After the extracts were chromatographed on the C18 reversed 
phase TLC plates, the plates were dried and CV026 along with synthetic AHL was 
poured on the TLC plate as an overlay and the positive result was visualized as the zone 
of inhibition in a purple background. On C18 reversed-phase plates, of the solvent 
systems evaluated, methanol/water (60:40, vol/vol) separated the two standard 
compounds tested (Figure 3.11). The CV026 reporter detected the two 3-oxo-acyl-HSL 
standards with side chains C10 and C12 (Lane 1 and 2 respectively). The reporter also 
detected the AHLs produced by the isolates. As shown in the figure, the zone of 
inhibition of the 5 isolates (lanes 3, 4, 6, 7 and 9) corresponded to the synthetic standard 
DHL (lane 1) (Rf value of 0.18) and so all these isolates produced AHLs with C10. 
These isolates were designated as S1, S11, S54, S93 and S117. For isolates S53 and 
S102 (lane 5, 8) the zone of inhibition tentatively corresponded to C12. Here, the 
standard used for C12 is N-3-Oxo-Dodecanoyl-L-Homoserine Lactone. But the signal 
C12 produced by the isolates S53 and S102 presented spots in a different position. This 
is because, each of the 3-oxo and 3-unsubstituted derivatives migrated with a 
characteristic Rf values. The 3-Oxo-C12 (Standard used in lane 2) has a Rf value of 
0.07, whereas, the 3-Unsubstituted- C12 has a Rf value of 0.02 (S53 and S102 in lane 5 
and 8 respectively). Thus, the isolates S53 and S102 would have produced 3-
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Unsubstituted- C12 signals. All the comparisons were done based on the inhibition zone 
produced by standard DHL and dDHL.  
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Figure 3.11: Thin layer chromatography bioassay. 
 
Acylated homoserine lactones (AHLs) chromatographed on a C18 reversed phase thin layer plate developed with methanol / water (60:40). The plate 
after development was visualised using  induced Chromobacterium violaceum CV026. 
 
Lane 1 : Standard Decanoyl Homoserine lactone (3-Oxo-C10) 
Lane 2 : Standard Dodecanoyl Homoserine Lactone (3-Oxo-C12) 
Lane 3 and 4 : Extracts from strain 1and 11 showing zone corresponding to C10 (3-Oxo-C10) 
Lane 5 : Extract from strain 53 showing zone of inhibition corresponding to C12 (3-Unsubstituted-C12) 
Lane 6 and 7 : Extracts from strains 54 and 93 showing zones corresponding to decanoyl homoserine lactone (3-Oxo-C10) 
Lane 8 : Extract from strain 102 showing  zone of inhibition corresponding to C12 (3-Unsubstituted-C12) 
Lane 9 : Extracts from strain 117 shows  zone corresponding to C10 (3-Oxo-C10) 
1 2 3 4 
5 8 
6 7 9 
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3.5.2 Mass Spectrometry (MS) 
3.5.2.1 Quantitation 
 Agilent MassHunter Quantitation Version B.04.00 was used to generate standard 
curves and calculate concentrations of AHLs present. Linear curves were fit to the linear 
portion of the curve with an acceptable R
2
 = 0.98. In the case of high concentration 
standards significant signal suppression was observed, in these cases high concentration 
points were removed from the standard curve. 
 
3.5.2.2 Standard Curves 
 A standard curve was run between the concentrations of 0.1 µM – 1000 µM 
(Figure 3.12). The concentrations of 500 and 1000 µM displayed significant signal 
suppression indicating that the standard curve had reached the limits of the dynamic 
range of the instrument. In each case a curve was fit over the appropriate range, with a 
linear curve attempted in all cases, except where high concentration points were 
required. For the experiment where concentrated samples were tested a limited 
concentration range 0.1 µM – 100 µM was used and this significantly reduced signal 
suppression and turnover of the standard curve.  
From the standard curves generated, the concentrations of the AHLs produced by the 
isolates were quantified. Care was taken when interpreting results below concentrations 
of 0.5 µM as there is significant variation and error found within the lowest 
concentrations measured (0.1 µM). Results above 0.5 µM indicated a positive result and 
the presence of the analyte. Initial results indicated samples from isolates S1, S11, S117, 
S53, S102, S93 and S54 contained measureable levels of longer chain AHL‘s (Table 
3.4). Samples 1, 11, 117, 93 and 54 contained high levels of decanoyl homoserine 
lactone with concentrations ranging from 0.8-2.6 mM. Concentrations of octanoyl were 
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also observed in significant amounts. Isolates S53 and S102 did not show considerable 
concentrations of the AHLs when compared with the standards used, as C12 standard 
was not included in the standard curve derivation. But, further mass spectrometric 
analysis showed the presence of C12 AHLs in S53 and S102. This result confirms the 
detection of AHLs by TLC (Section 3.5.1).  
 
RESULTS 
 
   Page: 109 
  
Figure 3.12: Standard curves generated for the initial quantification experiment measuring all samples. 
  
 
a. Standard curve for β-Ketocaproyl Homoserine 
Lactone, using a linear fit weighted (1/x) with 
standards 100 and 500 µM removed. 
b. Standard curve for Hexanoyl Homoserine Lactone 
using a linear fit weighted (1/x);  
 
c. Sstandard curve for Heptanoyl Homoserine 
Lactone using a power curve fit, weighted (1/x);  
 
  
 
d. Standard curve for octanoyl using a linear fit, 
weighted (1/x); 
e. Standard curve for Decanoyl Homoserine Lactone 
using a quadratic fit weighted (1/x). 
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Table 3.4: Initial quantification results expressed in micromolar (µM) 
Sample     β-Ketocaproyl 
Results 
Hexanoyl 
Results 
Heptanoyl 
Results 
Octanoyl 
Results 
Decanoyl Results 
Name Type Exp. Conc. Final Conc. Final Conc. Final Conc. Final Conc. Final Conc. 
Standard1 Cal 0.1 0.0000 0.0000 0.0287 0.0000 0.0326 
Standard2 Cal 0.5 0.7174 0.5773 0.2210 0.5356 0.5351 
Standard3 Cal 1 1.3390 1.5188 0.4767 1.1765 1.0372 
Standard4 Cal 5 7.1298 10.3666 4.1723 8.4506 6.2339 
Standard5 Cal 10 12.8769 19.4301 9.3205 16.0361 11.8248 
Standard6 Cal 50 52.4186 86.5213 60.0758 76.8614 56.8389 
Standard7 Cal 100 92.1640 154.7764 122.1592 141.5222 105.9861 
Standard8 Cal 500 349.5496 551.5049 536.2855 541.2738 448.4509 
Standard9 Cal 1000 589.2719 842.1959 894.7237 880.8895   
Sample_1 Sample   0.2938 0.6715 0.3076 16.5728 1054.3743 
Sample_11 Sample   0.0000 0.0122 0.2605 12.4294 808.3177 
Sample_117 Sample   0.0000 0.0000 0.2092 18.3667 1531.9985 
Sample_53 Sample   0.0000 0.0000 0.2538 0.0000 6.1387 
Sample_102 Sample   0.0000 0.0000 0.1671 0.0000 2.4168 
Sample_93 Sample   0.0000 0.0000 0.1229 30.4455 2684.0398 
Sample_54 Sample   0.0000 0.0000 0.0285 28.8595 1675.7330 
 
The concentrations of decanoyl homoserine lactone in samples 1, 11, 117, 93 and 54 ranging from 0.8-2.6 mM are highlighted in green.  
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3.5.2.3 Profiling of AHLs 
 An experimental setup where a blank was included between every sample 
injection was used to limit the potential of cross-contamination and carry-over between 
samples. Agilent MassHunter Qualitative Analysis Software B.03.01 was used to mine 
data generated from precursor ion scanning experiments. An automated Find 
Compounds by Targetted MS/MS procedure was used to identify compounds present. 
Spectra were searched in the mass range 100-1000 m/z with a peak filter of 5% of 
largest peak. An ‗excellent‘ hit provided all 3 product ions (71.1, 74.1 or 102.1) from 
the same parent peak within a 0.5 minute time window, a ‗good‘ hit was identified by 
observing at least the presence of two separate product ions and a ‗poor‘ hit only a 
single product ion. Summary of calculated potential AHLs are shown in figure 3.13. 
Here, the parent mass and the fragment breakdown for all the potential AHLs were 
detected using the standards and the possible chain lengths of the different AHLs were 
elucidated.  
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Figure 3.13: AHL Profiling - Summary of Calculated Potenial AHLs. 
Potential even chain length AHLs and supplied standards: 
 
 
 
 
  
214.11 
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Potential C12 AHLs: 
 
 
 
Potential odd chain length AHLs: 
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3.5.2.4  Identification of the AHLs  
 ChemBioDraw Ultra Version 11 was used to generate AHL structures and 
calculate molecular masses of the protonated and sodiated forms of the unsubstituted 
straight chain AHL‘s (C6-C18). β-keto/β-hydroxy derivatives and a C12 with a single 
alkene were calculated as only the protonated forms.  
 The samples were re-suspended in 200 µL of solvent. All quantification results 
have been corrected and are expressed as a concentration (µM) relative to this volume. 
Concentrations for the standard curve are expressed in µM. To derive actual 
concentrations extracted from the initial cell culture the final concentrations will require 
correction to the initial volume and cell mass. A DMRM method was generated to 
quantify concentrations of beta-ketocaproyl, hexanoyl, heptanoyl, octanoyl and 
decanoyl AHLs. Good separation and signal was observed for each AHL with longer 
chain AHLs eluting later. The trace ion current (TIC) of a mixture of standards is shown 
in figure 3.14 and the TIC of the tested samples are shown in figures 3.15 to 3.21. The 
selected compounds with observed masses, retention times and observed fragment ions 
are shown in Appendix 2 (Tables A1.1 to A1.14).   
 Extraction of AHLs was performed and concentrations of AHLs with beta-
ketocaproyl, hexanoyl, heptanoyl, octanoyl and decanoyl side chains were determined.  
Further identification of AHLs present was conducted by performing MS/MS 
experiments searching for characteristic AHL fragments. Each sample was analysed 
using a Precursor Ion method monitoring for the following common fragments: 102.1, 
74.1, 71.1. These fragments had been observed to be fairly common when performing 
optimization studies on the standards stated (β-ketocaproyl, hexanoyl, heptanoyl, 
octanoyl and decanoyl).  
 Mass spectrometric analysis confirmed the presence of C10 AHLs in the tested 5 
isolates (S1, S11, S54, S93 and S117) and 2 isolates (S53, S102) produced AHLs with 
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chain lengths C12 ( Figures 3.15 to 3.21). Of the masses that were reported the only ones 
that seem to make sense are 284 and 282 as an AHL with a 12 carbon acyl chain, with 
the lower mass (282) containing a single alkene (Tables A1.1-A1.14). An alkene could 
be anywhere along the chain length, however it can be rationalized that it could be a 
dehydration product from a beta-hydroxy derivative. The retention time at a later time 
than the decanoyl standard fits well. These masses were found in samples 53 and 102, 
which well confirms the TLC report. The TIC trace of each sample (1, 11, 53, 54, 93, 
102, 117) with overlaid common precursor ions are shown in Figures 3.15 -3.21.  
Results indicated the presence of decanoyl homoserine lactone in the isolates S1, S11, 
S54, S93 and S117. Other AHL‘s with higher masses (longer chain) than the provided 
standard were seen in S53 and S102 with C12 (Dodecanoyl homoserine lactone).  
 
  
RESULTS 
 
   Page: 116 
       
Figure 3.14: TIC of a mixture of standards 
 
 
 
Individual standards are highlighted; later eluting peaks correspond to other 
contaminants. 
 
Figure 3.15a: TIC trace of Sample 1 
 
 
 
Figure 3.15b: Combined overlay of TIC and Extracted compounds of sample 1  
 
 
 
RESULTS 
 
   Page: 117 
       
Figure 3.15c: Magnified view of extracted compounds in sample 1 
 
 
Figure 3.15d: Overlaid spectra of all common precursor Ions common in sample 1 
providing fragment Ions (71.1, 74.1, and 102.1): 
 
 
 
Figure 3.16a: TIC trace of Sample 11 
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Figure 3.16b: Combined overlay of TIC and extracted compounds of sample 11 
 
 
 
 
Figure 3.16c: Magnified view of extracted compounds in sample 11 
 
 
 
Figure 3.16d: Overlaid spectra of all common precursor Ions common in sample 
11 providing fragment Ions (71.1, 74.1, and 102.1): 
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Figure 3.17a: TIC trace of Sample 53 
 
 
 
Figure 3.17b: Combined overlay of TIC and Extracted compounds of sample 53 
 
 
 
Figure 3.17c: Overlaid spectra of all common precursor Ions common in sample 53 
providing fragment Ions (71.1, 74.1, and 102.1): 
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Figure 3.18a: TIC trace of Sample 54 
 
 
Figure 3.18b: Combined overlay of TIC and Extracted compounds of sample 54 
 
 
Figure3.18c: Magnified view of extracted compounds in sample 54. 
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Figure 3.19a: TIC trace of Sample 93 
 
Figure 3.19b: Magnified view of extracted compounds in sample 93. 
Figure 3.20a: TIC trace of Sample 102 
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Figure 3.20b: Combined overlay of TIC and Extracted compounds of sample 102 
 
Figure 3.21a: TIC trace of Sample 117 
 
Figure 3.21b: Combined overlay of TIC and Extracted compounds of sample 117 
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Figure 3.21c: Magnified view of extracted compounds in sample 117 
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3.6 Identification of the QS gene in Acinetobacter spp. and construction of its 
mutant 
3.6.1 Identification of abaI gene in Acinetobacter spp. producing the QS signal 
molecules 
 
 Polymerase Chain Reaction (PCR) for abaI gene, produced amplicons of 382 bp 
in all the 7 isolates (isolate no.S1, S11, S53, S54, S93, S102, S117) which produced the 
QS signal molecules. The electrophoretic banding patterns are shown in figure 3.22. 
PCR for abaI gene was carried out in all the 50 test isolates and the abaI gene product 
was also detected among 31 isolates which were negative for the AHL molecules. It is 
significant that all the seven isolates positive for the long chain AHL molecules showed 
the presence of the abaI gene. This abaI gene present in 31 of the other isolates that 
were negative for AHL molecules may not play a significant role in the AHL-mediated 
pathways.   
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Figure 3.22: The electrophoretic banding patterns of the PCR products using the 
primers for the abaI gene 
 
 
Lane 1 – 100bp DNA ladder 
Lane 2, 3, 4, 5, 6, 7, 8 – amplicons from isolates S1, S11, S53, S54, S93, S102 and S117 
respectively 
Lane 9 – Negative control. 
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3.6.2 Sequencing of the abaI gene of the test isolates  
 Sequencing of the detected abaI gene was done for all the seven isolates and 
softwares were used to compare and calculate the differences in the aminoacid 
sequences of the abaI gene. When compared to the sequence of the already reported 
AbaI protein (Niu et al., 2008), eight amino acid changes have been reported in AbaI 
protein of S117. Among the seven isolates, isolate S117 thus showed significant 
differences when compared to the already reported abaI gene. The amplicon of the abaI 
gene sequence from isolate S117 was further analysed.  The BLAST analysis program 
revealed that the abaI gene identified in Acinetobacter spp. isolate S117 is 92% 
identical to the corresponding protein reported in recently published A. baumannii 
ATCC 17978 genome. The AbaI protein shared 91% identity and 97% similarity with 
the already reported AbaI protein of A. baumannii M2 strain. Further, the BLAST 
analysis also revealed that the AbaI protein exhibited 61% identity and 79% similarity 
to the acyl homoserine lactone synthase of Halothiobacillus neapolitanus c2, 65% 
identity and 75% similarity to the autoinducer synthesis protein of Acidithiobacillus 
ferrooxidans ATCC 53993, 47% identity and 67% similarity with autoinducer 
synthatase family protein of Burkholderia mallei ATCC 23344 and 49% identity and 
63% similarity with N-acyl homoserine lactone synthase from Pseudomonas fluorescens 
(Table 3.5). The sequence analysis results of the seven isolates are shown in Figure 3.23 
to Figure 3.29. The abaI gene sequence of Acinetobacter spp. isolate S117 has been 
submitted to the NCBI Genbank (Accession number HQ013310). This is shown in 
figure 3.30. 
Table 3.5: Homology percentages of the abaI region in Acinetobacter spp. (S117) 
Identity Similarity Protein / Organism 
92%  A. baumannii ATCC 17978 genome 
91% 97% AbaI protein of A. baumannii M2 strain 
61% 79% AHL synthase of Halothiobacillus neapolitanus c2 
65% 75% Autoinducer synthesis protein of Acidithiobacillus ferrooxidans ATCC 53993 
47% 67% Autoinducer synthatase family protein of Burkholderia mallei ATCC 23344 
49% 63% N-acyl homoserine lactone synthase from Pseudomonas fluorescens 
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Figure 3.23: Sequence analysis of abaI gene from isolate S1 
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Figure 3.24: Sequence analysis of abaI gene from isolate S11 
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Figure 3.25: Sequence analysis of abaI gene from isolate S53 
 
RESULTS 
 
   Page: 130 
       
Figure 3.26: Sequence analysis of abaI gene from isolate S54 
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Figure 3.27: Sequence analysis of abaI gene from isolate S93 
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Figure 3.28: Sequence analysis of abaI gene from isolate S102 
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Figure 3.29: Sequence analysis of abaI gene from isolate S117 
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Figure 3.30: NCBI Genbank submission of abaI gene (Accession number 
HQ013310) 
Acinetobacter sp. S117 N-acyl homoserine lactone synthase (abaI) gene, partial cds 
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3.6.3 Cloning of the abaI gene (blue-white selection) and construction of the 
mutant of abaI gene (Tetracycline mutant) 
 The purified PCR product of abaI gene from isolate S117 was cloned into plasmid 
vector pCR 2.1-TOPO of the TOPO TA cloning kit. The plasmid vector pCR 2.1-TOPO 
is an activated linearized vector with overhanging 3‘ deoxythymidine (T) residues. This 
allows PCR inserts to ligate efficiently with the vector.  
 The recombinant plasmid was then transformed into chemically competent E.coli 
cells. These cells carrying the wild type abaI gene were selected on the plates 
containing ampicillin as the plasmid has antibiotic resistance marker. Blue-white 
selection was made in which the light blue and colourless colonies were positive for the 
abaI gene while the dark blue colonies were negative for abaI gene (Figure 3.31). 
 E.coli transformants with the abaI gene were confirmed by PCR using the primers 
specific for abaI gene. The gel electrophoretic banding patterns are shown in the figure 
3.32. The clones were further confirmed by restriction digestion of the recombinant 
plasmid with the enzyme EcoRI (Figure 3.33). 
 Acinetobacter spp. S117 with mutation in the abaI gene (abaI::Tc) was created by 
the introduction of plasmid pUC18.abaI::Tc into Acinetobacter spp. S117 by 
conjugation. The positive clones were selectively screened on the LB agar plates 
containing tetracycline antibiotic markers as seen in the figure 3.34. All the colonies on 
this selective plate are positive clones with the tetracycline mutant of abaI gene. These 
were confirmed by colony PCR using the primers for tetracycline gene. The 
electrophoretic banding patterns of the colony PCR is shown in figure 3.35. 
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Figure 3.31: Blue-white selection of the E.coli transformants carrying the abaI 
gene 
   
LB Amp plate (blue-white selection based on lacZ disruption)  
 
Positive transformants  
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Figures 3.32: Colony PCR of E. coli transformants for confirmation of the 
presence of abaI gene 
 
Lane 1: 1000 bp DNA ladder 
Lane 2-11: amplicons of colony PCR of abaI gene in positive transformants  
 
Figures 3.33: EcoRI fast digestion of the recombinant plasmid DNA 
 
 
 
 
 
 
 
 
 
Lane 1 & 6: 1 Kb DNA ladder 
Lane 2: Recombinant plasmid DNA 
Lane 3: EcoRI digested recombinant plasmid DNA 
Lane 4: Uncut recombinant plasmid DNA of the digestion reaction 
Lane 5: Negative Control 
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Figures 3.34: Conjugants with abaI::Tc mutant  
 
 
LB selective plate with tetracycline 
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Figure 3.35: Confirmation of the abaI:Tc mutant by colony PCR for tet gene 
 
 
Lane 1 1 Kb DNA ladder 
Lane 2 to 7 Isolates positive for tet gene 
Lane 8 and 9 Isolates negative for tet gene 
Lane 10 to 12 Isolates positive for tet gene 
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3.6.4 Biofilm formation in wild type and mutant abaI gene 
 After the construction of the abaI mutant, the wild type abaI gene and the 
abaI::Tc mutant were analyzed for AHL production. It was found that the wild type 
abaI produced the same kind of AHL signal produced by S117 in the TLC overlay 
while its mutant counterpart, abaI::Tc mutant failed to produce any detectable signals 
using the biosensor strain. The examination of the ability of the wild type and the 
abaI::Tc mutant to form biofilms showed that when evaluated after 24 hrs of 
incubation, there was no signicifant biofilms in both the wild type and the mutant. But, 
after prolonged incubation for 48 hrs, there was considerable biofilm formation in the 
wild type abaI which was twice (OD-2.25) as much more when compared to its mutant 
counterpart (OD-0.9) under the same incubation time. Thus, there was inhibition in the 
biofilm formation in the abaI::Tc mutant when compared to the wild type. This is 
shown in the figure 3.36a. 
The mutation complementation experiment with the ethyl-acetate extracts of the culture 
supernatants from wild type and the abaI::Tc mutants showed that the addition of ethyl-
acetate extracts from the wild type cells restored the ability of the abaI::Tc mutants to 
form normal biofilms. But, the ethyl-acetate extracts from the abaI::Tc mutants failed to 
restore the biofilm forming capabilities in the abaI::Tc mutant (Figure 3.36b).  
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Figure 3.36a: Biofilm formation of the wild type abaI and abaI::Tc mutant in 
microtiter plate 
 
 
Figure 3.36b: Mutation complementation experiment 
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3.7 Natural sources as potential quorum quenchers 
3.7.1 Isolation of soil Bacilli and detection of aiiA homologue gene 
 Plating the serially diluted soil samples yielded about 25 bacterial isolates. Of 
these only two isolates were positive for the genus identification for Bacillus using the 
specific 16S rDNA primers. The two isolates were identified to be Bacillus sp. 
producing an amplicon length of approximately 1500bp. The gel picture is shown in 
figure 3.37.  
 Further sequencing and web-based analysis of the sequenced data revealed that 
the soil isolates B1 and B2 belong to the genus Bacillus. The 16S rDNA sequences (962 
nucleotides) of the isolate B1 shared 99% sequence identity with 16S rDNA of Bacillus 
thuringiensis strain Y22 (GenBank accession number JN084160.1) and the 16S rDNA 
sequences (1005 nucleotides) of the isolate B2 also shared 99% sequence identity with 
16S rDNA of Bacillus sp. akoli (GenBank accession number JF681181.1).  
 The two isolates identified as Bacillus sp. and designated as B1 and B2 were 
further screened for the presence of the AHL-degrading enzyme aiiA homologue gene. 
PCR specific for this gene produced amplified copies of this gene in B1 and B2. The 
amplicon size was approximately equal to 800bp which is shown in figure 3.38. 
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Figure 3.37: PCR amplication of the soil bacterial isolates for the presence of 16S 
rDNA gene specific for the genus Bacillus.  
 
Lane 1: 1 kb DNA ladder 
Lane 2: PCR product of isolate 1 
Lane 3: PCR product of isolate B2 
Lane 4: Negative control (non-template). 
The amplicon size is approximately equal to 1500bp. 
 
Figure 3.38: PCR detection of the soil bacterial Bacillus sp. isolates (B1 and B2) for 
the presence of aiiA homologue gene (coding for AHL-degrading enzyme).  
 
Lane 1: 100bp DNA ladder 
Lane 2: PCR product of isolate 1 
Lane 3: PCR product of isolate B2 
Lane 4: Negative control (non-template). 
The amplicon size is approximately equal to 800bp. 
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3.7.2 AHL inactivation assay of the soil Bacillus spp. extracts 
 We further screened the two Bacillus sp. isolates B1 and B2 for their AHL-
inactivating activity. Since both of these isolates possessed the aiiA gene they also 
exhibited a strong AHL-degrading activity. Nearly all AHLs used in the bioassay were 
degraded after incubation with the isolate B1 for 9 hours and after 3 hours in B2. This 
indicates the rapid degradation of the AHLs. The results are shown in figure 3.39. 
Escherichia coli DH5α and PBS served as the negative controls in which no apparent 
degradation was observed. Here, E. coli DH5α was used as negative control because it 
does not contain the aiiA homologue genes and so it is expected that there would not be 
any AHL degradation.  
 The aiiA gene amplification by PCR is a preliminary screening for quorum 
quenching activity. A total of two bacterial isolates containing the aiiA gene were 
selected to confirm their quorum quenching activity by AHL inactivation assay. Using 
the AHL-inactivation assay, both the isolates showed rapid AHL degradation in vitro. 
The pH of the reaction mixture was buffered to pH 6.5 to avoid alkali lactonolysis 
because AHLs are easily hydrolyzed under alkaline conditions (Yates et al., 2002).  
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Figure 3.39: Bioassay for the detection of AHL-degrading enzyme activity of the 
soil Bacillus sp. isolates B1 and B2. 
 
 
Chromobacterium violaceum strain cv026 was used as a reporter strain for the bioassay 
to detect exogenous N-hexanoyl homoserine lactone (HHL) in the experiment for 
screening the soil Bacillus sp.  isolates capable of inactivating acyl homoserine lactones. 
Escherichia coli DH5α and PBS were used as negative controls in which no degradation 
of AHL was observed. Degradation was evident by the loss of purple pigment in the 
biosensor strain. 
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3.7.3 Inhibition of biofilm formation among the clinical Acinetobacter spp. isolates  
           The biofilm forming capabilities of Acinetobacter spp. clinical isolates after 
treatment with the soil Bacillus sp. extracts were analyzed. There was considerable 
inhibition in biofilm formation. After incubation for 24 and 48 hrs (figure 3.40 and 
figure 3.41 respectively), the treated isolates showed that their biofilm forming 
capabilities were reduced to half when compared to the untreated isolates. The clinical 
isolates were treated with extract from E.coli DH5α (control), and no inhibition of 
biofilm formation was noted.  
 The seven clinical isolates of Acinetobacter spp. treated with the extracts from 
soil Bacillus sp. isolates and were also screened for the presence of long chain AHLs 
and the results reveal that all the seven isolates showed negative results in this screening 
test (results not shown). The extracts after treatment were also subjected to TLC which 
also showed the absence of AHLs in all the seven isolates.  
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Figure 3.40: Biofilm formation in Acinetobacter spp. isolates treated with the soil 
Bacilli extracts (24 hrs) 
 
 
Figure 3.41: Biofilm formation in Acinetobacter spp. isolates treated with the soil 
Bacilli extracts (48 hrs) 
 
Microtitre plate method was done for the biofilm formation and there is considerable 
decrease in biofilm formation in the treated samples showing that the soil extracts 
significantly inhibit the biofilm formation in the clinical isolates of Acinetobacter spp. 
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3.7.4 Use of plant extracts to inactivate AHLs among clinical  Acinetobacter spp. 
isolates  
 Four species of Phyllanthus extracts, garlic and lemon extracts were evaluated for 
their quorum quenching activity and were all found to exhibit quorum quenching 
activity. The halos produced on lawns of the biomonitor strains could be the result of 
either (i) inhibition of cell growth or (ii) quenching of QS signals. The halo-effect is 
created by pigmentless (QS interrupted) cells adjacent to the well, and the presence of 
violacein-producing (QS active) cells further out. In this test, bacterial growth inhibition 
would result in a clear halo around the well, while a positive result of quorum sensing 
inhibition is exhibited by a turbid halo harboring pigmentless bacterial cells of the 
Chromobacterium violaceum CV026 monitor strain. To differentiate, the halo was 
examined under a higher magnification. Measurements were made from the outer edge 
of the wells to the edge of the zones of anti-QS inhibition. Loss of purple pigment in 
Chromobacterium violaceum is indicative of QS inhibition by the plant products used. 
The levels of anti-QS activity is calculated based on the diameter of the halo of 
pigmentless colonies of Chromobacterium violaceum CV026 monitor strain. Garlic had 
the strongest anti-QS activity (20 mm), followed by lemon extract (10 mm), and then 
Phyllanthus spp. extracts (all the four species showed similar colourless colony zone of 
5 mm). The varying zones of colourless colonies are shown in figure 3.42.  
 Analysis of the biofilm forming capabilities of the seven clinical isolates of 
Acinetobacter spp. after treatment with the extracts from Phyllanthus spp., lemon, and 
garlic showed that there was considerable inhibition in biofilm formation. After 
incubation for 48 hrs (figure 3.43), the treated isolates showed that their biofilm forming 
capabilities were reduced to half when compared to the untreated isolates. The exact 
values (A570) of reduction are given in figure 3.43. Treated clinical isolates of 
Acinetobacter spp. were also screened for the presence of long chain AHLs and the 
results reveal that all the seven isolates showed negative results in this screening test 
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(results not shown). The extracts after treatment were also subjected to TLC which also 
showed the absence of AHLs in all the seven isolates.  
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Figure 3.42: Anti-QS activity using Chromobacterium violaceum CV026 monitor 
system.  
  
 
 
  
  
 
 
 
Anti-QS activity was tested using 20 µl of methanolic extracts of P. amarus, P. niruri, 
P. urinaria, and P. watsonii and 20 µl of ethanolic extracts of garlic and lemon. Sterile 
DMSO was used as a negative control. 
Phyllanthus amarus 
 
Phyllanthus niruri 
 
Phyllanthus urinaria 
 
Phyllanthus watsonii 
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Figure 3.43: Biofilm formation in Acinetobacter spp. isolates treated with the extracts from Phyllanthus species, garlic and lemon.  
 
Microtitre plate method was done for the biofilm formation and there is considerable decrease in biofilm formation in the treated samples 
showing that the extracts significantly inhibit the biofilm formation in the clinical isolates of Acinetobacter spp. Garlic which is shown to 
have maximum anti-QS activity inhibits biofilm formation considerably followed by lemon extracts. All the four Phyllanthus species have 
more or less the same level of activity as quorum quenchers and they also have an effect as biofilm inhibitors.   
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 The extraordinary ability of certain bacteria to develop resistance to antibiotics 
has been a great concern among clinicians and health care professionals for several 
years. Antibiotics were first discovered through a providential experiment by Alexander 
Fleming in 1928. His work eventually led to the large-scale production of penicillin 
from the mould Penicillium notatum in the 1940s. The resistant strains of bacteria began 
to appear in the late 1940s. Currently, it is estimated that more than 70% of the bacteria 
that cause hospital-acquired infections are resistant to at least one of the antibiotics used 
routinely to treat them. Antibiotic resistance continues to expand for a multitude of 
reasons, including over-prescription of antibiotics by physicians, non-completion of 
prescribed antibiotic treatments by patients, use of antibiotics in animals as growth 
enhancers, increased international travel, and poor hospital hygiene.  
 Among the many pathogens which are evolving to be multi-drug resistant 
Acinetobacter is emerging as an important pathogen in traditional and nontraditional 
healthcare settings. Its ability to infect healthy hosts and its propensity to develop 
antimicrobial drug resistance has caused concern among the infectious diseases 
community. Among the Acinetobacter genomic species, Acinetobacter baumannii is 
recognized as the species most frequently isolated from patients (Bergogne-Berezin and 
Towner, 1996). Acinetobacters have been isolated from various types of opportunistic 
infections, including septicemia, pneumonia, endocarditis, meningitis, skin and wound 
infection, and urinary tract infection (Bergogne-Berezin and Towner, 1996). The 
distribution by site of Acinetobacter infection does not differ from that of other 
nosocomial Gram-negative bacteria. In several surveys, the main sites of Acinetobacter 
infection are the lower respiratory tract and the urinary tract. Often, Acinetobacter spp. 
emerged as important pathogens in the ICU setting, and this is probably due to the 
increasingly invasive diagnostic and therapeutic procedures used in hospital ICUs over 
the last two decades (Hartstein et al., 1988). As it is a multi-drug resistant organism, 
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infections are difficult to treat (Falagas and Karveli, 2007), resulting in mortalities of 
23% for hospitalised patients and 43% for patients under intensive care (Falagas et al., 
2006). Thus, Acinetobacter spp. is emerging as an increasingly important multidrug 
resistant pathogen, spreading in hospitals, and causing severe adverse outcomes. It has 
become a leading nosocomial pathogen in many hospitals as compared to other non-
fermenting Gram-negative bacilli. Therefore, a new strategy in the successful treatment 
of Acinetobacter infections is an absolute necessity.  
 In this study, 50 strains of Acinetobacter spp. isolated between August 2003 and 
March 2004 from University Malaya Medical Center and confirmed biochemically to 
belong to the Acinetobacter baumannii/calcoaceticus complex were chosen. Among 
these isolates, 39 of them were carbapenem resistant. Of the 50 strains, 30.6% were 
isolated from the ICU, 12.2% isolated from geriatric units, 12.2% from patients 
associated with bone marrow transplant (BMT), 10.2% from the paediatric units and 
34.7% from the surgical wards. This suggests that these strains may be a pathogen 
among immunocompromised patients and may be circulating in the hospital setting. 
These strains are also suggested to be colonizers rather than direct pathogens as it was 
mostly non-invasive isolates (89.8%) (Table 3.1). The routine methods of identification 
were performed and they belong to the Acinetobacter baumannii/calcoaceticus 
complex. 
4.1 Biofilm formation by Acinetobacter spp. clinical isolates 
 Survival in the hospital environment is one of the important challenges faced by 
microorganisms and they have in the course of time evolved various mechanisms to 
tolerate these adverse conditions. Nosocomial pathogens have to survive from the 
antimicrobial agents, disinfectants and also nutrient depletion. Among all the 
pathogenic bacteria, Acinetobacter spp. is the microorganism that has adapted 
DISCUSSION 
 
 Page: 155 
efficiently to overcome these adverse conditions. A high intrinsic resistance to 
antibiotics, disinfectants and its ability to acquire new resistance genes prevents the 
elimination of this pathogen from the hospital environment. The ability of this organism 
to resist desiccation is the key factor that facilitates the persistence of Acinetobacter spp. 
for longer periods on inanimate objects. Biofilm formation is a possible explanation for 
its survival under desiccation and it could be responsible for the device-related 
infections. The biofilm structures could protect these organisms under adverse 
conditions, than existing as planktonic forms.    
 Most Acinetobacter spp. research to date has focused on cataloguing and 
understanding the variety of antimicrobial resistance genes and mechanisms found 
within the species (Bonomo and Szabo, 2006; Navon et al., 2007; Tsakris et al., 2006;  
Vila et al., 2007). Apart from the molecular mechanisms involving the drug-resistant 
genes, it has been shown that A.baumannii forms biofilm with enhanced antibiotic 
resistance (Vidal et al., 1997; Vidal et al., 1996). Biofilm formation is a trait closely 
related to pathogenicity. According to a public announcement from the US National 
Institutes of Health more than 80% of all microbial infections involve biofilms (Ren et 
al., 2005; Rasmussen et al., 2006).  
 In this study, biofilm formation was analysed in 50 clinical Acinetobacter spp. 
isolates collected from University of Malaya Medical Centre. Thirty of the clinical 
isolates (60%) were able to significantly (p < 0.5) form biofilm structures in 96-well 
polystyrene microtiter plate under prolonged period of incubation (48 hrs); the 
experiment was done in triplicates. In a previous study, it was shown that 63% of A. 
baumannii clinical isolates formed solid-liquid interface-biofilm (Rodriguez-Baño et 
al., 2008). Similar results were obtained in a study done by Marti et al., 2011. They 
have also shown that 63% of A. baumannii clinical isolates formed solid-liquid 
interface-biofilm.  
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 Formation of these sessile biofilm communities and their inherent resistance to 
antimicrobial agents are at the root of many persistent and chronic bacterial infections. 
Biofilms represent microbial societies with their own defense and communication 
systems. The current view of biofilm infections leads to the realization that their 
effective control will require a concerted effort to develop therapeutic agents that target 
the biofilm phenotype and community signaling–based agents that prevent the 
formation, or promote the detachment, of biofilms (Costerton et al., 1999). While the 
distribution of biofilms is quite ubiquitous, many fundamental aspects of their 
physiology remain unknown. Several molecules have been associated with the 
coordination of activities of microorganisms within a community. These include AHL, 
oligopeptides, amino acids such as glutamate and aspartate, and fatty methyl esters. It is 
conceivable that one or more of these molecular signals may impact biofilm physiology 
(Loehfelm et al., 2008; McLean et al., 1997). 
 Genetic analysis of biofilm formation has led to the proposal that extracellular 
signals and quorum sensing regulatory systems are essential for differentiated biofilms. 
Although such a model fits the concept of density-driven cell–cell communication and 
appears to describe biofilm development in several bacterial species and conditions, 
biofilm formation is multifactorial and complex. Hence, differentiated biofilms may 
also be the net result of many independent interactions, rather than being determined by 
a particular global Quorum Sensing system (Kjelleberg and Molin, 2002). 
4.2 Identification of QS signal molecules among clinical Acinetobacter spp. 
isolates 
 QS is a regulatory mechanism which enables bacteria to make collective decisions 
with respect to the expression of a specific set of genes. These may include genes 
involved in biofilm formation and virulence. They play a key role in orchestrating the 
expression of exoproteases, siderophores, exotoxins and several secondary metabolites, 
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and participate in the development of biofilms. It has been shown that in contrast to the 
other QS systems, the AHL-mediated QS signalling system appears to control genes 
essential for colonisation of eukaryotes across a large number of bacterial species. This 
process is facilitated by bacterial biofilms (Costerton et al., 1999). The high density of 
bacteria within biofilms has led to the speculation that quorum-sensing genes and AHL 
production may be fundamentally associated with biofilm physiology. At least in some 
bacteria, mutations in autoinducer synthesis lead to the formation of biofilms with 
abnormal structures (Niu et al., 2008). The presence of AHL activity in naturally 
occurring aquatic biofilms has already been reported (McLean et al., 1997). Reports 
have also suggested that the autoinducer (AI), quorum sensing signal molecules may 
play an important role in biofilm formation (Camilli and Bassler, 2006; Domka et al., 
2007). Cell-to-cell signalling is often mediated by the production of N-acyl-homoserine 
lactone (AHL) signalling molecules (Fuqua et al., 1996).  
 In this study, we report the detection of AHL signal molecules among the 50 
biofilm forming clinical isolates of Acinetobacter spp. using the C. violaceum CV026 
biosensor monitor system. The CV026 induction assay which detects the presence of 
short-chain AHLs revealed that none of our isolates produced short-chain AHL 
molecules. So, we further carried out the CV026 inhibition assay, in which the induced 
CV026 will be inhibited in the presence of the long-chain AHLs produce by the clinical 
isolates. The results of this assay showed that 7 of the biofilm forming isolates 
significantly produced long-chain AHL molecules. We present here the first report of 
biofilm formation and long chain AHL molecules in Acinetobacter samples from our 
medical center. The method presented here for screening pure cultures of Acinetobacter 
spp. for AHL production using the Chromobacterium violaceum CV026 monitor system 
was developed and shown to be rapid and does not require sterile supernatants or AHL 
extractions from cultures. It also has the advantages of only requiring monitor strains 
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and the ability of the strains tested to grow on LB media. Six strains can be tested on the 
same plate simultaneously. The only limitation of this assay is that the detection limit 
lies within the scope of the signal monitor system CV026 that was used.  
 AHLs can be partially characterized by TLC on C18 reversed phase plates. This 
organic extraction procedure increases many-fold the sensitivity of biosensors 
(McClean et al., 1997; Shaw et al., 1997; Schaefer et al., 2000). Separation by TLC 
coupled with detection by AHL biosensors gives a rapid and direct visual index of the 
AHL(s) produced by the tester bacteria. Previous studies have shown AHL production 
by Acinetobacter spp. by TLC (Gonzalez et al., 2001). In A. calcoaceticus BD413 
supernatants four compounds were detected in a time-dependent manner, and maximal 
activity was reached at stationary phase (Gonzalez et al., 2001). In a variety of gram-
negative bacteria, it has also been demonstrated that biofilm development can be 
dependent on AHL signaling (Davies et al., 1998; Huber et al., 2001; Lynch et al., 
2002).  
 In this study, thin layer chromatography bioassay was thus used to confirm the 
presence of AHL molecules and semi-qualitatively identify the AHL molecules. TLC 
analysis has revealed that our clinical isolates produced C10 and C12 AHLs. All these 
were predicted based on their Rf values and in comparison with the standard DHL 
(Decanoyl homoserine lactone and dDHL (Dodecanoyl homoserine lactone). Kang et al. 
(2010) showed by TLC bioassay that Acinetobacter sp. DR1 strain generated three 
putative acyl homoserine lactones, while the DR1R produced only one signal and Niu et 
al. (2008) similarly detected the presence of three different AHLs in Acinetobacter 
baumannii strain M2. In A. calcoaceticus BD413 supernatants, Gonzalez et al. (2001) 
detected four compounds by TLC in a time-dependent manner, and maximal activity 
was reached at stationary phase. 
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 The AHL biosensors can also be used for quantifying AHLs by measuring the 
activity of the reporter system present in the biosensor bacterial strain. This is useful for 
studying regulation of AHL synthesis and for identifying strain-level differences in 
AHL production. In order to quantify accurately one must determine, using the 
synthetic AHL, the minimal amount of AHL required for a response as well as the 
amount necessary for a saturated response in order to plot the linear dose response. 
 In our study, we semi-quantitatively determined the amount AHLs produced by 
the 7 clinical isolates designated as S1, S11, S53, S54, S93, S102, S117 using the well-
diffusion assay. Based on the standard curves, extraction efficiencies were calculated 
for DHL and HHL using both acidified and non-acidified ethyl acetate. Approximately 
twice as much AHL was extracted when using acidified ethyl acetate as compared to 
non-acidified. This is consistent with the results shown by Shaw et al., 1997. Extraction 
efficiencies were tested on supernatants from Acinetobacter strains and it was observed 
that acidified extractions gave better yields as compared to the non-acidified extractions. 
This revealed that a minimum of approximately 2 x 10
-9 
moles and a maximum of 6 x 
10
-9 
moles of AHLs were detected among the clinical isolates of Acinetobacter spp. The 
presence of such high levels of AHLs in these clinical isolates could be a key factor that 
aids in their biofilm development, which in turn confers resistance to these organisms in 
adverse environments. 
 AHLs cannot be unambiguously identified using TLC. However, their 
chromatographic properties can be used to assign tentative structures, as Rfs calculated 
for the samples can be compared with Rfs of AHL standards. AHL structures are 
unequivocally determined on the basis of spectroscopic properties (Schaefer et al., 
2000) including Mass Spectrometry (MS) and nuclear magnetic resonance spectroscopy 
(NMR). We accurately quantified and determined the structures of the AHLs produced 
by the clinical Acinetobacter spp. isolated by Mass Spectrometry. Each sample was 
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analysed using a Precursor Ion method monitoring for the following common 
fragments: 102.1, 74.1, 71.1. These fragments had been observed to be fairly common 
when performing optimization studies on the standards (β-ketocaproyl, hexanoyl, 
heptanoyl, octanoyl and decanoyl). By monitoring for these fragments any AHL present 
was identified. Mass spectrometric analysis confirmed the presence of C10 AHLs in the 
tested 5 isolates (S1, S11, S54, S93 and S117) and AHLs with chain lengths C12 in other 
2 isolates (S53, S102). Of the masses that were reported the only ones that seem to make 
sense are 284 and 282 as an AHL with a 12 carbon acyl chain, with the lower mass 
(282) containing a single alkene. An alkene could be anywhere along the chain length, 
however it can be rationalized that it could be a dehydration product from a beta-
hydroxy derivative. The retention time at a later time than the decanoyl standard fits 
well. These masses were found in samples 53 and 102, which confirms the TLC report. 
The TIC (trace ion current) trace of each sample (1, 11, 53, 54, 93, 102, 117) with 
overlaid common precursor ions are shown in the results section. In a previous study by 
Niu et al. (2008), AHL signals directed by Acinetobacter baumannii strain M2 were 
identified by mass spectrometry as being C12 and in another study by Chan et al. 
(2011), it was shown that AHLs produced by Acinetobacter spp., upon analysis by 
liquid chromatography (LC) coupled to hybrid quadruple-linear ion trap mass 
spectrometry (LC-MS/MS), revealed the presence of C12. These findings further 
confirm results of our study.  
4.3 Investigation of the gene involved in QS and construction of its mutant as a 
QS control strategy 
 Quorum sensing signal molecules are autoinducers, as they induce their own 
genes in a positive feedback loop. An autoinducer synthase gene in A.baumannii that 
was designated as abaI has already been identified and characterised. The deduced AbaI 
protein was highly similar to the members of the LuxI family. It has been shown that 
DISCUSSION 
 
 Page: 161 
this autoinducer synthase was required for normal biofilm development (Niu et al., 
2008). In our study we have identified and analysed abaI gene which encodes a similar 
protein. Polymerase Chain Reaction (PCR) for abaI gene, produced amplicons of 382 
bp in all the 7 isolates (isolate no.S1, S11, S53, S54, S93, S102, S117) that produced the 
QS signal molecules. The amplicon of the abaI gene from all these isolates were further 
sequenced and analysed. Isolate S117 showed the maximum differences in the 
nucleotides and thus the aminoacid sequence of the autoinducer synthase protein when 
compared with the already reported abaI gene sequences (Table 3.19). Hence the abaI 
gene from S117 was chosen for all subsequent experiments. The BLAST analysis 
program revealed that the abaI gene identified in Acinetobacter spp. isolate S117 is 
92% identical to the corresponding protein reported in recently published A. baumannii 
ATCC 17978 genome (Smith et al., 2007). The AbaI protein from our isolate S117 
shared 91% identity and 97% similarity with the already reported AbaI protein of A. 
baumannii M2 strain (Niu et al., 2008). Further, the BLAST analysis also revealed that 
the AbaI protein exhibited 61% identity and 79% similarity to the acyl homoserine 
lactone synthase of Halothiobacillus neapolitanus c2, 65% identity and 75% similarity 
to the autoinducer synthesis protein of Acidithiobacillus ferrooxidans ATCC 53993, 
47% identity and 67% similarity with autoinducer synthatase family protein of 
Burkholderia mallei ATCC 23344 and 49% identity and 63% similarity with N-acyl 
homoserine lactone synthase from Pseudomonas fluorescens. The similarity of the 
identified AbaI protein from S117 to various species of Burkholderia, Pseudomonas 
fluorescens and Acidithiobacillus ferrooxidans suggests a common origin of these 
genes. Niu et al., also identified the abaI gene in a clinical isolate A. baumannii strain 
M2 and when compared to the recently published A. baumannii ATCC 17978 genome, 
this AbaI protein from A. baumannii strain M2 was 96% identical to the corresponding 
protein (GenBank accession number NC_009085.1). However, the AbaI protein 
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identified from strain M2 was predicted to be 56 amino acids shorter at the amino 
terminus. Using the BLAST analysis program, the AbaI protein exhibited 54% identity 
and 69% similarity to the AfeI protein of Acidithiobacillus ferrooxidans and to LuxI 
proteins from Burkholderia cepacia (46% identity and 64% similarity) and Ralstonia 
solanacearum (41% identity and 65% similarity).  
 In this study, we have further cloned the abaI gene from Acinetobacter spp. 
isolate S117 into a plasmid vector, further mutated this gene by insertional inactivation 
and a abaI::Tc mutant of the gene was created. The abaI::Tc mutant was shown to have 
inhibition in the biofilm formation. This shows that the abaI gene product was required 
for biofilm formation. The differences between the wild type and the abaI::Tc mutant 
clearly showed that abaI directed AHL pathway is required for efficient biofilm 
formation. In a similar study, the ability of the wild type and the isogenic abaI::Km 
mutant to form biofilms was examined in wells of a microtiter plate and it was observed 
that there is inhibition in biofilm formation (Niu et al., 2008). 
 The above mentioned results in our study have revealed that it is likely that QS 
regulation is important for biofilm development. In a given setting, the biofilm 
associated community will exploit all available adaptive mechanisms and the 
corresponding network of regulatory activities (including QS) and it is not possible to 
unequivocally assign a specific determining regulatory factor for the structure/function 
relationship of the community. Further identification of the exact AHL signals and thus 
their gene sequences encoding them will allow the identification of signal antagonists 
that inhibit biofilm development. These antagonists may also reduce the ability of 
Acinetobacter sp. to survive on environmental surfaces for extended periods, a key 
component of its ability to form biofilms and persistence in intensive care wards. 
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4.4 Preliminary investigations into possible natural sources as potential quorum 
quenchers  
 Quorum sensing signal molecules in many of the organisms control many 
phenotypic traits, such as bioluminescense (Nealson and Hastings, 1979), antibiotic 
production (McGowan et al., 1995), and virulence factor synthesis (Pearson et al., 
1997). In the plant pathogen E. carotovora, virulence related exoenzyme genes are 
regulated through the quorum sensing system (Jones et al., 1993). 
 The continuing search for new and novel antimicrobials and antipathogenic agents 
has focused on exploiting the fact that plants surviving in an environment with high 
bacterial density have been seen to possess protective means against infections (Cos et 
al., 2006). Using this argument, researchers are increasingly looking at herbal products 
in the quest for new therapeutic and antipathogenic agents which might be nontoxic 
inhibitors of quorum sensing, thus controlling infections without encouraging the 
appearance of resistant bacterial strains (Hentzer and Givskov, 2003). Current literature 
estimates that 10% of all terrestrial flowering plants on earth have been used by 
different communities in treating diseases, however, only around 1% have gained 
recognition and validation (Lewis and Ausubel, 2006). Controlled studies indicate the 
great potential of phytochemicals to be the richest reservoir of new and novel 
therapeutics (Kumar et al., 2006). Searching the literature, it is surprising to find very 
few works discussing plant extracts and their antiquorum sensing activities. It is 
believed that plant extracts with well documented antimicrobial activities could possess 
antipathogenic as well as antivirulent activities, which may not be linked to the growth 
and inhibition of the microorganism (Vattem et al., 2007). The antiquorum sensing 
activity of herbal plants is very poorly investigated and it is very likely that it will be 
found that the antimicrobial efficacy is mediated by quorum sensing inhibition.  
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 Anti- QS activity has also been shown in a number of southern Florida seaweeds 
and a few terrestrial plants (Allison et al., 2006). However, so far, only a handful of 
higher plants have been studied, and nothing has been published with regard to anti-QS 
activity in medicinal plants. The plant of the genus Phyllanthus belongs to the family 
Euphorbiaceae and has been reported to have pharmacological effects such as antiviral 
activity, anti-bacterial activity, anti-hepatotoxic or liver-protecting activity as well as 
anti-tumour and anti-carcinogenic properties. The plant genus Phyllanthus has thus been 
shown to be of medical importance. The anti-QS properties of these plants have not 
been reported before. So we sought to study the quorum quenching properties of four 
Phyllanthus species (P. amarus, P. niruri, P. urinaria, and P. watsonii). The anti-QS 
properties of garlic extract have been well studied before and it has a strong anti-QS 
property. Garlic extract with strong anti-QS property was used to quench the QS system 
in clinical extracts of Acinetobacter spp. The extracts of lemon and Phyllanthus spp. 
were also studied for their quorum quenching property. The anti-QS activity was 
evident with the growth of the biosensor reporter strain with colourless colonies rather 
than the zone of clearance. In all the extracts, there was no growth inhibition as there 
was a turbid halo of colourless colonies. In all the above biofilm inhibition analysis, the 
concentrations of the extracts used were also found to have no impact on the growth of 
the cultures. This indicates that the biofilm inhibition is probably due to the QS 
inhibition rather than growth inhibition.  
 Quorum quenching employing the AHL-degrading enzyme can be successfully 
used to attenuate the pathogenicity in highly virulent organisms resulting in disruption 
of all the traits associated with quorum sensing. There are various reports on the 
presence of AHL-degrading enzymes in Bacillus sp. Thus, we sought to isolate spore 
forming Bacillus sp. from the Malaysian soil. The heat treatment prior to isolation by 
serial dilution probably killed all the numerous vegetative forms of bacteria in the soil, 
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with which screening would have been more difficult. Sequencing and web-based 
analysis of the sequenced data revealed that the soil isolates B1 and B2 belong to the 
genus Bacillus. PCR for aiiA homologue gene, which is a reported AHL-degrading 
enzyme, for the 2 isolates confirmed that they belong to the genus Bacillus. Through the 
AHL-inactivation bioassay, it was confirmed that there was AHL degrading activity in 
the extracts from the soil Bacillus sp. isolates. But it was found that there was varying 
degrees of degrading activities exhibited by the isolates. Isolate B1 degraded almost all 
the AHLs used in the assay in 9 h, whereas B2 degraded in just 3 h treatment. After the 
confirmation of the AHL degrading capacity of the soil Bacilli extracts, we sought to 
use these extracts to disrupt quorum sensing in clinical isolates of Acinetobacter spp. 
Recently, a similar AHL-degrading enzyme gene (aiiA) from Bacillus sp. strain 240B1 
was identified (Dong et al., 2000). Transgenic tobacco and potato expressing the 
bacterial gene aiiA inactivated exogenous AHL and reduced the virulence of gram-
negative E. carotovora (Dong et al., 2001). Also they cloned a novel lactonase gene 
from a Bacillus sp. This gene designated as aiiA encodes an enzyme that can degrade 
the AHL molecules. Expression of aiiA gene in transformed Erwinia carotovora, that 
causes soft rot disease in many plants, reduces the release of AHL, decreases 
extracellular pectrolytic enzyme activities, and attenuates pathogenicity for potato, egg-
plant, celery, carrot, cauliflower, Chinese cabbage, and tobacco (Dong et al., 2000). An 
isolate of Variovorax paradoxus has been reported to use AHL molecules as energy and 
nitrogen sources, indicating that AHL-degrading enzymes are present in this organism 
(Leadbetter and Greenberg, 2000).    
 After the quorum quenching properties of all these plant extracts and soil Bacillus 
sp., were analysed, they were used to treat the seven biofilm forming clinical isolates of 
Acinetobacter spp. These clinical isolates have already been screened for the production 
of quorum sensing signal molecules and their biofilm forming capabilities analysed. In 
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the tests done to attenuate the pathogenicity of Acinetobacter spp. using the extracts 
from soil bacilli, the extracts could effectively degrade the AHLs produced and also 
inhibit the biofilm formation to a considerable extent. To our knowledge, this is the first 
report of the use of soil bacilli extracts to inhibit the biofilm formation in clinical 
isolates of Acinetobacter spp. 
 Since the aiiA gene product from Bacillus sp. and the plant extracts tested are 
found to interfere with the quorum sensing system, these extracts can be used to 
effectively attenuate the pathogenic organisms whose virulence is associated with the 
quorum sensing system. From our present study we have proved that the AHL 
degrading enzyme aiiA from the soil Bacillus sp. and the plant extracts of Phyllanthus 
spp., garlic bulb and lemon efficiently inhibited the biofilm formation in the clinical 
isolates of Acinetobacter spp. This makes the recombinant protein of aiiA gene or the 
extract from the Bacillus sp. producing these proteins and the extracts from the tested 
plant sources to be promising agents that could attenuate the pathogenicity in any 
organism producing quorum sensing signal. The use of all these extracts is only first 
step. After further fractionation and purification of the extracts, the chemical nature of 
the QS-inhibiting compound should be known before an application. 
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 In conclusion, the increasing emergence of multidrug resistance in Acinetobacter 
spp. has urged the scientific community to find alternatives to antibiotics as 
antimicrobial agents. This has led to the development of novel strategies in controlling 
Acinetobacters. One approach is to attenuate the pathogenicity, rather than killing the 
pathogen. This is called quorum sensing inhibition or quorum quenching. Using a 
microtitre-plate assay it was shown that 60% of the 50 Acinetobacter spp. isolates 
significantly formed biofilms under prolonged period of incubation. Further detection 
showed that 7 of these biofilm forming strains designated as S1, S11, S53, S54, S93, 
S102, and S117, produced long chain signal molecules. On analysis of the biofilm 
forming capabilities of these isolates, they all form biofilms significantly. We present 
the first report of long chain AHL molecules in Acinetobacter samples from our medical 
center. 
 Thin layer chromatography bioassay confirmed that five of these isolates 
produced N-decanoyl homoserine lactone and two isolates produced acyl-homoserine 
lactone with a chain length C12. The data are consistent with the presence of quorum 
sensing signal molecules among the biofilm forming clinical isolates of Acinetobacter 
spp. Mass spectrometric analysis further confirmed the TLC results. Quantification of 
the QS molecules by well diffusion assay and mass spectrometric analysis revealed that 
a minimum of approximately 2 x 10
-9 
moles and a maximum of 6 x 10
-9 
moles of AHLs 
were detected among the clinical isolates of Acinetobacter. 
 In our study we have identified and analysed abaI gene which encodes AbaI 
protein. The BLAST analysis revealed that the AbaI protein has only 91% identity with 
the already reported protein, but still retains its function as a quorum sensing 
autoinducer synthase. The identified AbaI protein from S117 was found to be similar to 
various species of Burkholderia, Pseudomonas fluorescens and Acidithiobacillus 
ferrooxidans suggests a common origin of these genes.  
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 A mutant of the cloned abaI gene was created and shown to inhibit biofilm 
formation. The differences between the wild type and the abaI::Tc mutant indicated that 
abaI directed AHL pathway is required for efficient biofilm formation.  
 Since there are various reports on the presence of AHL-degrading enzymes in 
Bacillus sp., we sought to isolate spore forming Bacillus sp. from the Malaysian soil. 
These extracts were found to disrupt quorum sensing in clinical isolates of 
Acinetobacter spp. by degrading the AHLs produced and also by inhibiting the biofilm 
formation to a considerable extent. To our knowledge, this is the first report of the use 
of soil bacilli extracts to inhibit the biofilm formation in clinical isolates of 
Acinetobacter spp. 
 Preliminary investigations into other sources of anti-QS activity were noted with 
lemon extract, garlic bulb and Phyllanthus spp., with garlic having the strong quorum 
quenching activity. All extracts used indicated that there was a considerable inhibition 
in biofilm formation among the clinical isolates tested.  
 In conclusion, this study has revealed that it is likely that QS regulation is 
important for biofilm development. The use of quorum sensing signal blockers to 
attenuate bacterial pathogenicity is therefore highly attractive, particularly with respect 
to the emergence of multi antibiotic resistant bacteria. Since the aiiA gene product from 
Bacillus sp. and the plant extracts tested are found to interfere with the quorum sensing 
system, they can be used to effectively attenuate the pathogenic organisms whose 
virulence is associated with the quorum sensing system.   
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APPENDIX – 1 
Gram staining reagents 
 
1. Crystal violet: 
Solution 1 Crystal violet 2 g 
 Ethanol 95 % 20 ml 
Solution 2 Ammonium oxalate 0.8 g 
 Distilled water 80 ml 
Solution 1 and 2 were mixed and allowed to stand for at least 24 hours,    and 
filtered before use. 
 
 
2. Lugol’s Iodine: 
Potassium iodide 2 g 
Iodine 1 g 
Distilled water 300 ml 
 
3. Diluted carbol fuschin: 
Stock solution Safranine O 2.5 g 
 Ethanol 95 % 100 ml 
Working solution Stock solution 10 ml 
 Distilled water 90 ml 
 
Media preparation 
 
1. Mueller Hinton Agar: 
Beef infusion       300 g 
Casein        17.5 g 
Starch        1.5 g 
Agar        17 g 
Distilled water      1000 ml 
 Sterilize by autoclaving. 
 Blood may be added as described for blood agar. 
 
2. Nutrient agar (NA): 
Nutrient agar (Oxoid, UK) 28g 
Double-distilled water 1000 ml 
 
3. Luria-Bertani (LB) broth: 
Luria-Bertani (Difco, France) 25g 
Double-distilled water 1000 ml 
 
 Sterilized by autoclaving. 
 LB agar plates were prepared by adding 15 g/L of agar to the the above 
mixture. 
 LB ampicillin plates were prepared by adding 50 µg/ ml ampicillin to 
sterilized LB agar medium. 
 LB tetracycline plates were prepared  by adding 20 µg/ ml tetracycline to 
sterilized LB agar medium. 
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4. 40% Luria-Bertani glycerol stock: 
40% Glycerol (Sigma, USA) 30 ml 
LB broth 100 ml 
 
5. TY broth: 
Bacto tryptone  8 g 
Yeast extract 5 g 
NaCl 5 g 
Distilled water 1000 ml 
 
 Sterilized by autoclaving. 
 TY agar plates were prepared by adding 15 g/L of agar to the the above 
   mixture. 
 
 
Standard biochemical reagents 
 
1. Catalase reagent: 
Hydrogen peroxide 3 % 
 Stored in refrigerator at 4C 
     
 
2. Mc Farland 0.5 Turbidity Standard: 
0.048 M BaCl2 0.5 ml 
0.35 M NH2SO4 99.5 ml 
 
3. Saline: 
Sodium chloride 0.9 g 
Distilled water 100 ml 
 Sterilized by autoclaving 
 
 
4. Tris-acetate EDTA (TAE) buffer (50X) : 
Tris base  242 g 
Glacial acetic acid  57.1 ml 
EDTA   18.61 g 
Distilled water       1000 ml 
 Sterilized by autoclaving. 
 
 
5. Tris-borate EDTA (TBE) buffer (10X) :  
Tris base  121.2 g 
Boric acid  61.8 g 
EDTA   0.745 g 
Distilled water      1000 ml 
  Sterilized by autoclaving. 
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6. Tris-EDTA  (TE) buffer : 
1 M Tris-HCL, pH8.0  1ml (final concentration = 10mM) 
 0.5 M EDTA 200 µl (final concentration = 1mM) 
Distilled water    100ml 
 Sterilized by autoclaving. 
 
7. 0.5 M EDTA, pH7.0, 7.5, or 8.0 
Disodium EDTA.2H20     18.61 g 
Distilled water      60 ml 
  The pH was adjusted as desired with 1 M NaOH and then made upto 
100 ml with distilled water. 
 Sterilized by autoclaving. 
 
 
8. 10 mM Tris-HCL, pH 7.5 
Tris base 0.12 g 
Distilled water     80 ml 
 The pH is adjusted as desired with concentrated HCL and then made 
upto 100 ml with distilled water. 
 Sterilized by autoclaving. 
 
 
9. Phosphte-buffered saline (PBS) 
NaCl    10 g 
KCL    0.25 g 
Na2HPO4  1.43 g 
KH2PO4  0.25 g 
 Adjusted to pH7.3 
 Distilled water 1000 ml 
 Sterilized by autoclaving. 
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APPENDIX - 2
Table A1.1: Selected compounds with observed mass, retention time and observed 
fragment ion in sample 1. 
Sample Compound Mass RT Fragment 
1 1 274.7 4.94 102.1 
  547.8  102.1 
  274.7 4.94 74.1 
  547.8  74.1 
  274.6 4.94 71.1 
 2 256.7 5.59 102.1 
  512  102.1 
  256.7 5.59 74.1 
  512  74.1 
  256.7 5.59 71.1 
  512  71.1 
 3 512 7.51 102.1 
  316.6  102.1 
  297.7  102.1 
  256.7  102.1 
 
Table A1.2: Full list of compounds found in Sample 1 
Cpd Area 
Base 
Peak 
Height m/z RT 
1 45958 202.4 14557 102.1 0.576 
2 19034 236.3 2947 74.1 0.639 
3 284445 316.8 70290 102.1 0.654 
4 15704 317.5 3337 102.1 0.791 
5 6876 250.5 895 74.1 1.104 
6 16861 198.5 3239 71.1 1.171 
7 2560 226.6 443 74.1 1.251 
8 4762 240.3 688 74.1 1.499 
9 1861 316.3 657 102.1 1.735 
10 11325 240.4 1703 74.1 1.799 
11 823 148.3 294 102.1 1.815 
12 52631 212.5 5745 71.1 1.934 
13 1838 256.6 568 74.1 1.992 
14 149771 212.7 17487 71.1 2.25 
15 81124 246.4 11695 71.1 2.998 
16 26014 430.7 4415 102.1 3.935 
17 11394 246.3 3335 74.1 4.102 
18 74870 471.9 20761 102.1 4.331 
19 27975 274.5 6777 102.1 4.545 
20 71846 274.5 17183 74.1 4.55 
21 9752 274.7 2769 71.1 4.558 
22 54164 228.5 14395 74.1 4.693 
23 40098 228.3 9760 102.1 4.704 
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Cpd Area 
Base 
Peak 
Height m/z RT 
24 242439 274.7 64396 102.1 4.838 
25 160177 274.9 41271 71.1 4.841 
26 1103225 274.7 291003 102.1 4.94 
27 3554355 274.7 916483 74.1 4.941 
28 540954 274.6 135572 71.1 4.941 
29 25599 242.6 6332 71.1 5.17 
30 11685 242.4 3312 102.1 5.171 
31 55340 274.5 7700 74.1 5.174 
32 3151191 256.7 694673 74.1 5.594 
33 3492433 256.7 773989 71.1 5.595 
34 6994584 511.9 1765250 102.1 5.595 
35 133074 256.5 24117 102.1 5.77 
36 43789 256.6 7724 74.1 5.936 
37 4714 256.5 2595 102.1 6.036 
38 2517 256.6 1315 71.1 6.045 
39 18950 256.6 4127 74.1 6.053 
40 24217 256.6 4900 74.1 6.101 
41 6901 256.9 2416 102.1 6.117 
42 136 256.6 256 71.1 6.123 
43 9346 256.7 2874 74.1 6.214 
44 4543 256.6 1817 71.1 6.246 
45 44251 284.5 12183 74.1 6.343 
46 54276 284.5 13956 102.1 6.344 
47 22971 284.6 8057 71.1 6.344 
48 -4650 256.4 -265 71.1 6.428 
49 38299 233.6 11893 71.1 6.553 
50 11263 256.5 2295 74.1 6.583 
51 1854 256.7 1256 71.1 6.647 
52 4370 228 1544 102.1 6.847 
53 23084 256.5 2432 74.1 6.873 
54 13446 256.6 4297 71.1 6.944 
55 41760 415 10485 71.1 7.035 
56 -9994 391.7 -2775 71.1 7.18 
57 2880 372.8 1109 74.1 7.195 
58 6399 273.5 2784 71.1 7.266 
59 13105 256.2 2522 74.1 7.328 
60 165259 256.7 41900 74.1 7.512 
61 130831 256.8 37192 71.1 7.516 
62 362135 256.7 90958 102.1 7.516 
63 6776 256.3 2954 102.1 7.625 
64 9966 257 3141 74.1 7.628 
65 28830 282.8 9068 71.1 7.654 
66 13401 353.9 2615 74.1 7.716 
67 3421 228.6 1341 102.1 7.871 
68 60 391.6 116 71.1 7.908 
69 43526 391.8 10269 71.1 7.998 
Table A1.2 Continued 
APPENDIX 
 
 Page: 208 
Cpd Area 
Base 
Peak 
Height m/z RT 
70 39557 284.4 10687 102.1 8.187 
71 4274 284.5 2094 71.1 8.189 
72 19699 284.7 4941 74.1 8.19 
73 680 419.6 647 71.1 8.243 
74 -22912 419.8 -336 71.1 8.377 
75 2033 256.8 1002 71.1 8.603 
76 3955 256.5 1127 102.1 8.819 
77 21395 391.7 3232 71.1 8.915 
78 7699 391.7 2327 71.1 9.038 
79 17050 447.5 3496 71.1 9.22 
80 35503 445.1 7833 71.1 9.34 
81 17955 448 4050 71.1 9.507 
 
Table A1.3: Selected compounds with observed mass, retention time and observed 
fragment ion in sample 11. 
Sample Compound Mass RT Fragment 
11 1 317.6 1.36 102.1 
     
 
2 274.7 4.92 102.1 
  
274.8 
 
74.1 
  
318.9 
 
74.1 
  
548.1 
 
74.1 
  
274.8 
 
71.1 
  
318.9 
 
71.1 
  
548.1 
 
71.1 
     
 
3 256.6 5.57 102.1 
  
512 
 
102.1 
  
256.7 
 
74.1 
  
300.9 
 
74.1 
  
512 
 
74.1 
  
256.7 
 
71.1 
  
334.7 
 
71.1 
  
512 
 
71.1 
 
Table A1.4: Full list of compounds found in Sample 11 
Cpd Area 
Base 
Peak 
Height m/z RT 
1 50031 202.3 16617 102.1 0.581 
2 14179 166.3 2817 74.1 0.592 
3 310785 302.7 70943 102.1 0.661 
4 24679 262.7 3622 71.1 0.872 
5 51353 262.4 7091 71.1 1.062 
6 388369 316.9 47834 102.1 1.132 
7 18349 198.6 4289 71.1 1.204 
8 717841 317.6 53203 102.1 1.364 
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Cpd Area 
Base 
Peak 
Height m/z RT 
9 11915 212.2 2709 71.1 1.879 
10 69887 212.5 10850 71.1 2.031 
11 131166 212.6 16693 71.1 2.373 
12 96352 246.6 14417 71.1 3.049 
13 5515 430.7 1604 102.1 3.964 
14 34977 246.4 10235 74.1 4.111 
15 79161 472.1 20872 102.1 4.314 
16 149095 274.8 42237 74.1 4.526 
17 36085 274.3 9001 102.1 4.531 
18 81401 228.8 23093 74.1 4.681 
19 77049 228.4 20382 102.1 4.685 
20 380858 274.7 103714 102.1 4.829 
21 200700 274.7 55514 71.1 4.833 
22 771833 274.7 185304 71.1 4.92 
23 4797493 274.8 1141941 74.1 4.921 
24 1672850 274.5 385988 102.1 4.922 
25 25973 242.4 6418 102.1 5.139 
26 43633 242.7 12818 71.1 5.146 
27 75639 242.5 14794 74.1 5.152 
28 9869517 511.9 2210319 102.1 5.571 
29 4354282 256.7 842996 74.1 5.572 
30 4249202 256.7 859222 71.1 5.573 
31 180293 256.6 28727 102.1 5.769 
32 89168 256.8 11648 71.1 5.935 
33 72257 256.7 9854 74.1 5.982 
34 33651 256.6 9433 71.1 6.01 
35 59394 256.3 9384 74.1 6.056 
36 2355 256.4 1788 102.1 6.128 
37 44040 256.6 8266 71.1 6.169 
38 -8684 256.6 -612 102.1 6.208 
39 24011 256.4 5767 74.1 6.227 
40 50315 256.7 9105 71.1 6.253 
41 79748 284.6 22472 102.1 6.346 
42 82579 284.8 19089 74.1 6.346 
43 80145 284.5 17138 71.1 6.35 
44 15065 256.5 4380 74.1 6.461 
45 20242 256.5 4087 74.1 6.533 
46 94792 233.5 20889 71.1 6.577 
47 -713 256.4 289 102.1 6.586 
48 17706 256.4 3282 74.1 6.671 
49 2460 256.3 987 102.1 6.686 
50 15403 256.5 2913 71.1 6.73 
51 13310 256.5 3889 71.1 6.79 
52 5778 256.6 1419 74.1 7.035 
53 115635 256.3 18964 71.1 7.057 
54 5668 256.4 1325 102.1 7.1 
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Cpd Area 
Base 
Peak 
Height m/z RT 
55 3582 256.5 1376 74.1 7.123 
56 66810 256.5 9653 71.1 7.311 
57 38795 256.9 8514 74.1 7.577 
58 46938 256.7 12759 102.1 7.577 
59 54472 256.8 9238 71.1 7.578 
60 71331 282.7 17823 71.1 7.725 
61 6126 270.8 1472 102.1 7.823 
62 7014 282.6 3094 71.1 7.824 
63 27165 391.8 3763 71.1 8.999 
64 5200 256.4 1194 74.1 9.926 
 
Table A1.5: Selected compounds with observed mass, retention time and observed 
fragment ion in sample 53. 
Sample Compound Mass RT Fragment 
53 1 317.7 1.45 102.1 
 
2 212.6 2.37 71.1 
 
3 246.6 3.02 71.1 
 
4 471.1 4.34 102.1 
 
5 274.8 4.85 102.1 
  
318.8 
 
102.1 
  
274.7 
 
71.1 
 
6 318.8 4.99 74.1 
    
102.1 
 
7 300.1 5.51 74.1 
    
102.1 
 
8 256.9 7.54 74.1 
  
297.9 
 
74.1 
  
256.7 
 
102.1 
  
297.5 
 
102.1 
  
256.8 
 
71.1 
  
297.6 
 
71.1 
 
9 282.8 7.68 71.1 
 
10 284.6 8.23 102.1 
  
327 
 
102.1 
 
 
 
Table A1.6: Fill list of compounds found in Sample 53 
Cpd Area 
Base 
Peak 
Height m/z RT 
1 43890 202.8 13355 102.1 0.581 
2 22774 166.4 3602 74.1 0.635 
3 254927 316.8 66390 102.1 0.66 
4 12229 262.5 3382 71.1 0.805 
5 6058 317.7 1580 102.1 0.83 
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Cpd Area 
Base 
Peak 
Height m/z RT 
6 39450 317.3 7287 102.1 1.028 
7 117562 198.5 12747 71.1 1.066 
8 176770 317.7 19408 102.1 1.453 
9 83296 212.5 9399 71.1 2.026 
10 185159 212.6 18245 71.1 2.374 
11 76482 246.6 9795 71.1 3.026 
12 11412 430.8 2421 102.1 3.948 
13 95914 471.7 26614 102.1 4.337 
14 4056 272.8 1305 74.1 4.681 
15 4968 272.4 1310 102.1 4.684 
16 213392 274.8 56340 102.1 4.85 
17 163707 274.7 41883 71.1 4.856 
18 170850 318.8 46349 74.1 4.989 
19 57487 318.7 16565 102.1 4.992 
20 241296 300.9 67826 74.1 5.515 
21 442315 300.7 124661 102.1 5.518 
22 7955 256.6 1600 74.1 5.641 
23 21461 362.8 5212 102.1 5.773 
24 33115 322.9 3849 71.1 6.352 
25 22784 233.8 5955 71.1 6.571 
26 5291 363.6 2021 71.1 6.656 
27 58571 458.8 14753 71.1 7.039 
28 10536 273.7 3286 71.1 7.286 
29 141583 256.9 36794 74.1 7.54 
30 278264 256.7 72668 102.1 7.543 
31 143466 256.8 37271 71.1 7.543 
32 56711 282.8 15013 71.1 7.681 
33 5239 327.2 1387 71.1 8.119 
34 42404 284.6 11250 102.1 8.234 
35 8627 284.6 2394 74.1 8.237 
36 18206 284.5 5232 71.1 8.239 
37 4246 256.3 664 74.1 8.333 
38 1758 186.8 579 102.1 8.423 
39 1816 737.9 455 74.1 8.54 
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Table A1.7: Selected compounds with observed mass, retention time and observed 
fragment ion in sample 54. 
Sample Compound Mass RT Fragment 
54 1 274.7 4.59 102.1 
  
548.2 
 
102.1 
  
274.8 
 
74.1 
  
274.8 
 
71.1 
  
547.9 
 
71.1 
 
2 256.8 5.26 74.1 
  
512 
 
74.1 
  
256.8 5.26 71.1 
  
512 
 
71.1 
  
256.8 5.26 102.1 
  
512 
 
102.1 
 
Table A1.8: Full list of compounds found in Sample 54. 
Cpd Area 
Base 
Peak 
Height m/z RT 
1 216602 302.8 48232 102.1 0.657 
2 16285 233.8 2088 74.1 0.657 
3 8061 145.1 1752 71.1 0.725 
4 2703 145.5 962 71.1 0.873 
5 2142 262.3 1214 71.1 0.974 
6 11071 198.7 2680 71.1 1.097 
7 54624 212.6 7391 71.1 1.992 
8 52964 246.6 11246 71.1 2.884 
9 11267 202.3 3432 71.1 3.536 
10 14207 430.7 2909 102.1 3.639 
11 12418 246.7 3230 74.1 3.804 
12 34824 471.7 9586 102.1 3.984 
13 9933 274.6 3105 71.1 4.199 
14 96116 274.7 24481 74.1 4.207 
15 20365 274.7 5845 102.1 4.211 
16 5326 230.4 1757 71.1 4.353 
17 30065 228.7 8507 74.1 4.376 
18 143334 274.7 38381 102.1 4.481 
19 94608 274.8 25394 71.1 4.482 
20 729988 274.7 193182 102.1 4.598 
21 2528103 274.8 670925 74.1 4.599 
22 374769 274.8 98654 71.1 4.6 
23 20624 242.6 5192 71.1 4.824 
24 24547 274.5 2531 74.1 4.829 
25 5326 275.2 1467 74.1 5.009 
26 2250096 256.8 549485 74.1 5.258 
27 2305620 256.7 545552 71.1 5.259 
28 4745387 511.9 1247980 102.1 5.259 
29 21279 256.6 6403 102.1 5.43 
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Cpd Area 
Base 
Peak 
Height m/z RT 
30 36140 256.6 6704 74.1 5.459 
31 38159 256.5 5487 102.1 5.543 
32 36488 256.4 4511 71.1 5.651 
33 15328 256.7 2928 74.1 5.673 
34 12646 256.4 2463 102.1 5.791 
35 10505 256.5 2412 74.1 5.803 
36 10062 256.6 2204 71.1 5.814 
37 12027 256.5 3435 71.1 5.944 
38 21121 284.3 4671 71.1 6.011 
39 25247 284.8 5317 74.1 6.018 
40 16802 284.4 3432 102.1 6.022 
41 15875 256.2 2242 102.1 6.113 
42 21617 300.8 4780 71.1 6.125 
43 8123 256.4 1495 74.1 6.16 
44 27113 233.3 5247 71.1 6.234 
45 7239 256.5 1951 102.1 6.236 
46 3161 256.8 569 102.1 6.326 
47 2266 256.6 633 102.1 6.426 
48 5974 256.6 1428 102.1 6.603 
49 7454 256.5 2307 74.1 6.623 
50 58603 256.3 8793 71.1 6.703 
51 1187 256.4 513 74.1 6.757 
52 9886 301.1 1905 71.1 6.944 
53 4846 256.4 1280 74.1 7.007 
54 34221 256.8 5720 71.1 7.186 
55 18728 256.8 5555 102.1 7.194 
56 19622 256.3 5665 74.1 7.197 
57 31478 282.8 8010 71.1 7.338 
58 6319 284.5 1621 102.1 7.814 
 
 
Table A1.9: Selected compounds with observed mass, retention time and observed 
fragment ion in sample 93. 
Sample Compound Mass RT Fragment 
93 1 274.7 4.59 102.1 
  
318.8 
 
102.1 
  
548.1 
 
102.1 
  
274.7 
 
71.1 
  
548.1 
 
71.1 
  
274.7 
 
74.1 
  
548.1 
 
74.1 
 
2 256.7 5.58 102.1 
  
511.9 
 
102.1 
  
256.7 
 
71.1 
  
511.9 
 
71.1 
  
256.7 
 
74.1 
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511.9 
 
74.1 
 
3 256.6 7.51 71.1 
  
298.5 
 
71.1 
  
256.6 
 
74.1 
  
298.5 
 
74.1 
     
 
Table A1.10: Full list of extracted compounds found in Sample 93 
Cpd Area 
Base 
Peak 
Height m/z RT 
1 27724 202.6 9127 102.1 0.579 
2 169827 302.7 42407 102.1 0.661 
3 4808 262.6 1589 71.1 0.771 
4 10501 262.3 3174 71.1 1.027 
5 38426 212.6 5263 71.1 1.986 
6 111962 212.6 11541 71.1 2.376 
7 55880 246.5 9035 71.1 3.047 
8 6482 333.1 2014 102.1 3.357 
9 10619 202.3 2677 71.1 3.833 
10 8214 464.8 1318 102.1 4.002 
11 6104 246.4 1805 74.1 4.122 
12 27754 471.6 8185 102.1 4.341 
13 80281 274.6 22689 74.1 4.575 
14 15800 274.5 4602 102.1 4.576 
15 32663 228.8 9409 74.1 4.719 
16 13436 228.5 4078 102.1 4.724 
17 178462 274.7 51181 102.1 4.847 
18 121957 274.6 35324 71.1 4.854 
19 886608 274.7 232971 102.1 4.947 
20 399938 274.8 103651 71.1 4.947 
21 2853377 274.8 748862 74.1 4.947 
22 25666 274.6 5678 74.1 5.086 
23 9182 274.8 2572 74.1 5.146 
24 5463 242.6 1701 102.1 5.159 
25 25726 242.4 7216 71.1 5.161 
26 5782247 511.9 1456528 102.1 5.581 
27 2616145 256.7 604405 71.1 5.581 
28 2830367 256.8 656945 74.1 5.581 
29 63870 256.4 6840 102.1 5.794 
30 39281 256.6 7723 74.1 5.8 
31 21213 256.6 4823 74.1 5.917 
32 16219 256.6 3981 102.1 5.918 
33 1557 256.4 1039 71.1 5.941 
34 2713 256.6 1298 71.1 6.015 
35 17454 256.7 3211 102.1 6.034 
36 29429 256.6 5043 74.1 6.05 
37 708 256.4 646 71.1 6.111 
38 12013 256.3 3289 74.1 6.125 
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Cpd Area 
Base 
Peak 
Height m/z RT 
39 22808 376.4 5021 102.1 6.129 
40 6722 256.5 2221 71.1 6.204 
41 14871 256.6 2525 74.1 6.246 
42 11491 256.5 3317 102.1 6.279 
43 50378 284.7 8207 74.1 6.348 
44 9739 284.5 3275 71.1 6.351 
45 48036 284.6 7264 102.1 6.356 
46 6942 233.2 2287 71.1 6.574 
47 2255 256.6 887 71.1 6.739 
48 26035 415 6712 71.1 7.019 
49 11361 273.5 2936 71.1 7.252 
50 279599 256.6 72187 102.1 7.508 
51 144145 256.6 33238 71.1 7.509 
52 168955 256.8 40106 74.1 7.509 
53 27531 282.8 7830 71.1 7.672 
54 6231 256.5 1672 74.1 8.051 
55 6058 284.8 2210 71.1 8.242 
56 54495 284.8 14893 102.1 8.245 
57 18296 284.6 4449 74.1 8.249 
 
Table A1.11: Selected compounds with observed mass, retention time and 
observed fragment ion in sample 102. 
Sample Compound Mass RT Fragment 
102 1 317.6 1.4 102.1 
 
2 212.5 1.93 71.1 
 
3 212.5 2.39 71.1 
 
4 246.7 3.04 71.1 
 
5 274.8 4.83 102.1 
  
318.5 
 
102.1 
  
274.8 
 
71.1 
  
230.7 
 
71.1 
 
6 318.8 4.98 74.1 
 
7 301 5.58 74.1 
  
301 
 
102.1 
 
8 363.1 5.79 102.1 
 
9 256.8 7.52 71.1 
  
297.8 
 
71.1 
  
256.8 
 
102.1 
  
297.8 
 
102.1 
  
256.8 
 
74.1 
  
297.8 
 
74.1 
 
10 284.7 8.16 102.1 
  
325.9 
 
102.1 
  
284.6 
 
74.1 
  
326.1 
 
74.1 
  
284.9 
 
71.1 
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Table A1.12: Full list of extracted compounds found in Sample 102. 
Cpd Area 
Base 
Peak 
Height m/z RT 
1 73732 202.4 25006 102.1 0.582 
2 17748 116.6 2782 71.1 0.637 
3 14324 208 2578 74.1 0.641 
4 364438 316.8 91796 102.1 0.658 
5 9675 418.2 1751 102.1 0.82 
6 11048 262.3 2763 71.1 0.844 
7 23320 262.5 4913 71.1 0.936 
8 44144 198.4 7657 71.1 1.088 
9 30876 198.4 6916 71.1 1.194 
10 170543 317.6 17612 102.1 1.406 
11 36767 212.5 6237 71.1 1.928 
12 7123 212.6 2348 71.1 2.038 
13 115900 212.5 11057 71.1 2.389 
14 54700 246.7 8981 71.1 3.037 
15 7070 202.6 1880 71.1 3.819 
16 14128 430.9 2554 102.1 3.952 
17 7997 236.7 2027 71.1 3.961 
18 49885 471.7 13022 102.1 4.31 
19 4856 318.3 1459 102.1 4.592 
20 177913 274.8 46671 102.1 4.835 
21 131016 274.8 34834 71.1 4.84 
22 25007 318.8 7135 74.1 4.987 
23 14812 318.7 4709 102.1 4.988 
24 6370 362.8 1001 74.1 5.289 
25 7202 336.5 1393 102.1 5.297 
26 106435 301 30184 74.1 5.518 
27 140314 300.8 39519 102.1 5.518 
28 1581 374.9 572 74.1 5.644 
29 29173 363.1 7981 102.1 5.793 
30 2075 398.9 536 74.1 6.04 
31 18390 376.7 5212 102.1 6.178 
32 6291 305.5 1622 71.1 6.311 
33 7196 441.3 2229 102.1 6.354 
34 8515 256.9 1504 71.1 6.422 
35 2077 101.8 717 74.1 6.453 
36 16666 233.8 3556 71.1 6.603 
37 4315 479.1 700 74.1 6.714 
38 2806 469.2 826 102.1 6.717 
39 6361 423.7 1400 71.1 6.745 
40 17956 228.8 3088 71.1 6.888 
41 33763 459 7636 71.1 7.066 
42 12282 273.2 3230 71.1 7.29 
43 149775 256.8 39753 71.1 7.519 
44 341476 256.6 86801 102.1 7.519 
APPENDIX 
 
 Page: 217 
Cpd Area 
Base 
Peak 
Height m/z RT 
45 166252 256.7 42696 74.1 7.521 
46 12179 282.6 3410 71.1 7.641 
47 10585 256.3 2314 102.1 7.693 
48 4955 282.3 1361 71.1 7.724 
49 52867 284.7 14877 102.1 8.158 
50 23433 284.6 6219 74.1 8.167 
51 14176 284.9 4069 71.1 8.171 
52 3876 338.4 1307 71.1 8.977 
 
 
Table A1.13: Selected compounds with observed mass, retention time and 
observed fragment ion in sample 117. 
Sample Compound Mass RT Fragment 
117 1 274.7 4.92 71.1 
  
548 
 
71.1 
  
274.8 
 
74.1 
  
274.7 
 
102.1 
  
548 
 
102.1 
 
2 256.7 5.61 71.1 
  
512 
 
71.1 
  
256.7 
 
74.1 
  
512 
 
74.1 
  
256.7 
 
102.1 
  
512 
 
102.1 
 
3 256.7 7.52 71.1 
  
297.8 
 
71.1 
  
256.6 
 
74.1 
  
298 
 
74.1 
  
256.7 
 
102.1 
  
297.8 
 
102.1 
 
4 284.6 8.23 102.1 
  
325.6 
 
102.1 
 
Table A1.14: Full list of extracted compounds found in Sample 117 
Cpd Area Base 
Peak 
Height m/z RT 
1 5603 166.4 1129 74.1 0.618 
2 168222 316.8 39971 102.1 0.661 
3 4560 198.3 1460 71.1 1.103 
4 63320 317.4 12592 102.1 1.125 
5 54710 317.5 6837 102.1 1.274 
6 54526 317.6 9838 102.1 1.395 
7 36107 317.5 7979 102.1 1.481 
8 25948 212.5 4189 71.1 2.016 
9 51412 212.6 7015 71.1 2.362 
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10 20079 246.6 3230 71.1 3.011 
11 18479 430.6 3061 102.1 3.962 
12 5592 246.7 1685 74.1 4.114 
13 17721 471.8 5142 102.1 4.298 
14 25741 274.6 7353 74.1 4.512 
15 9489 274.8 2683 102.1 4.526 
16 7503 228.3 2363 102.1 4.676 
17 15990 228.3 4167 74.1 4.688 
18 61913 274.8 17692 71.1 4.803 
19 95698 274.6 27336 102.1 4.804 
20 233496 274.7 61350 71.1 4.924 
21 1766607 274.8 466540 74.1 4.924 
22 496799 274.7 138242 102.1 4.925 
23 14214 274.5 5368 74.1 5.042 
24 12583 242.6 3374 74.1 5.141 
25 6224 242.4 2094 71.1 5.156 
26 2192878 256.7 535895 71.1 5.614 
27 4256487 512 1115337 102.1 5.615 
28 2005486 256.7 490656 74.1 5.615 
29 64839 256.8 11857 71.1 5.761 
30 37136 256.7 7821 74.1 5.808 
31 16801 256.2 2857 102.1 5.885 
32 15672 256.4 3369 71.1 5.923 
33 12732 256.6 1560 74.1 6.046 
34 10629 256.8 2726 71.1 6.074 
35 3931 376.8 1206 102.1 6.126 
36 14261 256.3 2865 71.1 6.192 
37 3690 440.8 1261 102.1 6.282 
38 11543 284.7 3144 102.1 6.361 
39 27642 284.9 7224 74.1 6.363 
40 15017 284.3 3575 71.1 6.369 
41 6762 233.8 1610 71.1 6.594 
42 28120 353 5634 71.1 7.046 
43 154647 256.7 40698 71.1 7.523 
44 106131 256.6 29651 74.1 7.523 
45 270043 256.7 71954 102.1 7.524 
46 16417 282.6 4594 71.1 7.665 
47 61625 284.6 17856 102.1 8.224 
48 23424 284.6 7872 71.1 8.229 
49 30777 284.7 8534 74.1 8.232 
50 14347 338.9 4105 71.1 9.077 
51 25163 428.1 4624 71.1 9.243 
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 Quorum Sensing is a term that describes an environmental sensing system that 
allows bacteria to monitor their own population density. Many gram negative bacteria 
use N-acyl-homoserine lactones (AHLs) as Quorum Sensing (QS) signal molecules. 
This cell density dependent regulation of gene expression contributes significantly to 
the size and development of the biofilm. In this study, we sought to find out if the 
biofilm formation among clinical isolates of Acinetobacter spp. is under the control of 
autoinducing QS molecules.  
  
 Biofilm formation among 50 clinical isolates of Acinetobacter spp. was assessed 
by microtitre plate method and the statistical analysis showed 60% of the isolates 
significantly formed biofilms. The production of AHL molecules among seven of these 
isolates were detected using Chromobacterium violalecim cv026 biosensor system.  
Partial characterisation of autoinducers was carried out by thin layer chromatography 
(TLC) bioassay. Mass Spectrometric analysis to structurally characterise the type of 
AHL molecules further revealed that some of the strains produce N-decanoyl 
homoserine lactone signal molecules.  
 
 The presence of QS signal molecules among Acinetobacter spp. is of great 
significance as they aid in Biofilm formation which in turn confers various properties of 
pathogenecity including drug resistance. Further understanding of the rate of the QS 
mechanism in the regulation of pathogenecity may be used to elucidate new Quorum-
Quenching strategies to control cell-cell communication and thus attenuating the 
pathogenecity in multidrug resistant clinical isolates. Consequently, a drug capable of 
blocking QS is likely to increase the susceptibility of these pathogenic organisms to host 
defences and its clearance from the host. 
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Introduction 
In many of the Gram-negative bacteria, quorum sensing (bacterial communication) is 
mediated by a group of widely conserved signal molecules called N-acylhomoserine 
lactones (AHLs), known as autoinducers. These autoinducers are involved in the 
regulation of diverse biological functions, including expression of virulence genes in 
many pathogenic bacteria. Many soil bacteria are capable of interfering with the quorum 
sensing system by enzymatic degradation of AHLs, a process referred to as quorum 
quenching. Here we report the identification of two soil isolates with a strong AHL-
inactivating enzyme activity.  
Methods 
 
The soil isolates were subjected to preliminary taxonomic analysis. The extracts from 
soil isolates of the genus Bacillus were further subjected to AHL- inactivation assay to 
analyse their capability to degrade synthetic N-hexanoyl homoserine lactone (HHL). 
Polymerase chain reaction (PCR) was carried out to detect the presence of aiiA 
homologue gene. Strong biofilm-forming clinical isolates of Acinetobacter spp., which 
were capable of producing quorum sensing signal molecules, were tested for the 
inhibition of their biofilm forming capabilities after treatment with the extracts from 
these soil bacilli with quorum quenching activity.  
 
Results 
 
Morphological phenotypes and 16s rDNA sequence analysis showed that these isolates 
probably belong to the genus Bacillus. The AHL-inactivation assay showed that the two 
isolates rapidly degrade the synthetic N-hexanoyl homoserine lactone (HHL). We also 
identified the aiiA homologue gene in both the Bacillus sp. isolates by PCR analysis. 
Results showed that the soil bacillus extracts were capable of inhibiting the biofilm 
formation and also degrade the AHLs produced by the clinical isolates of Acinetobacter 
spp.  
 
Conclusion 
Our results indicate that the AHLs -inactivation approach represents a promising 
strategy for prevention of diseases in which virulence is regulated by quorum sensing. 
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 One of the most fascinating discoveries in microbiology is that bacteria 
communicate with each other. Bacterial communication is called 'Quorum Sensing'(QS) 
because it is a density-dependent process that functions when a population is of 
sufficient size. It involves the production of diffusible signal molecules that co-ordinate 
gene expression. Quorum Sensing systems are widespread and modulate many 
physiological processes in bacteria associated with humans, plants, animals, soils, 
marine and fresh waters. Understanding the role of quorum sensing in pathogenecity 
offers the opportunity to develop novel approaches to combat human, animal and plant 
diseases. There is increasing evidence that animals and plants 'listen' to bacterial signals 
and utilise these signals in complex ways. Some plants and animals produce molecules 
that mimic quorum sensing molecules and so confuse regulation in bacteria; blocking of 
cell-to-cell signalling may have evolved as a successful strategy to resist infection by 
pathogenic bacteria. 
 
 The most obvious alternative to antibiotic-mediated killing or growth inhibition 
would be to attenuate the bacteria with respect to pathogenecity. The regulation of 
virulence via quorum sensing confers a strategic advantage over host defences. The use 
of quorum sensing signal blockers to attenuate bacterial pathogenecity, rather than 
bacterial growth, is therefore highly attractive, particularly with respect to the 
emergence of multi-antibiotic resistant bacteria. Characterisation of the crystal 
structures of several types of quorum-quenching enzymes has provided valuable 
information to elucidate the catalytic mechanisms, as well as clues for future protein 
tailoring and molecular improvement.  
 
 Acinetobacter is frequently isolated in nosocomial infections and is especially 
prevalent in intensive care units, where both sporadic cases as well as epidemic and 
endemic occurrence is common. The spectrum of antibiotic resistances of these 
organisms together with their survival capabilities makes them a threat to hospitals as 
documented by recurring outbreaks. Thus a study on their mode of drug resistance and 
ways to block these mechanisms becomes necessary.  
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Objectives of the proposed project 
 
The proposed project aims to investigate the various QS molecules involved in 
Acinetobacter and also study the quorum quenching strategies that can effectively block 
QS and thus attenuate Acinetobacter pathogens. 
 
Key objectives: 
1. To prove that the Acinetobacter spp. isolated from nosocomial infections have 
QS mediated virulence. 
2. To perform various assays to identify, quantify and characterise the QS 
molecules (N-acyl homoserine lactones
 
(AHL) in gram negative organisms)  
3. To study the QS molecules and construct analogues to QS molecules which can 
be used to block the QS mediated processes. 
4. To use the molecular techniques to elucidate the QS molecule binding sequences 
in the DNA and thus create sequence homologues which can be used for quorum 
quenching. 
5. To study about the effects of natural sources as potential Quorum quenchers. 
 
 A few of the possible mechanisms for exploiting the regulatory mechanisms of 
pathogenic bacteria employing QS systems can definitely be elucidated at the end of 
this proposed research. This approach will definitely be helpful in formulating drugs 
that are capable of attenuating not only human pathogens, but also control crop diseases 
as well as manipulate
 
plant-microbe interactions for improved crop production in the
 
future. This research would for sure lay foundation for novel advances in chemotherapy 
in the future. 
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Quorum Sensing is a term that describes an environmental sensing system that 
allows bacteria to monitor their own population density. Many gram negative bacteria 
use N-acyl-homoserine lactones (AHLs) as Quorum Sensing (QS) signal molecules. 
This cell density dependent regulation of gene expression contributes significantly to 
the size and development of the biofilm. In this study, we sought to find out if the 
biofilm formation among clinical isolates of Acinetobacter spp. is under the control of 
autoinducing QS molecules.  
Biofilm formation among 50 clinical isolates of Acinetobacter spp. was assessed 
by microtitre plate method and the statistical analysis was done using SPSS software 
which showed that 60% of the isolates significantly formed biofilms. The production of 
AHL molecules among seven of these isolates were detected using Chromobacterium 
violaceum CV026 biosensor system. AHLs from selected strains were profiled by thin 
layer chromatography. The simultaneous use of monitor strains in the top-layer was 
necessary for the detection of the AHLs. An agar well-diffusion assay based on 
Chromobacterium violaceum CV026 was used for quantifying AHLs from the bacterial 
supernatants. Partial characterisation of autoinducers by thin layer chromatography 
(TLC) bioassay showed that some of the strains produce N-decanoyl homoserine 
lactone signal molecules.  
The presence of QS signal molecules among Acinetobacter spp. is of great 
significance as they aid in Biofilm formation which in turn confers various properties of 
pathogenecity including drug resistance. Further understanding of the rate of the QS 
mechanism in the regulation of pathogenecity may be used to elucidate new Quorum-
Quenching strategies to control cell-cell communication, thus attenuating the 
pathogenecity in multidrug resistant clinical isolates. Consequently, a drug capable of 
blocking QS is likely to increase the susceptibility of these pathogenic organisms to host 
defences and its clearance from the host.  
 
